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 1 
Objectives 
 
 
 
Biopharmaceuticals are powerful therapeutics to treat or even cure severe diseases like 
cancer or autoimmune diseases. However, adverse effects, in particular immune reactions 
caused by protein particles have been reported. Hence, the formation of protein particles and 
their administration to patients has to be prevented. The aim of this thesis is to offer and 
evaluate approaches that minimize the number of such protein particles in 
biopharmaceuticals. To this end, bedside filtration as well as novel polymeric primary 
packaging materials are considered and investigated for their potential to improve the quality 
of liquid biotech drugs.  
 
In order to characterize and validate the two suggested approaches, this thesis has five 
objectives and is structured accordingly in five chapters: 
 
- Research on the current status of bedside filtration of worldwide approved 
biopharmaceuticals with regard to the dosage form, time of filtration, filter membrane 
and pore size.  
 
- Investigation of an expansion of bedside filtration to a broad variety of 
biopharmaceuticals with different concentrations and molecular weights. Thereby 
technical aspects such as filter types, filtration effectiveness, filter cleanliness, protein 
loss or syringeability shall be considered.  
 
- Analysis of three antivascular epidermal growth factor biopharmaceuticals for ocular 
use regarding their silicone oil and protein particle levels. 
 
- Evaluation of the suitability of a novel silicone and tungsten free polymer syringe 
system for the long-term storage of biopharmaceuticals in comparison to siliconized 
glass syringes. 
 
- Comparison of innovative monolayer and multilayer plastic vials to standard glass 
vials with regard to product quality and long-term stability of biopharmaceuticals. 
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Abstract 
Protein drug products play an important role in the treatment of severe diseases. However, 
due to the instability of these complex molecules, protein aggregates can form which can 
compromise drug safety and efficacy including immunogenic reactions. In-line filtration during 
the administration of these drugs can serve as a final safeguarding step to protect patients 
from risks associated with proteinaceous particles. A unique analysis of more than 300 
marketed protein drug products revealed that already around 16 % of all these products are 
filtered during preparation or administration. Further, the research revealed that no 
standardized filtration practice exists. Broad variances regarding filter membrane or pore size 
are found and sometimes no specifications are mentioned at all. The benefits as well as 
possible negative impacts of filtration like filter shedding, extractables or drug adsorption are 
critically assessed. Several proposals to improve the current filtration practice and to expand 
the number of in-line filtered protein drug products are made. The suggestions include the 
demand for the specific usage of one filter membrane type, the establishment of a filtration 
routine for unfiltered protein drugs and a statistical analysis between filtered and non-filtered 
products with similar formulations to identify possible differences in the immunogenicity rate. 
 
 
 
Disclaimer 
Although the authors have done a careful piece of work by reviewing the current status of the 
filtration of selected drugs, they cannot be responsible for the completeness of the data, for 
any omissions or errors, the timeliness of data, or for any consequences that may arise. The 
reader is advised to consult the newest professional information, like a package insert, 
available for the product of interest.  
 
 
Keywords 
particulate matter, particle, protein, biopharmaceutical, in-line filtration, immunogenicity 
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1.1. Introduction 
1.1.1 Regulatory specifications 
Biopharmaceuticals have been rising for many years and their share on the total drug market 
will increase in the future to up to 20 % (Walsh, 2014). They are commonly administered 
intravenously or subcutaneously (Jiskoot et al., 2012). Hence, protein drug products have to 
comply with the criteria set forth for parenteralia in the United States and European 
Pharmacopeia (European Directorate For The Quality Of Medicine, 2011c; The United States 
Pharmacopeial Convention, 2011a). One major aspect is that biopharmaceuticals need to be 
practically free from visible particles (European Directorate For The Quality Of Medicine, 
2011c; The United States Pharmacopeial Convention, 2011a) and must not exceed limits for 
subvisible particles (European Directorate For The Quality Of Medicine, 2011a; 
Pharmaceuticals and Medical Devices Agency, 2011; The United States Pharmacopeial 
Convention, 2011b). Particles become visible above approximately 50 µm, and are well 
detected by the unaided eye at sizes of about 100 µm (Das, 2012; den Engelsman et al., 
2011; Doessegger et al., 2012). At the moment particle number limits in the subvisible range 
are only defined for particles larger than 10 and 25 µm (European Directorate For The 
Quality Of Medicine, 2011a; Pharmaceuticals and Medical Devices Agency, 2011; The 
United States Pharmacopeial Convention, 2011b). However, in the recent years it has 
become common practice by the authorities to request data for particle sizes below 10 µm for 
this drug product class (Wang et al., 2012) and (The United States Pharmacopeial 
Convention, 2015). The European Pharmacopeia also contains a monograph called 
“Monoclonal antibodies for human use”, which allows the presence of protein particles in 
protein drug products (European Directorate For The Quality Of Medicine, 2011b). But these 
particles are only tolerated if they are well characterized and the data is accepted by the 
regulatory authorities (Doessegger et al., 2012; European Directorate For The Quality Of 
Medicine, 2011b). Nevertheless, these product inherent particles have to be reduced to a 
minimum (Doessegger et al., 2012; European Directorate For The Quality Of Medicine, 
2011b).  
 
1.1.2 Negative impacts of particles 
Particles in parenteral solutions can derive among others from formulation components or 
other sources like silicone oil, cellulose fibers, cotton, glass microflakes, rubber, plastic or 
metal (Bethune et al., 2001; Doessegger et al., 2012; Paolo et al., 1990; Shaw and Lyall, 
1985; Tran et al., 2006; Waller and George, 1986). Based on estimations of the year 1987, 
an adult intensive care patient gets more than 107 particles with a size larger than 2 µm 
infused within 24 hours (van Lingen et al., 2004). Ten years earlier, in 1977, Mehrkens et al. 
Particle contamination of parenteralia and in-line filtration of proteinaceous drugs 
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found two million particles larger than 2 µm during the same infusion interval (Bethune et al., 
2001). Many reports describe the negative impact of particle contamination. For example, a 
correlation between the frequency of site reactions and the particulate matter is witnessed. A 
high particle number results in an increased number of adverse effects (Doessegger et al., 
2012). Further, particles affect mainly organs like eyes, brain, lungs, heart, kidney, spleen, 
stomach and intestine (Boehne et al., 2013; Paolo et al., 1990; Puntis et al., 1992; Waller 
and George, 1986), whereas large particles remain in the lung and small ones are 
transported within the systemic circulation (Boehne et al., 2013; Langille, 2013; Puntis et al., 
1992). If particles are larger than 7 µm, capillary occlusion is a reason why these organs are 
harmed by particles, because the diameter of the smallest capillary vessel is around 7 µm 
(Hearse et al., 1986; Shaw and Lyall, 1985; Tran et al., 2006; Waller and George, 1986). 
Moreover, pulmonary granuloma is associated with the presence of particles in humans 
(Cant et al., 1988; Lehr et al., 2002; Shaw and Lyall, 1985; Shay et al., 1997; van Lingen et 
al., 2004). Granuloma formation is also observed for drugs like amphetamines, methadone or 
methylphenidate, intended to be administered orally but are misused intravenously 
(Doessegger et al., 2012; Jorens et al., 2009). This further indicates that particles are 
capable of inducing granuloma. Next, a large number of microthrombi are connected to 
particles with a size less than 2 µm, which also account for the majority of the particles in 
intravenous fluids, as Walpot et al. note (Lehr et al., 2002; Tran et al., 2006; Walpot et al., 
1989).  
 
1.1.3 Protein aggregate formation 
Beside these non-proteinaceous particles, protein drugs can contribute to the particle burden 
of a formulation, because they are prone to chemical and physical degradation (Manning et 
al., 2010). Two very important chemical degradation pathways are deamidation and 
oxidation. Muromonab-CD3, human growth hormone or insulin are examples of 
pharmaceutical relevant drugs in which deamidation, a hydrolysis of asparagine or 
glutamine, is detected. Several factors like the amino acid sequence or pH have an impact. 
Oxidation processes can occur at any time. Among others light or metals can cause 
oxidation. Especially histidine, methionine, cysteine, tyrosine or tryptophan are sensitive 
towards oxidation. Physical degradation can be denaturation, caused for example by 
temperature or chemicals, or aggregation with different mechanism like chemically modified 
monomers or surface interfaces (Manning et al., 2010). Even the best formulation and 
storage condition cannot totally exclude such degradation products (Brange et al., 1992). 
External factors like temperature, pH, shaking, shearing, etc. can cause particle formation 
(Wang, 2005). Silicone oil, a non-proteinaceous particle, (Basu et al., 2013; Thirumangalathu 
et al., 2009) may foster protein aggregation by acting as heterogeneous nuclei (Mahler et al., 
Chapter 1 
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2009; Zölls et al., 2012). Generally, protein aggregates can be dimers or multimers in the 
lower nanometer range or may assemble to large particles even in the visible range above 
100 µm (den Engelsman et al., 2011; Singh et al., 2010).  
 
1.1.4 Immunogenicity of protein particles 
In contrast to non-proteinaceous particles, aggregates formed by proteins require additional 
vigilance. For several monoclonal antibody drug products, for example adalimumab, 
abciximab, omalizumab or trastuzumab, immunogenic reactions are observed (Getts et al., 
2010).  
 
1.1.4.1 Causes for the immunogenic potential of proteins 
Not surprisingly proteins with an amino acid sequence differing from the human homologue 
are immunogenic. Hence, in the case of protein drug products the immunogenicity issue has 
been detected first by proteins deriving from animal origin, like porcine and bovine insulins 
(Schellekens, 2002). The response of the immune system towards drugs deriving from 
animal, microbial or plant origin is rapid and occurs immediately after a single administration. 
Hereby, neutralizing antibodies are formed. However, immunogenic reactions also take place 
for recombinant human proteins like human insulin. The reason is a breach of the immune 
tolerance (De Groot and Scott, 2007; Hermeling et al., 2004). The antibodies, formed by this 
slow process, disappear either after the end or in the long term of a treatment (Schellekens, 
2005a). Several steps have been taken to reduce the immunogenic potential of proteins. The 
generation of fully humanized proteins, and consequently avoiding proteins based on murine 
structures, can be one improvement, but is no guarantee for a diminished immune response 
(Getts et al., 2010). Other approaches are glycosylation, PEGylation, sequence 
modifications, reduction of process impurities and formulation optimization (Chirino et al., 
2004; De Groot and Scott, 2007; Hermeling et al., 2004; Schellekens, 2002). It is of utmost 
importance to reduce impurities and protein aggregates, because they are the main cause 
for the breakdown of the immune tolerance (Schellekens, 2005a). The potential of 
aggregates to induce immune reactions is common knowledge since the 1950s (Rosenberg, 
2006). Aggregates may cause an immune response via T cell in- as well as dependent 
pathway. It is assumed that T cells recognize repetitive patterns on the surface of the 
aggregates which are similar to the unique epitope arrangement of microbial antigens 
(Carpenter et al., 2010; De Groot and Scott, 2007; Hermeling et al., 2004). For example, 
antigenic sites exist for the aggregated, in contrast to the native, species of insulin 
(Hermeling et al., 2004). A cross-linking of a B cell receptor by an aggregate might trigger a T 
Particle contamination of parenteralia and in-line filtration of proteinaceous drugs 
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cell dependent pathway (De Groot and Scott, 2007). Next, antigen-presenting cells, marking 
the start of the immune reaction, take up particulate antigens very fast (Rosenberg, 2006).  
 
1.1.4.2 Consequences of anti-drug antibodies 
The clinical and biological consequences of the antibody formation against 
biopharmaceuticals are often negligible. Yet, severe immune responses like anaphylaxis, 
allergic reactions or serum sickness can also occur, although the use of highly purified 
products with a high quality diminishes these incidents nowadays. Neutralization of an 
essential endogenous protein can be life threatening (Carpenter et al., 2009; Hermeling et 
al., 2004; Kessler et al., 2006; Sharma, 2007). An example of a severe immunogenic 
reaction is the pure red cell aplasia, resulting from the formation of anti-erythropoietin 
antibodies (Schellekens, 2005b). Neutralizing antibodies against adalimumab also exist, 
hereby reducing its efficacy (van Schouwenburg et al., 2013), whereas the formation of non-
neutralizing anti-drug antibodies does not influence the efficacy of etanercept (Dore et al., 
2007). The potential of protein aggregates to induce immune reactions in other cases is 
documented as well. For aggregates of insulin (Schernthaner, 1993), interferon alpha (Braun 
et al., 1997) and human growth hormone antibody formation occurs (Moore and Leppert, 
1980). Investigation of different interferon products reveals a correlation between the amount 
of neutralizing antibodies and aggregate, respectively, particle level of the drug products 
(Barnard et al., 2013). Also for interleukin-2 neutralizing antibodies are found because the 
protein drug product is produced as an aggregate with highly immunogenic properties 
(Rosenberg, 2006). A recent study by Ahmadi et al. implies that the clinical immunogenicity 
profile of the protein drug may influence the potential of present aggregates to induce an 
immune response (Ahmadi et al., 2015). Trastuzumab, which has a low clinical 
immunogenicity, is a strong activator of the immune system after the presence of small 
amounts of aggregated protein (< 3% of total protein content). On the contrary, stressed 
rituximab, with the native species showing high clinical immunogenicity, does not increase 
the immune reaction (Ahmadi et al., 2015). But aggregates do not always lead to an immune 
response. Their properties like secondary structure, solubility or size have an impact on their 
potential to induce immunogenicity (Freitag et al., 2015; Shomali et al., 2014). For 
aggregated recombinant human factor VIII no enhanced immunogenicity is observed (Purohit 
et al., 2006). As this example shows there is no direct correlation between clinical evidence 
of immune reactions and particles in parenteralia. To establish such a relation is problematic, 
because several factors including the immune status of the patient, dose, dosage frequency, 
duration or route of administration as well as other factors influence immunogenicity 
(Carpenter et al., 2010; Carpenter et al., 2009; Rosenberg, 2006; Schellekens, 2005b).  
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Further, the larger particles do not need to be more immunogenic than smaller ones 
(Rosenberg, 2006) or  vice versa (Singh, 2011). But a look at the particle count of marketed 
biologic drug products reveals that particles smaller than 2 µm account for the overwhelming 
majority of particles, whereas large ones, as monitored according to the pharmacopoeia, 
represent only a small fraction of the total particle count (Barnard et al., 2013; Singh et al., 
2010) Hence, it has to be assumed that particles with a small size are potentially more 
harmful due to their higher amount in formulations. 
 
1.1.5 Usage of in-line filters to solve the particle problem 
1.1.5.1 Benefits of in-line filtration 
A way to overcome negative aspects associated with particles can be the usage of in-line 
filters, which are incorporated in the infusion set proximal to the patient (Allcutt et al., 1983; 
Bethune et al., 2001). In-line filters with pore sizes ranging from 0.2 to 0.45 µm reduce the 
occurrence of phlebitis (Allcutt et al., 1983; Dorris et al., 1977; Falchuk et al., 1985; Gasch et 
al., 2011; Ortolano et al., 2004; Paolo et al., 1990; Waller and George, 1986). However, a 
systematic review of randomized controlled trials shows an uncertain benefit regarding the 
reduction of phlebitis, due to methodological shortcomings and unexplained statistical 
heterogeneity in studies ranging from 1973 to 1990 (Niel-Weise et al., 2010). Besides, in-line 
filtration decreases the frequency of systemic inflammatory response syndrome in critically ill 
children very effectively (Boehne et al., 2010). Another study shows several positive effects 
of the usage of in-line filters in sick newborn infants. The rates of sepsis, infection, thrombi 
and necrotizing enterocolitis are reduced (van Lingen et al., 2004). A recent study from 2012 
with 807 critically ill children shows a significant positive effect of in-line filtration (Jack et al., 
2012). Filter usage decreases complications like sepsis, circulatory failure or acute renal 
failure, whereas in-line filtration significantly reduces the occurrence of systemic 
inflammatory response syndrome and the duration of the hospitalization and mechanical 
ventilation (Jack et al., 2012). A follow up study has investigated the impact of filtration on 
organ dysfunction and reveals a positive impact of in-line filters regarding the respiratory, 
renal and hematologic function (Boehne et al., 2013). In-line filters can also diminish the risk 
of infection especially for immunocompromised individuals (Ennis et al., 1983; Francomb et 
al., 1994; Gasch et al., 2011).  
Hospital pharmacies recommend that depending on the administered solution filtration 
should be considered (Doessegger et al., 2012). Yet, filters are rarely used beside the 
preparation of anticancer drugs or for administration of total parenteral nutrition, due to costs 
and time reasons (Lee et al., 2011). However, the usage of in-line filters in sick newborn 
infants results in considerable financial and nursing time savings (van Lingen et al., 2004). 
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Other studies observe a prolonged use of the infusion set and saving time of the nurses for 
not changing the set, as well as a better recovery of the patient, if in-line filters are applied. 
Hence, costs and also waste are reduced (Bethune et al., 2001; Gasch et al., 2011; Jack et 
al., 2012).  
 
1.1.5.2 Reduction of particles with in-line filters and filtration recommendations of institutions 
Among others the U.S. Food and Drug Administration and the Intravenous Nurses Society 
advocate the usage of a final filter for the administration of intravenous drugs (Kuramoto et 
al., 2006). In Japan, in-line filters are considered to be essential due to their ability to remove 
insoluble particles (Kuramoto et al., 2006). However, data supporting the usage of final filters 
are rare and date back to 1979. A more recent study by Kuramoto et al. provides evidence 
regarding particle numbers and not clinical pictures for the usefulness of final filters 
(Kuramoto et al., 2006). They investigated nine different freeze dried drugs after 
reconstitution and they reduced the number of particles larger than 5 µm for all products to 0 
to 2 particles/5 mL (Kuramoto et al., 2006). Further, intravenous administration sets with an 
incorporated 15 µm in-line filter significantly reduce the amount of large particles, 
independent of their origin which can be the parenteral solution or administration set (Paolo 
et al., 1990). 
Beside these in-line filters, filter needles can be used to eliminate impurities. For example 
filter needles are able to prevent the aspiration of glass particles from opened glass 
ampoules as shown in several studies (Sabon et al., 1989). However, one other study did not 
find this positive effect, because penetration of the filter by glass particles occurred during 
aspiration (Carbone-Traber and Shanks, 1986). The aspiration technique might influence the 
particle contamination of the aspirated solution (Preston and Hegadoren, 2004). 
Yet, the Centers for Disease Control and Prevention are one example that the use of inline 
filters is not generally recommended. Its decision is based on the fact that total parenteral 
nutrition solutions are already filtered by the pharmacies before they are used in the hospital 
(Allcutt et al., 1983; Kuramoto et al., 2006). The U.S. Food and Drug Administration, the 
National Advisory Group and Standards and Practice guidelines for Parenteral Nutrition and 
the British Pharmaceutical Nutrition Group Working Party recommend a filtration with a 
1.2 µm pore size filter for parenteral nutrition solutions containing a fat emulsion (Ortolano et 
al., 2004). Non lipid total parenteral nutrition solutions shall be administered with a 0.2 µm 
filter (Bethune et al., 2001; Driscoll et al., 1996).  
Particulate matter has a severe impact, which can lead to organ failure, morbidity and 
mortality, particularly in individuals with a disturbed microcirculation, including patients after 
major surgeries, with sepsis, ischemia and other disorders as data implies (Jack et al., 2012; 
Lehr et al., 2002). Especially intensive care and immunosuppressed patients, neonates and 
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children may benefit from a reduction of the particle burden, because they all are exposed to 
a high amount of intravenously administered fluids (Bethune et al., 2001).  
 
Considering the consequences of particle containing drug solutions and the use of filters in 
the clinical practice, the purpose of this review is to provide a comprehensive overview on 
the filtration recommendations for commercial protein drug products, because to our 
knowledge such a broad analysis is so far not available in the literature. Our review shall fill 
this gap by providing important pieces of practical information with a product independent 
view. Because in-line filtration is a controversially discussed routine with high relevance, we 
make several proposals at the end to establish uniform standards for the filtration of protein 
drug products. Overall, we believe that many immunogenicity issues caused by protein drug 
products may be eliminated by in-line filtration. Further, it might be worth to consider a 
change of the overall routine in the field to ensure the highest level of patient safety as 
possible. 
1.2. Filtration of protein drug products 
On the one hand, particles possess the potential to reduce the efficacy or safety of the 
protein drug product or induce immunogenicity (Kessler et al., 2006; Rosenberg, 2006; 
Schellekens and Casadevall, 2004). On the other hand, the usages of filters show positive 
effects. Weighing these two options, it might be beneficial, if protein drug products would be 
filtered prior to administration. Indeed, there exist a number of protein drug products, which 
are filtered during preparation or administration. To identify these drugs, the Rote Liste (Rote 
Liste® Service GmbH Frankfurt/Main, 01/2015, 2013), a register for traded drugs in Germany, 
as well as other sources from the U.S. Food and Drug Administration (U.S. Food and Drug 
Administration, 2014) or European Medicines Agency (European Medicines Agency, 2014) 
were analyzed. In the process, more than 150 protein molecules were found and more than 
320 different marketed formulations of these molecules were investigated. Some of the 
described protein drug products are also listed in publications which deal with filtered drugs 
in general (Chen and Martinez, 1998; Ipema et al., 2012; Turcasso and Bush, 2001; Wolters 
Kluwer Health / Facts and Comparisons, 2007). 
We focused for statistical analysis purposes on all protein drug products registered in the 
Rote Liste because not all marketed products are approved worldwide. Nevertheless, 
Table 1 also includes proteins which are filtered in other countries but are not included into 
the calculation.  
The Rote Liste contains 142 drug substances and 314 marketed products plus their various 
dose variants (Rote Liste® Service GmbH Frankfurt/Main, 01/2015, 2013). The largest class 
of drug molecules is hormones (27.46 %), followed by IgGs (21.13 %), enzymes (16.90 %), 
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cytokines (11.27 %), antihemophilic molecules (7.75 %) and others (Rote Liste® Service 
GmbH Frankfurt/Main, 01/2015, 2013). Considering all the marketed products of these 
molecules, excluding their dose variants, the shares look slightly different. Products with 
hormones lead the market with 40.45 %, followed by IgG (11.46 %), immunoglobulins (9.87 
%), cytokines (8.60 %), enzymes (8.60 %) and antihemophilic (7.96 %) drugs before other 
classes (Rote Liste® Service GmbH Frankfurt/Main, 01/2015, 2013).  
For parenteral administration the dosage forms solution, lyophilisate or suspension are 
interesting. The leading dosage form is solution (54.78 %), followed by lyophilisate (33.12 %) 
and suspensions (7.64 %) (Figure 1) (Rote Liste® Service GmbH Frankfurt/Main, 01/2015, 
2013). The percentage of tablets, capsules and gels are summarized as other forms in 
Figure 1. 
 
 
Figure 1: Share of the dosage forms of all marketed protein products listed in the Rote Liste® (Rote Liste® Service 
GmbH Frankfurt/Main, 01/2015, 2013). 
 
In the following, the most prominent examples of protein drugs with their respective filtration 
instruction are reviewed. As the reader will realize, the instructions are in parts very detailed, 
in other aspects, e.g. filter type or pore size surprisingly wide recommendations are provided. 
Overall, a general picture of the current routine emerges. Table 1 displays a condensed 
overview of the filtered drug products. 
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Table 1: O
verview
 about proteins w
hich are filtered during preparation (P
) or adm
inistration (A
). Their dosage form
 (lyophilisate (L) or solution (S
)) as w
ell as recom
m
ended filter 
pore sizes or filter m
em
branes are stated as far as declared by m
anufacturers or publications. The table provides further im
portant, but not all inform
ation about the indication, 
(soluble) protein concentration and several data about adm
inistration. A
bbreviations: h = hour; m
in = m
inutes; m
ax. = m
axim
um
; i.v. = intravenous; s.c. = subcutaneous; i.m
. = 
intram
uscular. 
 Fusion proteins 
Drug product 
(Trade nam
e) 
Indication 
(Com
pany) 
Dosage 
form
 
Protein concentration 
Route of adm
inistration 
Dosage and frequency of adm
inistration 
Citation 
Filter pore size 
recom
m
endations 
Filter type 
recom
m
endations 
Filter usage 
during P or A 
abatacept  
(O
rencia) 
Adult 
rheum
atoid 
arthritis / Juvenile 
idiopathic arthritis 
(Bristol-M
yers 
Squibb) 
L / S 
after reconstitution: 25 m
g/m
L 
w
eight dependent dose 
initial dose, 2 and 4 w
eeks after initial dose, then 
every 4 w
eeks thereafter over 30 m
in i.v. 
prefilled syringe:125 m
g/m
L 
initial i.v. dose (w
eight dependent), w
ithin a day 
125 m
g s.c., afterw
ards w
eekly 125 m
g s.c.. S
.c. 
only for patients > 18 years 
(O
rencia 
- 
Anhang 
1 
- 
Zusam
m
enfassung 
der 
M
erkm
ale 
des 
Arzneim
ittels, 
accessed 
08/13; 
O
rencia (abatacept) [Package insert], 12/2011) 
0.2 µm
 to 1.2 µm
 
infusion 
set 
w
ith 
filter  
(only infusion) 
 
A 
aflibercept  
(E
ylea™
)  
N
eovascular 
& 
age-related 
m
acular 
degeneration 
(R
egeneron 
Pharm
aceuticals, 
Inc.) 
     
S 
40 m
g/m
L 
2 m
g/0.05 m
L m
onthly for the first 3 m
onths, 
follow
ed 
by 
every 
2 
m
onths 
by 
ophthalm
ic 
intravitreal injection 
(E
ylea™
 
(aflibercept) 
Injection 
[P
ackage 
insert], 
11/2011) 
19 
gauge 
x 
1.5-
inch, 
5 
µm
 
filter 
needle 
 
P 
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ziv-aflibercept 
(Zaltrap
®)  
M
etastatic 
colorectal cancer  
(sanofi-aventis 
U
.S. LLC
) 
S 
stock solution: 25 m
g/m
L 
final concentration: 0.6 to 8 m
g/m
L. 
every 2 w
eeks 4 m
g/kg over 1 h  
(Zaltrap
® 
(ziv-aflibercept) 
[Package 
insert], 
08/2012) 
0.2 µm
 
polyethersulfone  
but no 
polyvinylidene 
fluoride or nylon filter 
A 
belatacept 
(N
ulojix)  
Prophylaxis of 
kidney rejection 
(Bristol-M
yers 
Squibb C
om
pany) 
L 
25 m
g/m
L 
10 m
g/kg over 30 m
inutes on day 1 & 5, end of 
w
eek 2, 4, 8 & 12 
5 m
g/kg on end of w
eek 16 and every 4 w
eeks 
thereafter 
(N
ulojix (belatacept) [Package insert], 04/2013) 
0.2 µm
 to 1.2 µm
 
infusion 
set 
w
ith 
filter  
 
 
A 
   Antibodies or antibody fragm
ents 
Drug product 
(Trade nam
e) 
Indication 
(Com
pany) 
Dosage 
form
 
Protein concentration 
Route of adm
inistration 
Dosage and frequency of adm
inistration 
Citation 
Filter pore size 
recom
m
endations 
Filter type 
recom
m
endations 
Filter usage 
during P or A 
abcixim
ab 
(R
eoPro
®)   
Prevention 
of 
cardiac 
ischem
ic 
com
plications 
(C
entocor 
B.V. 
Leiden) 
S 
2 m
g/m
L 
i.v. bolus w
ith 0.25 m
g/kg 10 to 60 m
in before PC
I 
start; thereafter continuous i.v. infusion of 0.125 
µg/kg/m
in (to m
ax. 10 µg/m
in) for 12 h 
dose is different for unstable angina 
(R
eoPro
® (abcixim
ab) [Package insert], 11/2005) 
0.2 µm
 or 5 µm
 
(preparation) 
0.2 µm
 or 0.22 µm
 
(adm
inistration) 
polyvinylidene 
fluoride filter 
(M
illipore 
SLG
V
025LS or 
SLSV025LS) or 
Abbott #4524 or 
equivalent 
P or A 
cetuxim
ab 
(Erbitux
®)    
H
ead, 
neck, 
colorectal cancer 
(Im
C
lone LLC
) 
   
S 
2 m
g/m
L 
initial dose: 400 m
g/m
2 over 2 h  
w
eekly dose: 250 m
g/m
2 over 1h 
use infusion or syringe pum
p 
m
ax. infusion rate of 10 m
g/m
in 
(Erbitux
® (cetuxim
ab) [Package insert], 08/2013) 
0.22 µm
 
 
A 
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digoxin 
im
m
une 
Fab 
(D
igibind
®)    
D
igoxin antidote 
(G
laxoSm
ithKline 
Australia P
ty Ltd.) 
 
L 
38 m
g/4m
L 
dosage depends on intoxication level  
i.v. over 30 m
in 
(D
igibind 
(D
igoxin 
im
m
une 
Fab) 
[Product 
inform
ation], 08/2008) 
0.22 µm
 
 
A 
gem
tuzum
ab 
ozogam
icin 
(M
ylotarg
®)    
(w
ithdraw
n) 
C
D
33 
positive 
acute 
m
yeloid 
leukem
ia 
(W
yeth 
Pharm
aceuticals 
Inc.) 
L 
1 m
g/m
L 
9 m
g/m
2 over  2 h 
use line only for gem
tuzum
ab ozogam
icin 
(M
ylotarg
® (gem
tuzum
ab ozogam
icin for Injection) 
[Package insert], 04/2010; U
.S. Food and D
rug 
Adm
inistration, 2010) 
0.22 µm
 or 1.2 µm
 
polyethersulfone 
(Supor ®) 
1.2 µm
 
acrylic 
copolym
er 
hydrophilic 
(Versapor ®) 
0.8 µm
 
cellulose 
m
ixed 
ester 
(acetate 
and 
nitrate)   
0.2 µm
 
cellulose 
acetate filter 
A 
 
Yttrium
-90 
ibritum
om
ab 
tiuxetan 
N
on-H
odgkin 
lym
phom
a 
(Spectrum
 
Pharm
aceuticals, 
Inc.) 
S 
3.2 m
g/2 m
L 
platelets concentration dependent:  
0.4 
m
C
i/kg 
or 
0.3 
m
C
i/kg 
Y
-90 
ibritum
om
ab 
tiuxetan on day 7, 8, or 9 after rituxim
ab treatm
ent 
test the w
hole infusion set including the syringe 
and 
filter 
after 
application 
for 
any 
rem
aining 
activity to ensure com
plete drug delivery  
(Zevalin
®)     (Fink-Bennett and Thom
as, 2003; 
H
agenbeek 
and 
Lew
ington, 
2005; 
Zevalin 
- 
Anhang 1 - Zusam
m
enfassung der M
erkm
ale des 
Arzneim
ittels, 
accessed 
08/2013; 
Zevalin
® 
(ibritum
om
ab tiuxetan) [Package insert], 11/2011) 
0.2 µm
 
w
et filter w
ith norm
al 
saline prior 
adm
inistration 
to 
reduce any residual 
activity 
of 
the 
drug 
on the filter 
flush the line w
ith at 
least 
10 m
L 
norm
al 
saline after injection 
to 
prevent 
an 
inadequate 
dosing 
due to drug retention 
by the filter   
  
A 
Particle contam
ination of parenteralia and in-line filtration of proteinaceous drugs 
17 
 
 
inflixim
ab 
(R
em
icade
®)  
Arthritis, psoriasis,  
C
rohn’s 
disease, 
ulcerative colitis & 
others 
(Janssen Biologics 
B.V. Leiden) 
L 
10 m
g/m
L 
rheum
atoid arthritis: 3 m
g/kg 
all other indications: 5 m
g/kg 
over 2 h 
Initial dose, 2 & 6 w
eeks after initial dose, all 6 to 8 
w
eeks 
afterw
ards 
depending 
on 
disease 
progression 
(R
em
icade
® (inflixim
ab) [Package insert], 06/2013) 
≤1.2 µm
 
infusion set w
ith in-
line filter 
A 
ipilim
um
ab 
(Yervoy
®)    
M
etastatic 
m
elanom
a 
(Bristol-M
yers 
Squibb C
om
pany) 
S 
5 m
g/m
L 
final concentration 1 to 2 m
g/m
L 
4 tim
es 3 m
g/kg over 90 m
in every 3 w
eeks 
flush i.v. line after adm
inistration w
ith an isotone 
sodium
 chloride solution or w
ith a 5 %
 dextrose 
injection 
(Bristol-M
yers Squibb, 2011; Knauth et al., 2010; 
Yervoy
® (ipilim
um
ab) [Package insert], 05/2013) 
0.2 µm
 
to 
1.2 µm
 
polyethersulfone  
0.2 µm
 nylon filter 
A 
 
m
urom
onab-CD3 
(O
rthoclone
® 
O
kt 3)            
Treatm
ent 
of 
different 
allograft 
rejections 
(Janssen-C
ilag 
G
m
bH
) 
 
 S 
1 m
g/m
L 
5 m
g/day as bolus over ≤ 1 m
in for 10 to 14 days 
children dose differs 
(O
rthoclone
® O
kt 3 [Package insert], 04/1998) 
0.2 or 0.22 µm
 
 
P 
ofatum
um
ab 
(Arzerra)  
C
hronic 
lym
phocytic 
leukem
ia 
(G
laxoSm
ith- 
Kline) 
S 
20 m
g/m
L concentrate 
first dose: 300 m
g 
follow
ing doses: 2 g  
8 tim
es w
eekly, break for 4/5 w
eeks before 4 tim
es 
w
eekly 
infusion rate starts w
ith 12 m
L/h but changes w
ith 
duration and frequency 
(Arzerra 
- 
Anhang 
1 
- 
Zusam
m
enfassung 
der 
M
erkm
ale des Arzneim
ittels, accessed 08/2013) 
 
0.2 µm
 
 
A 
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panitum
um
ab 
(Vectibix
®)     
M
etastatic 
colorectal 
carcinom
a 
(Am
gen Inc.) 
S 
20 m
g/m
L 
every 2 w
eeks:  
6 m
g/kg over 60 m
in (≤ 1000 m
g) or 90 m
in (> 
1000 m
g) w
ith infusion pum
p 
(Vectibix
® 
(panitum
um
ab) 
[Package 
insert], 
06/2013) 
0.2 or 0.22 µm
 
 
P 
ranibizum
ab 
(Lucentis
®)  
D
ifferent 
ophthalm
ic 
diseases 
(G
enentech Inc.) 
S 
10 
m
g/m
L 
(ranibizum
ab 
0.5 
m
g) 
or 
6 
m
g/m
L 
(ranibizum
ab 0.3 m
g)  
m
onthly ophthalm
ic intravitreal injections of 0.5 m
g 
(0.05 
m
L) 
or 
0.3 
m
g 
(0.05 
m
L) 
(disease 
dependent) 
(Lucentis
® 
(ranibizum
ab 
injection) 
[Package 
insert], 02/2013; M
ontero et al., 2012) 
5 µm
, 
19 
gauge 
filter 
needle 
supplied 
by 
m
anufacturer 
filter needle prevents 
injection 
of 
rubber 
particles into the eye 
P 
siltuxim
ab 
(Sylvant ®)  
M
ulticentric 
C
astlem
an 
disease 
(Janssen 
Biotech 
Inc. 
L 
20 m
g/m
L  
every 3 w
eeks: 11 m
g/kg over 1 h 
use 
of 
a 
polyvinyl 
chloride 
or 
polyurethane 
adm
inistration set 
(Sylvant ® (siltuxim
ab) [Package Insert], 06/2014) 
0.2 µm
  
polyethersulfone 
A 
tositum
om
ab and 
Iodine 
I 131 
tositum
om
ab 
(Bexxar)        
N
on-H
odgkin 
lym
phom
a 
(G
laxoSm
ith-
Kline) 
S 
Tositum
om
ab 14 m
g/m
L 
Iodine 
I 131 
tositum
om
ab 
solution: 
different 
concentrations available  
day 0: 450 m
g protein over 60 m
in follow
ed by 5 
m
C
i I-131 and 35 m
g protein over 20 m
in 
day 6 or 7: 75 cG
y total body dose  
day 7 to 14: 450 m
g protein over 60 m
in follow
ed 
by therapeutic dose C
i and 35 m
g protein over 20 
m
in 
(Bexxar 
(tositum
om
ab 
and 
iodine 
I 
131 
tositum
om
ab) [Package insert], 05/2013) 
    
0.22 µm
 
use 
sam
e 
filter 
for 
non- 
and 
labeled 
antibody 
otherw
ise 
possible 
drug loss up to 7 %
 
A 
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trastuzum
ab 
em
tansine 
(Kadcyla
®)    
M
etastatic 
breast 
cancer 
(G
enentech Inc.) 
L 
20 m
g/m
L 
every 3 w
eeks until disease progression or high 
toxicity: 3.6 m
g/kg  
first dose over 90 m
in 
subsequent ones over 30 m
in  
(Kadcyla
® - Anhang 1 - Zusam
m
enfassung der 
M
erkm
ale des Arzneim
ittels, accessed 07/2014; 
Kadcyla
® (ado-trastuzum
ab em
tansine) [Package 
insert], 2014) 
0.22 µm
 
polyethersulfone 
U
SA: filter is alw
ays 
applied 
G
erm
any: 
filter 
usage only if diluted 
w
ith a 0.9 %
 sodium
 
chloride solution, but 
not 
w
ith 
a 
0.45 
%
 
solution  
A 
   Im
m
une globulin 
Drug product  
(Trade nam
e) 
Indication 
(Com
pany) 
Dosage 
form
 
Protein concentration 
Route of adm
inistration 
Dosage and frequency of adm
inistration 
Citation 
Filter pore size 
recom
m
endations 
Filter type 
recom
m
endations 
Filter usage 
during P or A 
antithym
ocyte 
globulin 
(Atgam
®)         
(Pharm
acia 
& 
U
pjohn 
C
om
pany 
D
ivision 
of 
Pfizer 
Inc.)     
S 
inform
ation in publications not available 
(Atgam
® [Package insert], 11/2005) 
0.2 to 1 µm
 
 
A 
Thym
oglobulin
®
* 
Anti-hum
an-
thym
ozyten-
im
m
unglobulin 
(G
enzym
e 
C
orporation) 
L 
5 m
g/m
L 
daily for 7 to 14 days: 1.5 m
g/kg  
initial dose: over ≥ 6 h  
subsequent dose: over ≥ 4 h  
(different instructions in G
erm
any) 
(Thym
oglobulin Anti-thym
ocyte G
lobulin (R
abbit) 
[Package 
insert], 
09/2008; 
Thym
oglobuline 
5 
m
g/m
l [Package insert], 01/2013) 
   
0.22 µm
 
 
A 
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botulism
 im
m
une 
globulin IV
* 
(BabyBIG
®)          
Infant 
botulism
 
caused 
by 
toxin 
types A or B 
(C
alifornia 
D
epartm
ent 
of 
Public H
ealth) 
L 
50 m
g/m
L  
2.0 m
L/kg (100 m
g/kg) over 0.5 m
L/kg/h for 15 m
in 
before 
increase 
(if 
no 
adverse 
effects) 
to 
1.0 
m
L/kg/h 
(BabyBIG
® [Package insert], 09/2009; Botulism
us-
Antitoxin B
ehring [Package insert], 10/2011) 
18 µm
 
in-line or syringe-tip 
sterile, 
disposable 
filter 
 
A 
cytom
egalo-virus 
im
m
une 
globulin* 
(C
ytoG
am
®)        
Prophylaxis 
of 
cytom
egalovirus 
disease 
(C
SL B
ehring AG
) 
S 
50 ± 10 m
g/m
L 
m
ax. dosage 150 m
g/kg  
72 
h 
and 
8 
 
tim
es 
every 
2 
w
eeks 
post 
transplantation 
initial infusion rate of 15 m
g/kg/h increases to 30 
and 60 m
g/kg/h in 2 steps after certain periods of 
tim
e 
(C
ytoG
am
® 
C
ytom
egalovirus 
Im
m
une 
G
lobulin 
Intravenous (H
um
an) [Package insert], 03/2007; 
C
ytotect ® C
P Biotest 100 E/m
l, 04/2013) 
15 µm
 
0.2 µm
 
 
A 
im
m
une globulin 
IV 
 
S or L 
please consult package inserts 
(C
arim
une
® 
N
F 
[Package 
insert], 
10/2008; 
G
am
m
agard Liquid
®  [Package insert], 06/2012; 
G
am
m
agard S/D
® Im
m
une G
lobulin Intravenous 
(H
um
an) IgA
 less than or equal to 1 μg/m
L in a 5%
 
Solution [Package insert], 12/2011; G
am
m
agard 
S/D
® Im
m
une G
lobulin Intravenous (H
um
an) IgA 
less than or equal to 2.2 μg/m
L in a 5%
 S
olution 
[Package insert], 12/2011; G
am
unex
®-C
 [Package 
insert], 
06/2012; 
O
ctagam
® 
[Package 
insert], 
12/2005; 
Privigen 
[Package 
insert], 
02/2013; 
Section S: Blood Product O
verview
 - G
am
unex®
 
Intravenous Im
m
une G
lobulin (IVIG
) – 10%
 C
BS 
IG
IV-nex, 07/2009) 
15 µm
 
(stated 
for 
som
e 
im
m
une 
globulin IV drugs) 
filter 
incorporated 
into the infusion set 
and 
provided 
by 
distributer 
filter usage optional 
for 
G
am
m
agard 
Liquid
®
 
use 0.2 to 200 µm
 
filter for O
ctagam
® if 
adm
inistered 
w
ith 
infusion set 
A 
* no filtration in G
erm
an package insert/inform
ation sheet for professionals stated 
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 Horm
ones 
regular insulin  
diabetes 
S 
exact product nam
e unknow
n 
12 %
, respectively, 4 %
 insulin binds in the first 
150 m
L of a 5 %
 dextrose or norm
al saline solution 
steps 
(Trissel, 2007) 
 
Abbott Ivex integral 
filter 
and 
extension 
sets: 
m
odified 
cellulose ester filters 
A 
   Enzym
es 
Drug product  
(Trade nam
e) 
Indication 
(Com
pany) 
Dosage 
form
 
Protein concentration 
Route of adm
inistration 
Dosage and frequency of adm
inistration 
Citation 
Filter pore size 
recom
m
endations 
Filter type 
recom
m
endations 
Filter usage 
during P or A 
Alpha-1 
proteinase 
inhibitors: 
Prolastin
®  
(Talecris 
Biotherapeutics 
Inc.) 
Zem
aira
®  
Alpha-1-antitrypsin 
deficiency 
(C
SL 
Behring 
LLC
) 
   L    L 
   ≥ 20 m
g/m
L 
(Prolastin
® [Package insert], 06/2008) 
  50 m
g/m
L 
both drugs: 
w
eekly 60 m
g/kg over 30 m
in 
at a rate of ≥ 0.08 m
l/kg/m
in  
(R
em
edy H
ealth M
edia LLC
; Zem
aira
® [Package 
insert], 04/2013) 
   5 µm
 
   5 µm
 
   filter needle 
supplied by 
m
anufacturer 
 in-line 
filter 
in 
an 
adm
inistration set 
   P    A 
agalsidase beta 
(Fabrazym
e
®)       
Fabry disease 
(G
enzym
e 
C
orporation) 
  
L 
5 m
g/m
L 
every tw
o w
eeks 1 m
g/kg  
infusion rate ≤ 0.25 m
g/m
in (15 m
g/h) 
(Fabrazym
e
® (agalsidase beta) [Package insert], 
2010) 
0.2 µm
 
filter needles are not 
recom
m
ended 
for 
preparation 
A 
 
C
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alglucosidase 
alfa 
(M
yozym
e
®)         
Pom
pe disease 
(G
enzym
e 
C
orporation) 
 
L 
5 m
g/m
L 
every 2 w
eeks 20 m
g/kg over 4 h w
ith pum
p 
several steps for infusion volum
es and rates 
(M
yozym
e
® (alglucosidase alfa) [Package insert], 
2012) 
0.2 µm
 
filter needles are not 
recom
m
ended 
for 
preparation 
A 
asparaginase 
(Elspar ®)   
Acute 
lym
phoblastic 
leukem
ia 
(Lundbeck)            
 
L 
5000 I.U
/m
L i.m
. or 2000 I.U
./m
L i.v. 
3 tim
es w
eekly 6000 I.U
./m
2 
i.m
. single injection m
ax. 2 m
L; m
ultiple injection 
sites by volum
e > 2 m
L 
infusion over ≥ 30 m
in  
use reconstituted asparaginase 
im
m
ediately, 
otherw
ise a sm
all am
ount of gelatinous fiber-like 
particles can form
 
(Elspar ® (asparaginase) [Package insert], 07/2013; 
Ipem
a et al., 2012; Trissel, 2007) 
5 µm
 
no reduction of drug 
potency w
ith a 5 µm
 
filter, 
but 
 
possible 
drug loss w
ith a 0.2 
µm
 filter 
A 
elosulfase alfa 
(V
im
izim
™
)          
M
ucopoly-
saccharidosis type 
IVA 
(BioM
arin 
Pharm
aceutical 
Inc.) 
S 
1 m
g/m
L 
w
eekly 2 m
g/kg over ≥ 3.5 to 4.5 h depending on 
volum
e w
ith a pum
p  
duration and patient w
eight dependent rate 
(V
im
izim
™
 (elosulfase alfa) [P
roduct M
onograph], 
2014) 
0.2 µm
 
infusion set w
ith an 
incorporated filter 
A 
galsulfase 
(N
aglazym
e
®)          
M
ucopoly-
saccharidosis VI 
(BioM
arin 
Pharm
aceutical 
Inc.) 
   
S 
1 m
g/m
L 
w
eekly 1 m
g/kg over ≥ 4 h w
ith pum
p volum
e and 
duration dependent rates 
(Ipem
a 
et 
al., 
2012; 
N
aglazym
e
® 
D
osing 
& 
Adm
inistration G
uide, 2011) 
0.2 µm
 
polyvinyl 
chloride 
infusion set w
ith an 
incorporated filter 
A 
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idursulfase 
(Elaprase®
)  
H
unter syndrom
e  
S 
2 m
g/m
L 
w
eekly 0.5 m
g/kg over 3 h 
rate can be accelerated/decreased depending on 
hypersensitivity reactions 
(Elaprase
® (idursulfase) [Package insert], 06/2013) 
 
0.2 µm
 
infusion set w
ith an 
incorporated filter 
A 
im
iglucerase 
(C
erezym
e
®)      
G
aucher disease 
(Shire 
H
um
an 
G
enetic Therapies 
Inc.) 
L 
40 U
/m
L 
patient individual dosage betw
een 
3 tim
es w
eekly 2.5 U
/kg to 60 U
/kg once every 2 
w
eeks over 1 to 2 h 
(C
erezym
e
® (im
iglucerase for injection) [Package 
insert], accessed 08/2013) 
0.2 µm
 
 
A 
laronidase 
(Aldurazym
e)      
M
ucopoly-
saccharidosis I 
& 
others  
(G
enzym
e 
C
orporation) 
S 
2.9 m
g/5 m
L  
w
eekly 0.58 m
g/kg over 3 to 4 h at a rate of ≤ 200 
µg/kg/h 
use low
 protein binding container 
(Aldurazym
e 
(laronidase) 
[Package 
insert], 
04/2013) 
0.2 µm
 
no 
usage 
of 
filter 
needles 
due 
to 
possible 
agitation 
use 
low
 
protein 
binding 
infusion 
set 
w
ith in-line filter 
A 
Protein C 
(C
eprotin
®)  
C
ongenital 
Protein 
C
 
deficiency 
(Baxter H
ealthcare 
C
orporation) 
L 
100 IU
/m
L 
circum
stance dependent dose m
aintenance dose 
is 45 to 60 IU
/kg 
every 6 or 12 h  
infusion rate of 2 m
L/m
in or if body w
eight < 10 kg 
≤ 0.2 m
L/kg/m
in 
(C
eprotin
® [Package insert], 12/2011) 
 
filter needle 
P 
streptokinase     
throm
bolytic 
enzym
e 
L 
inform
ation in publications not available 
(C
hen and M
artinez, 1998; Trissel, 2007; W
olters 
Kluw
er H
ealth / Facts and C
om
parisons, 2007) 
≥ 0.8 µm
 
 
P 
taliglucerase alfa 
(E
lelyso™
)  
G
aucher disease 
(Pfizer 
Labs 
D
ivision 
of 
Pfizer 
Inc.) 
L 
200 U
nits/5 m
L 
w
eekly 60 units/kg over ≥ 60 m
in 
adult rate: 1.2 m
L/m
in (m
ax. 2.2 m
L/m
in) 
pediatric rate: 1 m
L/m
in (m
ax. 2 m
L/m
in) 
(E
lelyso™
 
(taliglucerase 
alfa) 
[P
ackage 
insert], 
09/2014) 
0.2 µm
 
 
A 
 
C
hapter 1 
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urokinase 
(Abbokinase
®)      
Lysis of pulm
onary 
em
boli 
(Abbott 
Laboratories) 
L 
50000 I.U
./m
L  
w
eight dependent concentration  
initial rate: 90 m
L/h for 10 m
in 
rate for 12 h period: 15 m
L/h 
(Abbokinase
® [Package insert], 10/2002) 
≤ 0.45 µm
 
cellulose 
m
em
brane 
filter 
A 
velaglucerase 
alfa 
(Vpriv
®)  
G
aucher disease 
(Shire 
H
um
an 
G
enetic 
Therapies, Inc.)  
L 
100 U
nits/m
L 
w
eekly 15 to 60 units/kg over 60 m
in 
(Vpriv
® (velaglucerase alfa for injection) [Package 
insert], 08/2013) 
0.2 µm
 
 
A 
  
 
 
 
 
 
Cytokines 
m
olgram
ostim
 
(M
acrogen™
)  
C
ancer 
chem
otherapy/ 
bone 
m
arrow
 
transplantation 
(Zenotech 
Laboratories 
Lim
ited) 
L 
4.4x10
6 I.U
./m
L (equivalent to 400 m
g) 
cancer: 5-10 µg/kg s.c for 7 to 10 days  
transplantation: 10 µg/kg i.v. 4 to 6 h; m
ax. duration 
30 days 
(M
olgram
ostim
 
M
acrogen™
 
 
[P
ackage 
insert], 
01/2006) 
0.2 µm
 
(only 
infusion not s.c.) 
 
A 
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Antihem
ophilic drugs 
D
rugs for blood coagulation 
For all antihem
ophilic drugs: disease progression depending dose and frequencies 
Drug product 
(Trade nam
e) 
Indication 
(Com
pany) 
Dosage 
form
 
Protein concentration 
Route of adm
inistration 
Dosage and frequency of adm
inistration 
Citation 
Filter pore size 
recom
m
endations 
Filter type 
recom
m
endations 
Filter usage 
during P or A 
Advate
®  
(Baxter 
H
ealthcare 
C
orporation) 
L 
250/500/1000/1500/2000/3000/4000 I.U
./5 m
L 
250/500/1000/1500 I.U
./2 m
L  
bolus infusion: ≤ 5 m
in (m
ax. infusion rate  
10 m
L/m
in) 
(Advate 250 IU
 pow
der and solvent for solution for 
injection 
- 
AN
N
EX 
I 
- 
Sum
m
ary 
of 
product 
characteristics, 03/2009; Advate [Package insert], 
06/2013, 07/2012) 
 
filter device 
P 
AlphaNine
® SD 
(G
rifols 
Biologicals Inc.)  
L 
500/1000/1500 I.U
. FIX/10 m
L 
(AlphaN
ine
® SD
 [Package insert], 01/2013) 
 
M
ix2Vial TM 
filter 
transfer device 
P 
Helixate FS
®  
(C
SL 
Behring 
LLC
) 
L 
250/500/1000 I.U
./2.5 m
L  
2000/3000 I.U
./5m
L 
patient dependent injection rate over 1 to  
15 m
in 
(H
elixate FS [Package insert], 05/2012) 
 
M
ix2Vial TM 
filter 
transfer device 
P 
Hem
ofil-M
® 
(Baxter 
H
ealthcare 
C
orporation) 
L 
250/500/1000/1700 I.U
./10 m
L 
injection rate: 10 m
L/m
in 
use of disposable plastic syringes due to sorption 
problem
s w
ith all-glass syringes 
(H
em
ofil M
 [Package insert], 11/2010) 
 
 
filter needle 
P 
Hum
ate-P
®  
(C
SL 
Behring 
G
m
bH
) 
L 
VW
F:R
C
o/vial 600 I.U
. / FVIII/vial 250 I.U
. / 5 m
L 
VW
F:R
C
o/vial 1200 I.U
. / FVIII/vial 500 I.U
./ 10 m
L 
VW
F:R
C
o/vial 2400 I.U
. / FVIII/vial 1000 I.U
./15 m
L 
infusion rate: ≤ 4 m
L/m
in 
(H
um
ate-P
® [Package insert], 05/2012) 
 
 
M
ix2Vial TM 
filter 
transfer device 
P 
 
C
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Koate
®-DVI  
(Kedrion 
Biopharm
a Inc.) 
L 
250/500 I.U
./5m
L 
1000 I.U
./10 m
L 
syringe injection or drip infusion  
patient dependent rate over 5 to 10 m
in 
(Antihem
ophilic 
Factor 
(H
um
an) 
Koate-D
VI 
[Package insert], 08/2012) 
 
 
filter needle 
P 
Kogenate FS
®  
(Bayer 
H
ealthC
are LLC
) 
L 
250/500/1000/2000/3000 I.U
.  
patient dependent injection rate over 1 to 15 m
in 
(Kogenate FS [Package insert], 01/2013) 
 
filter needle 
AND
 
in-line 
filter 
(provided 
w
ith 
adm
inistration set) 
otherw
ise 
use 
a 
com
patible filter 
P AND
 A
 
M
onarc-M
TM
  
(Baxter 
H
ealthcare 
C
orporation) 
L 
injection rate: ≤ 10 m
L/m
in 
use of disposable plastic syringes due to sorption 
problem
s w
ith all-glass syringes 
(M
onarc-M
TM [Package insert], 04/2005) 
 
filter needle 
P 
M
onoclate-P
®  
(C
SL 
Behring 
LLC
) 
L 
100 I.U
./ m
L  or 150 I.U
./ m
L 
injection rate: 2 m
L/m
in 
use of disposable plastic syringes due to sorption 
problem
s w
ith all-glass syringes 
(M
onoclate-P
® [Package insert], 10/2010) 
 
5 µm
 
filter needle or 
vented filter spike 
P 
NovoEight ®  
(N
ovo 
N
ordisk 
A/S) 
 
L 
250/500/1000/1500/2000/3000 I.U
. corresponds to  
62.5/125/250/375/500/750 I.U
./m
L  
slow
 injection over 2 to 5 m
in  
(N
ovoEight®
 
- 
AN
N
EX 
I 
- 
Sum
m
ary 
of 
product 
characteristics 
accessed 
07/2014; 
N
ovoEight®
 
Antihem
ophilic 
Factor 
(R
ecom
binant) 
[Package 
insert], accessed 07/2014) 
     
25 µm
 
vial adapter 
P 
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Hum
an 
Prothrom
bin 
Com
plex 
Beriplex
® 
P/N
 
250/500/1000  
(C
SL 
Behring 
G
m
bH
) 
   octaplex
®
  
(O
ctapharm
a 
Pharm
azeutika 
Produktionsges. 
m
.b.H
) 
   L       L 
   total protein am
ount: 6 to 14 m
g/m
L 
m
ax. dose: 5000 I.U
. 
injection rate: 8 m
L/m
in 
(G
ebrauchsinform
ation: 
Inform
ation 
für 
den 
Anw
ender Beriplex
® P/N
 250/500/1000, 01/2013)  
 total protein am
ount: 13 to 41 m
g/m
L 
injection rate: at beginning 1 m
L/m
in follow
ed by 2 to 
3 m
L/m
in 
(Product M
onograph octaplex
®, 08/2014) 
 
   M
ix2Vial TM 
filter 
transfer device 
     M
ix2Vial TM 
filter 
transfer device 
   P       P 
Antihem
ophilic drugs registered in Germ
any (17 of 25 are filtered) 
Beriate
® 
250/500/1000/ 
2000 
(C
SL 
Behring 
G
m
bH
) 
L 
100 I.U
./m
l or 200 I.U
./m
l 
slow
 injection 
(Beriate
® 
250/500/1000/2000 
Fachinform
ation, 
05/2014; Beriate
® [Package insert], 12/2011) 
 
M
ix2Vial TM 
filter 
transfer device 
P 
Berinin
® 
P 
300/600/1200  
(C
SL 
Behring 
G
m
bH
) 
L 
120 I.U
./m
l 
injection or infusion rate: ≤ 2 m
L/m
in 
(G
ebrauchsinform
ation: 
Inform
ation 
für 
den 
Anw
ender Berinin®
 P 300/600/1200, 08/2011) 
 
M
ix2Vial TM 
filter 
transfer device 
P 
Fanhdi ®  
(G
rifols 
D
eutschland 
G
m
bH
) 
L 
250/500/1000 
I.U
./10 
m
L 
or 
1500 
I.U
./15 
m
L 
injection rate: 3 m
l/m
in (m
ax. 10 m
L/m
in) 
(Fanhdi ® [Package insert], 09/2011) 
 
filter 
P 
Fibrogam
m
in
® 
250/1250  
(C
SL 
Behring 
G
m
bH
) 
L 
250 I.U
./4 m
L or 1250 I.U
./20 m
L 
injection or infusion rate: ≤ 4 m
L/m
in  
(Fibrogam
m
in
® 
250/1250 
G
ebrauchsinform
ation 
und Fachinform
ation, 05/2013) 
 
M
ix2Vial TM 
filter 
transfer device 
P 
Haem
onine
® 
250/500/1000  
L 
50 I.U
./m
L or 100 I.U
./m
L 
injection rate: 2 to 3 m
L/m
in (m
ax. 5 m
L/m
in) 
 
transfer system
 w
ith 
integrated filter 
P 
 
C
hapter 1 
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(Biotest 
Pharm
a 
G
m
bH
) 
(G
ebrauchsinform
ation: 
Inform
ation 
für 
den 
Anw
ender 
H
aem
onine®
 
250, 
03/2009; 
H
aem
onine
® 500/1000 Fachinform
ation, 04/2013) 
Im
m
useven 
(Baxter 
D
eutschland 
G
m
bH
)  
L 
60 I.U
./m
l  
injection rate: 2 m
l/m
in 
(Im
m
useven Fachinform
ation, 08/2013) 
 
filter needle 
P 
M
ononine
® 
1000 I.U.  
(C
SL 
Behring 
G
m
bH
) 
L 
100 I.U
./m
l 
bolus injection: 2 m
l/m
in 
infusion over hours or days 
(M
ononine
® 1000 I.E. [Package insert], 08/2007) 
 
filter 
transfer 
set 
20/13 
P 
Octanate
® 
250/500/1000  
(O
C
TAPH
AR
M
A 
G
m
bH
) 
L 
O
ctanate 250: 50 I.U
./m
l 
O
ctanate 500: 100 I.U
./m
l 
O
ctanate 1000: 200 I.U
./m
l 
injection rate: 2 to 3 m
L/m
in 
(O
ctanate 250/500/1000 [Package insert], 05/2011) 
 
 
filter 
P 
Recom
binate
® 
1000  
(Baxter 
H
ealthcare 
C
orporation) 
L 
100 I.U
./m
L 
injection rate: 10 m
L/m
in 
(G
ebrauchsinform
ation: 
Inform
ation 
für 
den 
Anw
ender 
R
ecom
binate 
Antihäm
ophilie 
Faktor 
(rekom
binant) 
1000, 
07/2012; 
R
ecom
binate
® 
[Package insert], 12/2010) 
 
BAX
JEC
T II 
P 
  Antithrom
bin substances 
Inhibitor of blood coagulation 
Drug product 
(Trade nam
e) 
Indication 
(Com
pany) 
Dosage 
form
 
Protein concentration 
Route of adm
inistration 
Dosage and frequency of adm
inistration 
Citation 
Filter pore size 
recom
m
endations 
Filter type 
recom
m
endations 
Filter usage 
during P or A 
Throm
bate III ®  
(G
rifols 
Therapeutics 
Inc.) 
L 
500 I.U
./10 m
L 
individual doses over 10 to 20 m
in  
(Antithrom
bin III (H
um
an) Throm
bate III ® [Package 
insert], 10/2012) 
 
filter needle 
P 
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recom
binant 
antithrom
bin 
(ATryn
®)  
(G
TC
 
Biotherapeutics 
Inc.)        
L 
1750 I.U
./10 m
L  
individual doses 
15 m
in initial dose follow
ed by continuous infusion 
(ATryn
®  [Package insert], 11/2010) 
0.22 µm
 
infusion set w
ith filter 
A 
   
 
Plasm
a protein Album
in 
H
ypovolem
ia, hypoalbum
inem
ia, cardiopulm
onary bypass surgery & others 
D
osage is patient dependent 
Drug product 
(Trade nam
e) 
Indication 
(Com
pany) 
Dosage 
form
 
Protein concentration 
Route of adm
inistration 
Dosage and frequency of adm
inistration 
Citation 
Filter pore size 
recom
m
endations 
Filter type 
recom
m
endations 
Filter usage 
during P or A 
Bum
inate
® 5 %
  
(Baxter 
H
ealthcare 
C
orporation) 
S 
5 g/100 m
L of album
in 
instructions printed on adm
inistration set container 
(Bum
inate
® 5%
 [Package insert], 09/2009) 
≤ 15 µm
 
integrate in-line filter 
in adm
inistration set 
A 
Flexbum
in
®
 
25 %
  
(Baxter 
H
ealthcare 
C
orporation) 
S 
25 g/100 m
L of album
in 
(Flexbum
in
® 25%
 [Package insert], 09/2009) 
≤ 15 µm
 
integrate in-line filter 
in adm
inistration set 
A 
Plasbum
in
®-5*  
(G
rifols 
Therapeutics 
Inc.) 
S 
Plasbum
in
®-5: 
2.5g/50 
m
L 
or 
12.5g/250 
m
L 
of 
album
in 
infusion rate: m
ax. 5 m
L/m
in 
(G
ebrauchsinform
ation 
und 
Fachinform
ation 
Plasbum
in®
 
20 
[Package 
insert], 
10/2011; 
Plasbum
in
®-5 [Package insert], 12/2011) 
 
filter needle 
A 
* no filtration in G
erm
an package insert stated 
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For a small number of proteins an explicit non-filtration statement exists, These proteins are 
etanercept (Enbrel® (etanercept) [Package insert], 06/2013), Gamunex® intravenous immune 
globulin (Section S: Blood Product Overview - Gamunex® Intravenous Immune Globulin 
(IVIG) – 10% CBS IGIV-nex, 07/2009), rasburicase (Elitek® (rasburicase) [Package insert], 
10/2009), palifermin (Kepivance™ (palifermin) [Package insert], 02/2013), aldesleukin 
(Proleukin® (aldesleukin) [Package insert], 07/2012) and sargramostim (Leukine 
Sargramostin [Package insert], 06/2002). Possible adsorption of the drug onto the filter might 
be possible for sargramostim (Trissel, 2007). 
Proteins which shall not be filtered are listed in Table 2. 
 
Table 2: The following listed protein drug products should not be filtered during preparation or administration 
 
NO filtration of the following drug products 
etanercept (Enbrel®) (Immunex Corporation) 
Gamunex® intravenous immune globulin (Talecris) 
rasburicase (Elitek®) (Sanofi-Aventis U.S. LLC) 
palifermin (Kepivance™) (A. Menarini Australia Pty Ltd) 
aldesleukin (Proleukin®) (Prometheus Laboratories Inc.) 
sargramostim (Leukine Sargramostin) (Berlex Laboratories Inc.) 
 
 
Table 3 shows a large group of products for which no data on filtration is available.  
 
Table 3: For a large number of proteins a filtration recommendation cannot be found. The list is not complete. 
 
No filtration recommendation available 
adalimumab (AbbVie Inc.) insulin lispro (Lilly USA, LLC) 
alipogen tiparvovec  
(uniQure biopharma B.V.) 
interferon alfa-2a  
(Roche) 
anakinra  
(Swedish Orphan Biovitrum AB (publ)) 
interferon beta-1a  
(Biogen Idec.) 
basiliximab  
(Novartis Pharmaceuticals Corporation) 
interferon alfa-2b  
(Schering Corporation) 
belimumab  
(GlaxoSmithKline Manufacturing SpA) 
interferon beta-1b (Novartis Pharmaceuticals 
Corporation) 
bevacizumab  
(Genentech Inc.) 
interferon gamma-1b  
(Vidara Therapeutics Inc.) 
brentuximab vedotin (Seattle Genetics Inc.)  
lenograstim (Chugai Pharmaceuticals Co. 
Ltd) 
canakinumab  
(Novartis Pharmaceuticals Corporation) 
liraglutid  
(Novo Nordisk A/S) 
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Table 3 continued 
catridecacog (Novo Nordisk A/S) lutropin alfa (EMD Serono Inc.) 
certolizumab pegol (UCB Inc.) mecasermin (Ipsen Pharma) 
choriogonadotropin alfa  
(EMD Serono Inc.) 
methoxy polyethylene glycol-epoetin beta 
(Roche Products Pty Limited) 
conestat alfa (Pharming Group N.V.) moroctocog alfa (Pfizer Limited) 
corifollitropin alfa (N.V. Organon) natalizumab (Biogen Idec Inc.) 
darbepoetin alfa (Amgen Inc.) nonacog alfa (Pfizer Limited) 
denosumab (Amgen Inc.) ocriplasmin (ThromboGenics Inc.) 
desirudin (Canyon Pharmaceuticals Inc.) omalizumab (Genentech Inc.) 
dornase alfa (Genentech Inc.) palivizumab (MedImmune LLC) 
dibotermin alfa (Medtronic BioPharma B.V.) pegfilgrastim (Amgen Inc.)  
eculizumab (Alexion Pharmaceuticals Inc.) peginterferon alfa-2a (Genentech Inc.) 
epoetin alfa (Janssen-Cilag Pty Ltd) peginterferon alfa-2b (Schering Corporation) 
epoetin beta (Roche Pharma AG) peginterferon beta-1a (Biogen Idec Inc.) 
epoetin theta (ratiopharm GmbH) pegloticase (Crealta Pharmaceuticals LLC) 
epoetin-zeta (Biosimilar)  
(HOSPIRA Enterprises B.V.) 
pegvisomant  
(Pharmacia & Upjohn Co) 
eptacog alfa (recombinant Factor VII) (Novo 
Nordisk A/S) 
pertuzumab  
(Genentech Inc.) 
eptotermin alfa  
(Olympus Biotech International Limited) 
rituximab  
(Genentech Inc.) 
factor VIII romiplostim (Amgen Inc.) 
filgrastim (G-CSF) (Amgen Inc.) simoctocog alfa (Octapharma AB) 
follitropin alfa 
 (EMD Serono Inc.) 
somatropin  
(Pharmacia & Upjohn Co) 
follitropin alfa/Lutropin alfa  
(Merck Serono Europe Limited) 
tasonermin  
(Boehringer Ingelheim Internation GmbH) 
follitropin beta (Merck Sharp & Dohme 
Corp.) teduglutid (Hospira Inc.) 
glucagon 
(Novo Nordisk Pharmaceuticals Pty Ltd ) 
tenecteplase  
(Genentech Inc.) 
golimumab (Janssen Biotech Inc.) teriparatid (Lilly USA LLC) 
insulin aspart (Novo Nordisk Canada Inc.) thyrotropin alfa (Genzyme Canada) 
insulin degludec/ insulin aspart  
(Novo Nordisk A/S) 
tocilizumab  
(Genentech Inc.) 
insulin detemir (Novo Nordisk A/S) trastuzumab (Genentech Inc.) 
insulin glargine (sanofi-aventis U.S. LLC) ustekinumab (Janssen Biotech Inc.) 
insulin glulisine  
(sanofi-aventis U.S. LLC) 
vedolizumab  
(Takeda Pharmaceuticals America, Inc.) 
insulin human (Novo Nordisk A/S)  
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1.3. Discussion 
1.3.1 Detailed analysis of the filtered protein drug products 
Our analysis identified worldwide more than 60 protein drugs with a mandatory filtration 
during preparation or administration (Table 1). Only for six proteins an explicit filtration 
prohibition has been found (Table 2). Figure 2 visualizes the ratio of filtered to non-filtered 
drugs registered in Germany. Interestingly, 4 out of 9 protein drugs, which entered the 
German market in 2014, are filtered (Govi-Verlag Pharmazeutischer Verlag GmbH; Kadcyla® 
- Anhang 1 - Zusammenfassung der Merkmale des Arzneimittels, accessed 07/2014; 
NovoEight® - ANNEX I - Summary of product characteristics accessed 07/2014; Sylvant® 
(siltuximab) [Package Insert], 06/2014; Vimizim™ (elosulfase alfa) [Product Monograph], 
2014). For another product the compatibility with polyestersulfone filters was at least checked 
(Gebrauchsinformation: Information für Patienten GazyvaroTM 1.000 mg Konzentrat zur 
Herstellung einer Infusionslösung, 07/2014). A closer look at Table 1 reveals the following. 
Filtration of the drugs is applied during preparation in 44.6 % and during administration in 
55.4 % of all cases, respectively. Further, the list contains 67.7 % lyophilisates and 32.3 % 
solutions whereupon intravenous immune globulin drugs are excluded in this ratio, because 
both dosage forms exist for intravenous immune globulins. For the majority of the listed 
protein solutions, filters are mainly applied during administration (80 %), whereas in 20 % the 
filtration step is carried out during preparation. Only abciximab solution is filtered during 
either preparation or administration.  
On the contrary, 55.6 % of the lyophilisates are filtered during preparation. Filtration of 
lyophilisates seems to be consistent considering the following facts. The lyophilized drug is 
stored in a glass vial and sealed with a rubber stopper. For reconstitution the liquid 
component, which has also an impact on particle formation (Zhang et al., 1996), of the final 
drug product is added to the lyophilisate. To this end, the stopper is punctured with a sharp 
cannula. Puncturing of the stopper is also necessary for the drug removal. During these 
penetration processes coring can occur. Coring describes the shedding of rubber particles 
into the solution due to the needle insertion (Asakura et al., 2001; Campagna et al., 2013; 
Waller and George, 1986). Particles present a risk for patients as discussed previously. 
Subsequently, an incorporated filter during the filling of the syringe or the administration via 
an infusion set shall protect the patient from the exposure to particles. The origin of these 
particles can be either inherent to the reconstituted drug solution (Chang and Pikal, 2009), 
the stopper (Asakura et al., 2001; Campagna et al., 2013) or any part of the infusion set 
(Madsen and Winding, 1996).  
Most of the proteins are filtered using a pore size of 0.2 µm or 0.22 µm, which is also 
commonly used for sterile filtration. Other frequently stated pore sizes are 5 µm and 15 µm. 
For some proteins like abatacept, belatacept, abciximab and others (see Table 1) the pore 
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size of the filter has a wide range from 0.2 µm to 5 µm or even larger. There are no 
explanations given for the large differences in the pore size. Maybe the manufacturers want 
to make sure that the medically reasonable application is not hindered ad hoc, due to a 
single logistic problem at the bedside, where a particular filter is just not readily available. 
“Better do something than nothing” appears to be the slogan. On the other hand, it may 
reflect the situation that “normally” the product is clean anyway and the filter is not so 
relevant. In case precipitation occurs and is not detected visually, also a larger pore size 
might reduce the particle load dramatically. According to the pharmacopoeia parenteral 
drugs need to be visually inspected to detect particulate matter and container with defects 
need to be rejected (European Directorate For The Quality Of Medicine, 2011c; The United 
States Pharmacopeial Convention, 2011a). Consequently, the drug products are 100 % 
visually inspected after filling by trained operators, semi- or automatic processes and 
acceptable quality level checks before release (Doessegger et al., 2012). Nevertheless, the 
chance exists that particles are formed during transportation and storage of the drug product. 
Besides, particulate matter is one of the top ten reasons for the recall of parenteral drugs 
(Doessegger et al., 2012). Hence, the visual inspection of the parenteral dosage form before 
administration by healthcare professionals or the patient is of utmost importance. Instructions 
for the performance of such a visual inspection can also be frequently found in package 
inserts. 
 
 
Figure 2: Filtration is already carried out for 15.9 % of all approved protein drugs listed in the Rote Liste® as the 
pie chart displays (Rote Liste® Service GmbH Frankfurt/Main, 01/2015, 2013). 
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1.3.2 Consideration of possible negative filtration impacts 
1.3.2.1 Filter shedding 
Although filters remove particle or bacteria, the following facts need to be considered. Filters 
themselves can be the source of particles and extractables (Eisenberg, 1974; Huang et al., 
2011; Liu et al., 2012). Already in 1974 the pharmaceutical industry was aware about the 
particle shedding from filter membranes (Eisenberg, 1974). At that time especially the 
shedding of toxic asbestos filters was a problem and led to an FDA announcement to 
improve the filtration methods (Eisenberg, 1974). However, particle shedding from filters is 
still a serious issue as a study by Liu et al. shows (Liu et al., 2012). Particle burden of a 
buffer and protein solution increased after filtration for some filter types (Liu et al., 2012). This 
also suggests different quality levels by the filters itself. Hence, the quality of the filters has to 
be harmonized. Until then, the manufacturers need to state clearly which filter should be 
applied for their product or even better provide the right filter with their product. Particulate 
matter can also not be easily diminished by preflushing. Further, the toxic impact of these 
particles is not known (Liu et al., 2012).  
 
1.3.2.2 Extractables deriving from filters 
Extractables are another important topic. Especially extractables of filter membranes used for 
protein filtration, like polyethersulfone or polyvinylidene fluoride, show surface activity. 
Depending on the membrane type the extractables can have a positive or negative influence 
on the particle level after agitation. Further, it is particularly important to know about the 
surface activity of the extractables, if only small volumes are filtered due to possible changes 
of the surface tension. Flushing the filter before usage is the best option to diminish the 
amount of extractables (Huang et al., 2011). For clinical reasons a study by Harrison and 
Healy is highly relevant suggesting a higher effectiveness of filters, if the flow rate is low 
(Harrison and Healy, 1974).  
 
1.3.2.3 Drug adsorption on filters 
Another critical aspect regarding the usage of filters is the possible retention of the drug or 
other formulation components. Protein fouling is of little importance if the solutions are 
aggregate free. If aggregates are present they associate with protein monomers (Kanani et 
al., 2008). Then fouling is able to reduce the flux and increase the membrane resistance, 
respectively, transmembrane pressure (Güell and Davis, 1996; Kanani et al., 2008). Severe 
filter clogging making filtration impossible during the investigated volumes and times was not 
observed (Güell and Davis, 1996; Kanani et al., 2008). The adsorption of the protein on the 
filter may be not a problem because in many cases the manufacturers do not instruct to use 
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a specific filter membrane. But it is also possible that protein drug adsorption on filters has 
not attracted enough interest by many of the manufacturers. Several package inserts just 
recommended the use of a “low protein binding filter”. This is not very precise, as many 
different filter membranes are available and not everybody in nursing is familiar with protein 
binding capacities of filter membranes. Membranes with low protein binding properties are 
polyethersulfone, polyvinylidene fluoride and cellulose acetate (Mahler et al., 2010). Intensive 
care units often use nylon or polyethersulfone membranes as a standard, cellulose filters get 
more and more unimportant (Gasch et al., 2011; Leopold et al., 2013). Specific guidance 
would therefore be needed as nylon would be a particularly inappropriate choice for protein 
drug products. The package inserts of two products exclusively mention the adsorption issue. 
For Bexxar® the manufacturer warns to switch the filter between the infusion of the non- and 
radiolabelled antibody, because this action will lead to a loss of the drug (Bexxar 
(tositumomab and iodine I 131 tositumomab) [Package insert], 05/2013). To ensure a 
complete drug delivery, a flushing of the infusion set including the filter takes place after 
administration of Yttrium-90 ibritumomab tiuxetan (Fink-Bennett and Thomas, 2003; Zevalin® 
(ibritumomab tiuxetan) [Package insert], 11/2011). For obinutuzumab the company has 
investigated incompatibilities between the final drug solution and polyethersulfone filters, 
even though filtration is not obligatory (Gebrauchsinformation: Information für Patienten 
GazyvaroTM 1.000 mg Konzentrat zur Herstellung einer Infusionslösung, 07/2014). Although 
no incompatibilities are found, the information about the filter is missing in the American 
package insert (Gazyva® (obinutuzumab) [Package insert], 12/2014; Gebrauchsinformation: 
Information für Patienten GazyvaroTM 1.000 mg Konzentrat zur Herstellung einer 
Infusionslösung, 07/2014). Unfortunately, adsorption studies for filters are lacking, 
particularly for proteins. A study by Gasch et al. in 2011, is the first independent binding 
study for polyethersulfone filters, although this filter membrane was already introduced in the 
late 1980ies (Gasch et al., 2011).  
However, taking a look at small molecule anticancer drugs, which present a formulation 
challenge due to their properties, for example their instability in aqueous systems, and the 
need for solubilizers (Hatefi et al., 2004), shows that the retention of drugs by filters should 
generally not be neglected. The examination of the adsorption of drugs on filters has started 
in the late 1970ies (Rusmin et al., 1977). Anticancer drugs were in the focus of the studies, 
because patients suffering from cancer are prone to infections due to their suppressed 
immune status (Bethune et al., 2001; De Vroe et al., 1990; Francomb et al., 1994). The most 
important facts, which can be learned from the investigation of the adsorption behavior of 
small molecule anticancer drugs onto filters and should be transferred to protein filtration, are 
shortly summarized.  
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Drug adsorption to the filter occurs frequently in the initial state of infusion. After a while the 
defined concentration is reached and the total loss of the drug is not of any clinical concern 
(De Vroe et al., 1990; Francomb et al., 1994; Rusmin et al., 1977). Although some drugs do 
not adsorb to different filter types, many cases provide evidence that each combination of a 
drug and filter needs to be evaluated before clinical administration (Gasch et al., 2011). A 
change of the filter type can have a severe influence on the concentration recovery as shown 
for vincristine (Butler et al., 1980; Ennis et al., 1983; Francomb et al., 1994; Pavlik et al., 
1983; Pavlik et al., 1982). But also the same membrane type of different suppliers can 
change the drug loss as demonstrated for bleomycin (De Vroe et al., 1990). Factors, which 
also need to be considered are drug concentration, pH, different infusion fluids or flow rates 
(De Vroe et al., 1990). In particular low concentrated drugs (Butler et al., 1980; Rusmin et al., 
1977) with a small volume or drugs with a short half-life with low flow rates are endangered 
to have a significant potency loss (Francomb et al., 1994). To prevent underdosing of vital 
drugs the Intravenous Nurses Society guidelines state that due to a retention of a drug on the 
filter membrane, the use of filters might be contraindicated for some drugs, particularly those 
administered in low doses (Ortolano et al., 2004). The binding of cytotoxic agents to filters 
might not be a large problem nowadays anymore as a recent study by Bononi et al. with 
paclitaxel suggests (Bononi et al., 2011). They conclude from their experiment that the filter 
manufactures have meanwhile rendered the membranes successfully to reduce the 
adsorption of drugs to a minimum (Bononi et al., 2011). However, a study confirming such an 
improvement for protein filtration is still lacking. 
As already pointed out above, the findings from the anticancer drugs are useful, because 
most of these drug molecules are hardly water soluble and/or hydrophobic. Hence, they stick 
more easily to the membrane material. Further, these molecules are instable in solution, 
showing a high tendency to precipitate, which can be triggered by filtration. However, drug 
adsorption on filters is only critical for low dose proteins like interferons or hormones, but not 
for monoclonal antibodies or enzymes. Moreover, low dosage protein products comprise a 
surfactant very often. Subsequently, extraction of filter components is another issue beside 
adsorption. For low dosage drugs the protein recovery from different membranes of various 
suppliers should be evaluated. Further, the impacts of the drug concentration, infusion fluid 
and flow rate also needs to be determined.  
 
1.3.3 Proposals for future filter usage 
Considering the facts, summarized above, the authors like to make some proposals. First, to 
qualify some lead qualities, for example the specific use of polyethersulfone or polyvinylidene 
fluoride as membrane type for protein drugs which are already filtered. Next, picking up an 
idea from Liu et al. (Liu et al., 2012), products, in this specific case filters, which do not shed 
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particles themselves need to be identified. On this field more basic and intensive research 
needs to be performed. The authors also like to encourage establishing a filtration routine for 
not yet filtered protein drugs. Any decision should be based on a risk analysis considering 
incidence of particle formation as well as incidence and severeness of potential 
immunogenicity related clinical consequences. An additional filtration step shall be 
considered as additional safety measure with the aim to reduce potential immunogenicity. In 
our point of view a more general usage of filters can be beneficial to all patients receiving 
protein drug products until particles can eventually be excluded as a potential cause for 
immunogenicity in the future. Patients who are treated with protein drugs suffer from severe 
diseases and are already weakened by their disease. A recent study by Ahmadi et al., which 
shows that particularly aggregates of proteins with little or no clinical immunogenicity have 
the potential to induce clinical immunogenicity supports our approach (Ahmadi et al., 2015). 
Further, the authors suggest to perform statistical analysis between same or similar products, 
which are filtered or not filtered to see, whether a difference in the immunogenicity rate can 
be found. 
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1.4. Conclusion 
Particles in parenteral preparations are associated with risks for the patient. In addition to 
injection site reactions or occlusion of capillary blood vessels, a more recent problem 
emerging is immunogenicity caused by non-native protein species. The authors therefore 
want to stimulate a discussion on a more widespread usage of in-line filters as a possible 
solution. This is supported by the fact that already 15.9 % of all protein drug products and a 
high percentage of newly approved drugs are filtered.  
Further, the filtration practice should be revised and harmonized. Three central questions 
need to be addressed. First, which filter membranes and pore sizes shall be used for protein 
filtration? Next, does significant protein adsorption occur, especially for low dosed drugs? 
Third, are filters beneficial or do they contribute to the particle burden? Studies to these 
topics are lacking, although important. Independent investigations shall be encouraged, but 
also the manufacturers should provide more details about their filter recommendations. This 
may finally ensure reasonable filter usage to as many as possible drugs for the reduction of 
immunogenicity issues and other risks associated with particles. 
With the proposed approach using in-line filters we might be able to improve the quality and 
safety of all protein drug products.  
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Abstract  
Today it is commonly accepted that protein aggregates and protein particles also in particular 
with silicone oil can induce immune reactions and can therefore endanger the safety and 
efficacy of a biopharmaceutical drug. A total absence of protein aggregate formation is even 
with the most stable formulation impossible to achieve. An application of bedside filtration, a 
filtration during the preparation or administration of the drug product, has the potential to 
increase the safety of every drug container and could diminish the undesired injection of 
particulate matter into the patient. In this study the high efficiency of filtration for reducing the 
amount of protein particles was demonstrated with more than 19 stressed and non-stressed 
biopharmaceutocal products which covered a broad concentration and molecular weight 
range. Further, critical aspects regarding the usage of filters such as particle shedding from 
filters, protein loss as a result of protein adsorption or the hold-up volume of the filter were 
assessed. Although differences between the filters were observed, no negative impacts were 
generally caused by the investigated filters. As bedside filtration provides great benefits, its 
broader application and its establishment are proposed. 
 
 
Keywords 
protein aggregates, immunogenicity, in-line filtration, bedside filtration, protein adsorption, 
leachables, ejection force, protein denaturation, particle, filter 
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CD, Circular Dichroism; DLS, Dynamic Light Scattering; FT-IR, Fourier Transform Infrared 
Spectroscopy; GC-MS, Gas Chromatography-Mass Spectrometer; HP-SEC, High-
Performance Size Exclusion Chromatography; ICP-OES, Inductively Coupled Plasma Optical 
Emission Spectrometry; LO, Light Obscuration; MFI, Micro-Flow Imaging; NTA, Nanoparticle 
Tracking Analysis; n.a., not analyzed; PdI, Polydispersity Index; PES, polyethersulfone; 
PVDF, polyvinylidene difluoride; RP-HPLC, Reversed-Phase High-Performance Liquid 
Chromatography; Z-Ave, Z-Average. 
 
 
Supplementary 
Additional information is available in the supplementary (Chapter 2 Supplementary). Figures 
and tables found in the supplementary are referred in the text to “Figure S <Number>” or 
“Table S <Number>”.  
Expanding bedside filtration – a powerful tool to protect patients from protein aggregates  
 
53 
2.1. Introduction 
Biopharmaceuticals are complex, sensitive and highly developed products which can 
generally be considered as relatively safe. Before the final high quality drug product is 
available on the market, a lot of research is invested in finding the best, most stable 
formulation. Even with all the current knowledge available it is nearly impossible to absolutely 
exclude the formation of protein aggregates in these optimized formulations [1-4]. Multiple 
factors like oxygen, light, shaking or temperature can lead to chemical and physical 
degradation of the protein resulting in the generation of protein aggregates [3-5].  
 
These non-native protein species are associated with immunogenicity risks. Anti-drug 
antibodies are only one type of immune reaction. The formation of antibodies against the 
therapeutic protein after administration is known for nearly all protein drug products [5]. Anti-
drug antibodies have been observed e.g. for adalimumab [6], insulin [7], human growth 
hormone [8], erythropoietin [9], interferon [10, 11], etanercept [12] and many more. Clinical 
consequences of these unwanted immune responses are often negligible, but can also be 
severe like anaphylaxis and serum sickness or can even be life threatening, if an 
endogenous protein like erythropoietin is neutralized [2, 9, 13]. Improvements in the design 
of human recombinant proteins like sequence modifications or fully humanized proteins have 
not been able to eliminate the issue of immune responses against non-native protein species 
[5, 11, 13-16]. Although dose, dosing frequency, route of administration or the immune status 
of the patient play a major role for the incidence of immunological reactions [5, 13, 17], the 
safety and efficacy of the drug is endangered by the presence of protein aggregates [5, 15, 
17, 18]. Beside protein aggregates, particles consisting of protein adsorbed to silicone oil or 
glass flakes can also be formed in the final product with both combinations known to activate 
the immune system [19, 20]. All these protein particles can be formed not only during the 
manufacturing and filling process, but also afterwards during shipping and storage [3, 5, 16, 
21].  
 
Product quality is monitored by the manufacturers by a comprehensive quality assurance 
such as stability tests, equipment validation or in-process controls. In the end a batch is 
statistically monitored before it is distributed and afterwards no more product characterization 
with analytical tools can be performed. The only check before administration will be visual 
inspection by the medical personnel or by the patient himself as instructed in package inserts 
[22]. Most of the particles found in such parenteral products have sizes of less than 10 µm 
[23]. An unaided eye, however, detects particles of a size from 100 µm upwards [17]. Hence, 
a lot of potentially immunogenic protein particles would go unnoticed and could be injected 
into the patient.  
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Being aware of the risks associated with the protein aggregates and the fact that it is 
impossible to totally exclude protein aggregation measures should be taken. The safety 
provided during product release should be complemented by an approach to ensure 
cleanliness for every single container. Therefore, expansion of bedside filtration which is 
already carried out for several biopharmaceuticals is proposed in this study. Due to the fact 
that bedside filtration is already used in the field, it should be easy to implement [16, 22]. 
Bedside filtration has the capability to provide more safety for every single container resulting 
in a lower exposure of the patients to particulate matter. A survey analysis of more than 300 
marketed protein drug products showed an application of bedside filtration during preparation 
and administration of the drug in already 16 % of all products. For less than 1.5 % of the 
drugs filtration was explicitly forbidden, but for the overwhelming majority no filtration 
recommendations exists [22]. However, new approvals of biopharmaceuticals in Germany in 
the last three years showed that about 45 % of these approvals are bedside filtered. So, a 
clear tendency towards more filtration is obvious. Our considerations are confirmed by the 
fact that authorities now request the additional monitoring of particles in the low micrometer 
range (< 10 µm) [16, 18, 24].  
 
Bedside filtration is mostly carried out with 0.2 µm filters with a low protein binding 
polyethersulfone membrane [22]. The usage of common 0.2 µm filters in clinical settings 
ensures a broad and cheap distribution and provides an additional sterile filtration step. 
Further, a reduction in the occurrence of sepsis, infection and thrombi is observed by the 
usage of 0.2 µm filters [25, 26].  
 
However, several technical aspects regarding the filter usage need to be addressed. First 
and foremost, it has to be assessed, if filters possess the capability to remove protein 
particles effectively. Second, literature reports about some filters shedding particles which 
could contribute to the overall particle count of protein solutions [27]. This would thwart the 
entire idea, because particulate matter should be effectively removed by filtration and it 
should be not exchanged by other impurities from filter components. Third, it has to be 
ensured that there is no protein loss due to adsorption to the filter membrane or due to 
protein denaturation caused by shear stress. Next, especially for products with small 
volumes, the filter hold-up volume, which represents the remaining volume in the filter 
housing after the filtration process, has to be as low as possible, because 
biopharmaceuticals are typically expensive and unnecessary overages have to be avoided. 
Further, it was determined, if soluble leachables are present in the filtered protein solutions 
[28, 29] and if a filter affects negatively the ejection force.  
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These important technical aspects are critically investigated in this study and a 
recommendation regarding the application of bedside filtration in a more routinely way is 
presented at the end. 
 
      
2.2. Materials and Methods 
2.2.1 Materials 
Products, materials and their brand names might be protected due to intellectual property 
rights although they might not be marked with intellectual property signs. 
 
2.2.1.1 Chemicals 
Pure sodium chloride was purchased from Bernd Kraft GmbH (Duisburg, Germany). di-
sodium hydrogen phosphate dihydrate p. A., sodium dihydrogen phosphate dehydrate p. A. 
and L-Arginine base pure Ph.Eur., USP were bought from AppliChem GmbH (Darmstadt, 
Germany). Sodium acetate, 99 %, anhydrous, p. A. was used from Grüssing GmbH (Filsum, 
Germany). Trisodium citrate, anhydrous, 99 % was purchased from Alfa Aesar GmbH & Co 
KG (Karlsruhe, Germany). Citric acid monohydrate AnalaR Normapur® derived from VWR 
BDH Prolabo® (Leuven, Belgium). Polysorbate 80 was from Fluka® Analytical (Buchs, 
Switzerland). Glycine ReagentPlus® ≥99 (TLC) was bought from Sigma Life Sciences 
(Taufkirchen, Germany) and mannitol was obtained from Boehringer Ingelheim (Ingelheim, 
Germany).  
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2.2.1.2 Proteins 
Proteins used in this study are listed in Table 1. All sam
ples w
ere received as expired m
aterial, except Beriglobin
®, from
 m
anufacturers, 
pharm
acies and hospital pharm
acies for non-m
edical, non-com
m
ercial use. All products w
ere stored at 2 °C
 to 8 °C
. 
 Table 1. List of proteins investigated in this study 
Inform
ation about brand nam
e, m
anufacturer/supplier, protein international nonproprietary nam
e, protein concentration, product form
ulation, prim
ary packaging and protein class is 
provided. 
 
Product Nam
e 
Protein Nam
e 
Concentration 
Form
ulation 
Prim
ary packaging 
Liquid or 
Lyophilisate 
Protein class 
Erypo
® 4000 
(Janssen-C
ilag G
m
bH
) 
Epoetin alfa 
4000 I.U
. 
Polysorbate 80, G
ly, N
aC
l, 
N
a
3 PO
4 , N
a
4 P
2 O
7  
G
lass vial 
Liquid 
cytokine 
Erypo
® 4000 
(Janssen-C
ilag G
m
bH
) 
Epoetin alfa 
4000 I.U
. 
Polysorbate 80, G
ly, N
aC
l, 
N
a
3 PO
4 , N
a
4 P
2 O
7  
Prefilled syringe 
Liquid 
cytokine 
Intron A
® Injection 1 M
io 
(Essex Pharm
a G
m
bH
) 
Interferon alfa-2b 
1 M
io I.U
./m
L 
G
ly, N
aH
2 PO
4 , N
a
2 H
PO
4 , H
SA 
G
lass vial 
Lyophilisate 
cytokine 
Kineret ® 100 m
g 
(Sw
edish O
rphan 
Biovitrum
 AB) 
Anakinra 
 
100 m
g/0.67 m
L 
N
a-citrate, N
aC
l, N
aED
TA, 
Polysorbate 80, N
aO
H
 
Prefilled syringe 
Liquid 
cytokine 
N
eoR
ecorm
on
®  
2000 IE 
(R
oche) 
 
Epoetin beta 
 
2000 I.U
. 
U
rea, N
aC
l, Polysorbate 20, 
N
aH
2 PO
4 , N
a
2 H
PO
4 , C
aC
l, G
ly, 
Leu, Isoleu, Thr, G
lu,  Phe 
G
lass vials 
Lyophilisate 
cytokine 
N
eoR
ecorm
on
®  
2000 IE 
(R
oche) 
 
Epoetin beta 
 
2000 I.U
. 
U
rea, N
aC
l, Polysorbate 20, 
N
aH
2 PO
4 , N
a
2 H
PO
4 , C
aC
l, G
ly, 
Leu, Isoleu, Thr, G
lu,  Phe 
Prefilled syringe 
w
ith 27G
 1/2 
Liquid 
cytokine 
N
eoR
ecorm
on
®  
10000 IE 
(R
oche) 
Epoetin beta 
 
10000 I.U
. 
U
rea, N
aC
l, Polysorbate 20, 
N
aH
2 PO
4 , N
a
2 H
PO
4 , C
aC
l, G
ly, 
Leu, Isoleu, G
ly, Thr, G
lu,  Phe 
Prefilled syringe 
w
ith 27G
 1/2 
Liquid 
cytokine 
 
Erythropoietin 
84 µg/m
L 
N
aC
l, Polysorbate 80, 
G
lass container 
cytokine 
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N
aH
2 PO
4  x 2 H
2 O
, N
a
2 H
PO
4  
x 2 H
2 O
, glycine  
Liquid 
R
ebif  ® 22 µg Injection 
solution 
(Serono) 
Interferon beta-1a 
22 µg/0.5 m
L 
M
annitol, H
SA, N
aO
Ac, H
O
Ac, 
N
aO
H
 
Prefilled syringe 
Liquid 
cytokine 
R
oferon
®-A 
(R
oche) 
Interferon alfa-2a 
3 M
io. I.U
./0.5 m
L 
N
H
4 O
Ac, N
aC
l, Benzyl alcohol, 
Polysorbate 80, H
O
Ac, N
aO
H
 
Prefilled syringe 
Liquid 
cytokine 
R
oferon
®-A 
(R
oche) 
Interferon alfa-2a 
9 M
io. I.U
./0.5 m
L 
N
H
4 O
Ac, N
aC
l, Benzyl alcohol, 
Polysorbate 80, H
O
Ac, N
aO
H
 
Prefilled syringe 
Liquid 
cytokine 
 C
erezym
e
®
 200 U
nits 
(40 U
/m
L) (G
enzym
e 
B.V.) 
Im
iglucerase  
2.5 U
nits/kg 
3.5 U
nits/kg 
M
annitol, N
a-citrate, Polysorbate 
80, C
itric acid or N
aO
H
 
G
lass vial 
Lyophilisate 
enzym
e 
H
ylase
® „D
essau“ 300 I.E
. 
(Pharm
a D
essau G
m
bH
) 
H
yaluronidase 
300 I.U
. 
G
elatine 
G
lass am
poule 
Lyophilisate 
enzym
e 
U
rokinase 100 000 H
S 
(m
edac) 
U
rokinase 
 
2 000 I.E./m
L 
N
a
2 H
PO
4 , N
aH
2 PO
4 , H
SA 
G
lass vial 
Lyophilisate 
enzym
e 
U
rokinase H
S m
edac 
500 000 I.E. (m
edac) 
U
rokinase 
 
50 000 I.E./m
L 
N
a
2 H
PO
4 , N
aH
2 PO
4 , H
SA 
G
lass vial 
Lyophilisate 
enzym
e 
 
R
eteplase 
1 m
g/m
L 
Arginine 
G
lass container 
(Thaw
ed) Liquid 
enzym
e 
 M
inirin
® parenteral 
(Ferring A
rzneim
ittel 
G
m
bH
) 
D
esm
o-
pressinacetat 
4 µg/1 m
L 
N
aC
l, H
C
l 
G
lass am
poule 
Liquid 
horm
one 
 
H
um
an G
row
th 
H
orm
one 
0.8 m
g/m
L 
G
ly, M
annitol, N
aH
2 PO
4 , 
N
a
2 H
PO
4  
G
lass container 
Liquid 
horm
one 
  
anti-TN
F-α IgG
 1 
1 m
g/m
L 
40 m
g/m
L 
N
aC
l, Polysorbate 80, 
N
aH
2 PO
4  x 2 H
2 O
, N
a
2 H
PO
4  
x 2 H
2 O
, M
annitol, C
itric 
acid x H
2 O
, Sodium
 citrate 
G
lass container 
Prefilled syringe 
Liquid 
antibody 
Beriglobin
® 
(C
SL B
ehring G
m
bH
) 
H
um
an 
antibodies 
against H
epatitis-
160 m
g/m
L 
G
ly, N
aC
l, N
aO
H
 or H
C
l 
Prefilled syringe 
Liquid 
antibody 
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A-Virus 
M
abthera
® 100 m
g 
(R
oche) 
R
ituxim
ab 
1 m
g/m
L 
1.5 m
g/m
L 
4 m
g/m
L 
 
N
a-citrate, Polysorbate 80, N
aC
l, 
N
aO
H
, H
C
l 
G
lass vial 
Liquid 
antibody 
O
rthoclone
® O
KT 3 
(Janssen-C
ilag G
m
bH
) 
M
urom
onab C
D
3 
1 m
g/m
L 
N
aH
2 PO
4 , N
a
2 H
PO
4 , N
aC
l, 
Polysorbate 80 
G
lass am
poule 
Liquid 
antibody 
Zenapax
® 5 m
g/m
L 
(R
oche) 
D
aclizum
ab 
0.5 m
g/m
L 
N
aC
l, N
a
2 H
PO
4 , N
aH
2 PO
4 , H
C
l, 
N
aO
H
 
G
lass vial 
Liquid 
antibody 
 Bioclate
TM Antihem
ophilic 
Factor (recom
binant) 250 
(C
enteon P
harm
a G
m
bH
) 
Blood coagulation 
factor VIII 
0.08 m
g/10 m
L 
H
SA, N
aC
l, H
is, M
acrogol 3350,  
C
aC
l2  x 2 H
2 O
 
G
lass vial 
Lyophilisate 
w
ith 16G
 filter needle 
antihem
ophilic 
drug 
H
elixate
® 250 
(C
enteon P
harm
a G
m
bH
) 
O
ctocog alfa 
250 I.U
. 
G
ly, N
aC
l, C
aC
l, H
SA 
 
G
lass vial 
w
ith filter needle 
Lyophilisate 
antihem
ophilic 
drug 
 Album
in (H
um
an) U
.S.P. 
Albutein
® 25 %
 solution 
(alpha
® Therapeutic 
C
orporation) 
H
um
an Serum
 
Album
in 
 
12.5 g/50 m
L 
N
a-caprylate, N
a-
acetyltryptophanate 
G
lass vial 
Liquid 
plasm
a protein 
 D
isclaim
er: 
The particle num
bers reported here shall by no m
eans represent the typical particle status of the respective product as they w
ere all expired, 
except one product and they w
ere analyzed at different points in tim
e after expiration. U
sing expired m
aterials w
as intended to challenge the filters 
w
ith w
orst case particle num
bers w
hich result from
 norm
al storage, from
 not artificial and untypical stress. 
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  2.2.1.3 Filter 
N
am
es and supplem
enting inform
ation about the filters applied in this study can be found in Table 2. 
 Table 2. List of filters used in the study 
B
rand nam
e, m
anufacturer and inform
ation about the filter m
em
brane, housing, diam
eter and pore size as w
ell as order num
ber and additional properties of the filters are listed. 
Filter Nam
e 
in Publication 
Brand Nam
e 
M
anufacturer 
Filter M
em
brane /  
Housing M
aterial 
Filter Diam
eter / 
Filter Pore Size /  
Filtration Area  
Additional Inform
ation / 
CAT Num
ber 
Filter diam
eter 13 m
m
 - polyethersulfone (PES) & polyvinylidene difluoride (PVDF) 
Pall Acrodisc 
Acrodisc
® 13 m
m
 
Syringe Filter  
Pall C
orporation 
(Ann Arbor, M
I, U
SA
) 
Supor ® M
em
brane 
(PES) w
ith P
P housing 
13 m
m
 
0.2 µm
 
1 cm
2 
sterile 
non-pyrogenic 
C
AT 4602 
M
illipore PES 13 
M
illex
®-G
P 
M
erck M
illipore Ltd. 
(Tullagreen, Irland) 
Fast Flow
 & Low
 Protein 
Binding M
illipore 
Express
® PES w
ith P
P 
housing 
13 m
m
 
0.2 µm
 
0.8 cm
2 
non-sterile 
C
AT SLG
PX
13N
L 
M
illipore PVDF 13 
M
illex
®-G
V 
M
erck M
illipore Ltd. 
(Tullagreen, Irland) 
Low
 Protein B
inding 
D
urapore
® (PVD
F) 
M
em
brane w
ith P
P 
housing 
13 m
m
 
0.2 µm
 
0.8 cm
2 
non-sterile 
C
AT SLG
VX
13N
L 
W
hatm
an PVDF 
13 
W
hatm
an
TM 
Puradisc
TM 13 m
m
 
Syringe Filter 
G
E H
ealthcare U
K 
Lim
ited 
(Buckingham
shire, U
K) 
PVD
F w
ith P
P housing 
13 m
m
 
0.2 µm
 
1.3 cm
2 
non-sterile 
C
AT 6779-1302 
 
 Filter diam
eter 25/28 m
m
 - polyethersulfone (PES) 
Pall Pharm
Assure 
PALL Pharm
Assure 
25 m
m
 Syringe 
Filter w
ith 0.2 µm
 
Supor ® M
em
brane  
Pall M
edical  
(C
ornw
all, U
K) 
Supor ® M
em
brane 
(PES) w
ith m
odified acryl 
housing 
25 m
m
 
0.2 µm
 
2.8 cm
2 
sterile 
non-pyrogenic 
C
AT H
P1002 
C
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Pall AEF 
Supor ® AEF 
Infusion Filter 
Pall M
edical  
(Fribourg, Sw
itzerland) 
Supor ® M
em
brane 
(PES) 
not declared 
0.2 µm
 
4.5 cm
2 
sterile 
non-pyrogenic 
C
AT AEF1N
TE 
M
illipore PES 
M
illex
®-M
P
 
M
erck M
illipore Ltd. 
(Tullagreen, Irland) 
Fast Flow
 & Low
 Protein 
Binding M
ilipore 
Express
® PES 
25 m
m
 
0.22 µm
 
3.9 cm
2 
sterile 
non-pyrogenic 
C
AT SLM
P025SS
 
W
hatm
an PES 
W
hatm
an
TM 
Puradisc
TM 25 AS  
 
G
E H
ealthcare U
K 
Lim
ited 
(Buckingham
shire, U
K) 
PES w
ith P
P housing 
25 m
m
 
0.2 µm
 
4.2 cm
2 
sterile 
non-pyrogenic 
C
AT 6780-2502 
Sartorius PES 
M
inisart ® H
igh Flow
 
Syringe Filter 
Sartorius AG
 
(G
oettingen, G
erm
any) 
H
ydrophilic PES w
ith 
m
ethacrylate-butadiene-
styrene housing 
28 m
m
 
0.2 µm
 
6.2 cm
2 
sterile  
C
AT 16532K 
I.V.Star ® 
C
odan I.V.Star ® 1.6 
C
O
D
AN
 M
edizinische 
G
eräte G
m
bH
 & C
o KG
  
(Lensahn, G
erm
any) 
PES w
ith m
ethyl 
m
ethacrylate-butadiene-
styrene housing 
20 m
m
 
0.2 µm
 
1.6 cm
2 
sterile 
non-pyrogenic 
C
AT 76.3365 
Filter diam
eter 25 m
m
 - polyvinylidene difluoride (PVDF) 
M
illipore PVDF 
Vented M
illex
®-G
V 
M
erck M
illipore Ltd. 
(Tullagreen, Irland) 
Low
 Protein B
inding 
D
urapore
® (PVD
F) 
M
em
brane 
25 m
m
 
0.22 µm
 
4.0 cm
2 
sterile 
non-pyrogenic 
C
AT SLG
VV255FF 
W
hatm
an PVDF 
W
hatm
an
TM 
Puradisc
TM 25 m
m
  
 
G
E H
ealthcare U
K 
Lim
ited 
(Buckingham
shire, U
K) 
PVD
F w
ith P
P housing 
25 m
m
 
0.2 µm
 
4.2 cm
2 
non-sterile 
C
AT 6746-2502 
 P
P
 = polypropylene 
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2.2.2 Methods 
2.2.2.1 Filtration effect 
Original products and stressed protein solutions were analyzed for particle count and size 
with particle measurement systems like light obscuration, Micro-Flow Imaging, dynamic light 
scattering and nanoparticle tracking analysis. To evaluate the capability of filters to remove 
protein aggregates, protein solutions were analyzed before and after filtration. Solutions were 
aspirated in sterile NORM-JECT® Luer Lock syringes (Henke Sass Wolf, Tuttlingen, 
Germany) and either no filter or a 0.2 µm filter was attached before analysis. NORM-JECT® 
Luer Lock syringes were flushed with highly purified water before aspiration of the protein 
solutions. Samples were pooled in case of small volume products. Filters used for a specific 
protein are listed in the measurement data tables (Tables S4 to S6 and Table 7) or figures 
(Figure 1 to 5 and Figure S2). Additional information about a specific filter is shown in 
Table 2. Measurements were carried out at least in triplicates and presented as mean ± 
standard deviation. 
 
2.2.2.1.1 Stressed protein drug products 
Proteins (anti-TNF-α IgG 1, erythropoietin, human growth hormone, Albumin (Human) U.S.P. 
Albutein® 25 % solution) were exposed to stirring with a stir bar at 300 rpm for 3 h on a 
Heidolph MR 3001 K (Heidolph Instruments GmbH & Co. KG, Schwabach, Germany) at 
room temperature. 
Harsh stress conditions were applied to Cerezyme® and Zenapax®: After dilution with an 
isotonic sodium chloride solution to their final concentration, 8.5 mL diluted protein solution 
were filled into 15 mL Greiner tubes (Greiner Bio-One GmbH, Frickenhausen, Germany), 
fixated horizontally on an Eppendorf Mixer 5432 (Eppendorf AG, Hamburg, Germany) and 
run at 1,450 rpm for 3 h at room temperature. Mabthera® 100 mg, Orthoclone® OKT 3, 
Erypo® 4000 and NeoRecormon® 2000 IE were stressed by exposing them in their original 
packaging to end-over-end rotation stress at 45 rpm for 3.5 h at room temperature.  
Measurements were performed at least in triplicates and presented as mean ± standard 
deviation. 
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2.2.2.1.2 Particle analysis 
2.2.2.1.2.1 Nephelometry 
The turbidity of the samples was assessed with a Nephla turbidimeter (Dr. Lange, 
Düsseldorf, Germany). Scattered light from a laser with a wavelength of 860 nm is detected 
at an angle of 90°. Results are presented in triplicates and in the form of formazine 
nephelometric units (FNU).  
 
2.2.2.1.2.2 Light Obscuration (LO) 
Particles in the sub- and visible particle range were quantified with a SVSS-C device from 
PAMAS GmbH (Rutesheim, Germany). For the analysis the PAMAS PMA Program V 2.1.2.0 
software was used. To ensure the system cleanliness the particle count of highly purified 
water was determined before each sample. The system was flushed with 0.3 mL or 0.4 mL 
sample before sample triplicates with a volume of either 0.2 mL or 0.3 mL were analyzed. 
Three of these runs were carried out for all samples resulting in a total of nine single 
measurements. The solution was aspirated at a speed of 10 mL/min. The system was 
calibrated with the usage of Duke StandardsTM covering the particle range from 1 µm to 
200 µm and Count-CalTM (5 µm) Particle Size Standards (both Thermo Scientific, Fremont, 
CA, USA). 
 
2.2.2.1.2.3 Micro-Flow Imaging (MFI) 
For the particle count and characterization a Micro-Flow Imaging DPA 4100 device 
(BrightWELL Technologies Inc., Ottawa, Canada) with a 100 µm flow cell in the operation 
mode “high magnification” was used. For the analysis the MFITM Particle Analyzer V6.9.7.2 
software was used. Flow cell cleaning was performed with highly purified water and flow cell 
cleanliness was evaluated between each run. Prior each sample run the flow cell was 
flushed with 0.5 mL of the appropriate protein solution buffer or with highly purified water to 
carry out “optimize illumination”. This step guarantees a correct system threshold. After 
“optimize illumination” the flow cell was flushed with at least 0.25 mL sample, before 0.65 mL 
sample were analyzed for particle count and characterization. Lower analysis volumes were 
used for some small volume products. The flow rate of the sample run was set to 0.1 mL/min. 
Triplicate measurements were carried out. Duke StandardsTM (10 µm) and Count-CalTM 
(5 µm) Particle Size Standards (both Thermo Scientific, Fremont, CA, USA) were used for 
the calibration of the MFI system. 
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2.2.2.1.2.4 Nanoparticle Tracking Analysis (NTA) 
To quantify and size nanoparticles, the movement of nanoparticles was recorded for 60 s 
with a NanoSight LM20 (NanoSight, Amesbury, UK) using the software NTA 2.3. The camera 
shutter was set to 1,499 for both proteins. The gain was set to 113 for NeoRecormon 2000 IE 
and 138 for anti-TNF-α IgG 1 40 mg/mL. Highly purified water was used to clean the flow 
cell. 0.5 mL sample were loaded air bubble free into the cell. Triplicate measurements were 
carried out. Between each measurement the cell content was replaced by another 0.1 mL 
sample. A 1 mL Terumo® Syringe without needle was used for cell loading (Terumo 
(Philippines) Corporation, Laguna, Philippines). No flow was applied during the 60 s of video 
capture.  
 
2.2.2.1.2.5 Dynamic Light Scattering (DLS) 
Dynamic light scattering was performed on a Zetasizer Nano ZS (Malvern Instruments, 
Worcestershire, UK) to determine the particle size and size distribution in the nanometer 
range. 400 µL protein solution were analyzed in triplicates at 20 °C. Particle size is given with 
the Z-Average [Z-Ave] value and the polydispersity index (PdI) represents the particle size 
distribution. 
 
2.2.2.2 Particle shedding from filters 
Filter cleanliness was tested by flushing the filters with ultra pure buffers. These buffers were 
first filtered (0.2 µm), then centrifuged with at least 4,000 rpm for 20 min. Only the 
supernatants of these purified solutions were used. Filters of interest were flushed with 2 mL 
of these buffers before the analysis with light obscuration and Micro-Flow Imaging. The 
investigated filters were Pall Acrodisc, Millipore PES and PVDF 13, Whatman PVDF 13 
(Table 2). The prepared buffers for flushing were a 50 mM acetate buffer pH 3.8 with an ionic 
strength of 154 mM and 200 mM, a 50 mM phosphate buffer pH 6.8 with an ionic strength of 
154 mM and a 50 mM phosphate buffer pH 8 with an ionic strength of 154 mM and 200 mM. 
Either no or 0.1 % polysorbate 80 was added to the buffers. Highly purified water was used 
for preparation and rinsing of container systems. Measurements were carried out at least in 
triplicates and presented as mean ± standard deviation. 
 
2.2.2.3 Protein Adsorption 
For the determination of protein loss caused by adsorption to the filter high-performance size 
exclusion chromatography (HP-SEC) was performed.  
The mobile phase consisted of 300 mM sodium chloride and 50 mM phosphate pH 7 in 
highly purified water. A flow rate of 0.5 mL/min was applied and a TSKgel 3000SWXL 
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column was used (Tosoh Bioscience GmbH, Stuttgart, Germany). Before analysis samples 
were centrifuged at 14,000 rpm for 10 min. Depending on the protein concentration various 
amounts of the protein solution were injected. Each sample was run in triplicates. A Waters 
2695 Alliance Separation Module (Waters Corporation, Milford, MA, USA) with a Waters 
2487 Dual λ Absorbance Detector for UV absorbance at 280 nm or a Dionex system with an 
ASI 100 autosampler, a RF 2000 Fluorescence (extinction: 295 nm; emission: 343 nm) and a 
UVD170U detector (280 nm) (all Thermo Fisher Scientific GmbH, Idstein, Germany) were 
used. Data analysis was carried out with Chromeleon V6.8. The area under the curve of non-
filtered samples was compared to the area under the curve of filtered samples. 
 
2.2.2.4 Hold-up volume 
The hold-up volume of Pall Acrodisc filters (n = 9) and seven filters with a diameter of 25 mm 
or 28 mm (n = 5) (see Table 2), all with a pore size of 0.2 µm, was assessed by filtration of 
1 mL or 2 mL highly purified water, respectively. The volume after filtration, the hold-up 
volume and the hold-up volume after 1 mL air purge were measured.  
 
2.2.2.5 Protein denaturation 
To evaluate possible changes in the protein structure caused by filtration four proteins were 
analyzed before and after filtration with a 0.2 µm and 13 mm or 25 mm filter with far-UV 
circular dichroism and Fourier transform infrared spectroscopy. 
 
2.2.2.5.1 Fourier Transform Infrared Spectroscopy (FT-IR) 
A Bruker Tensor 27 FT-IR device with a Bruker AquaSpec Cell (Brucker Optics, Ettlingen, 
Germany) was utilized for spectra recording of 40 mg/mL anti-TNF-α IgG 1 solutions. The 
sensor was constantly cooled before and during measurements with liquid nitrogen and a 
gaseous nitrogen flow. The spectra were background corrected with the corresponding 
buffer. The OPUS analysis software was used to obtain the second derivative of the spectra 
from a wavelength of 1,750 cm-1 to 1,450 cm-1 and to apply vector normalization.  
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2.2.2.5.2 Far-UV circular dichroism (CD) 
A Jasco J-715 spectropolarimeter (JASCO International Co. Ltd., Tokyo, Japan) was used 
for capturing far-UV spectra of Erythropoietin, human growth hormone, anti-TNF-α IgG 1 and 
Beriglobin®. The measurement software J-700 series control driver Vers 1.08.00 and for the 
analysis the software SpectraManager for Windows 95/NT Spectra Analysis Vers 1.53.07 
(Build 1) (both JASCO International Co. Ltd., Tokyo, Japan) were used. Protein solutions 
with a concentration of 0.150 mg/mL and for Beriglobin® 0.075 mg/mL were filled into a 
quartz cuvette with a path length of 0.1 cm. Spectra from 250 nm to 195 nm were recorded 
by a continuous scanning method at 4°C. Four scans were accumulated. Background 
correction of the corresponding buffer was performed for each protein spectrum. The data is 
shown in millidegrees of ellipticity as a function of wavelength.  
 
2.2.2.6 Leachable study 
For the determination of leachables seven different filters from various suppliers with a 
diameter of 25 mm or 28 mm and a pore size of 0.2 µm were investigated with reversed-
phase high-performance liquid chromatography, inductively coupled plasma optical emission 
spectrometry and gas chromatography-mass spectrometry. The filters were flushed either 
with 1 mL highly purified water or with an isotonic sodium chloride solution pH 4 containing 
0.1 % polysorbate 80. For the analysis the filtrate of five filters was pooled.    
 
2.2.2.6.1 Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) 
To detect UV active substances a YMC-Pack C4 (250 x 4.6 mml.D. S-5µm, 30 nm) column 
(YMC, Kyoto, Japan) was attached to an UltiMate 3000 system including a UV detector 
(Thermo Fisher Scientific GmbH, Idstein, Germany) as well as a column oven which was set 
to 37°C. The UV wavelengths were set to 214, 245, 280 and 330 nm and the extinction and 
emission wavelengths were at 280 nm and 343 nm, respectively. A linear gradient from 0 % 
to 100 % within 55 min followed by 5 min 0 % mobile phase B was applied at a flow rate of 
0.5 mL/min. Mobile Phase A consisted of 90 % highly purified water, 10 % HPLC grade 
acetonitrile and 0.1 % trifluoroacetic acid (w/w), whereas mobile phase B was made of 100 % 
HPLC grade acetonitrile and 0.1 % trifluoroacetic acid (w/w).  
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2.2.2.6.2 Inductively Coupled Plasma Optical Emission Spectrometry (ICP-OES) 
For trace analysis of several ions ICP-OES was applied. The following elements were 
monitored: Li, B, Na, Mg, Al, Si, P, K, Ca, Ti, Cr, Mn, Fe, Co, Ni, Cu, Zn, Ag, Cd, Sn, Ba, Hg, 
Pb. For this purpose a Varian Vista RL CCD simultaneous ICP AES Vista RL radial device 
from Varian (nowadays Agilent Technologies, Santa Clara, CA, USA) was used. 0.1 mL 
69 % nitric acid was added to the filtrate to obtain an aqueous 3 % nitric acid solution. 
Samples were then boiled at 105 °C for 30 min. 3 % standard solutions from Merck KGaA 
(Darmstadt, Germany) were used for system calibration. Blanks were measured before the 
samples were analyzed. For each element two to three emission wavelengths were chosen. 
Each sample was analyzed in triplicates. Instrument settings were the following: 
performance: 1.2 kW; nebulizer pressure: 180 kPa; pump speed: 17 rpm; plasma flow: 
13.5 l/min; auxiliary flow: 1.5 l/min; sample uptake time: 30 s; instrument stabilization time: 
45 s; measurement time: 9 s. The maximum percentage variance is 5 % and the minimum 
correlation coefficient is 0.98.    
The filtrates were analyzed by Jaroslava Obel from the analytical division of the Department 
of Chemistry and Pharmacy at the Ludwig-Maximilians-Universität Munich. 
 
2.2.2.6.3 Gas Chromatography-Mass Spectrometer (GC-MS) 
To identify and quantify leachables GC-MS was performed. 1 mL sample filtrate was mixed 
with either 2 mL of THF-methacrylate or BHT-aldehyde solutions and with 2 mL water for 
injection. The sample was adsorbed on a PDMS stir-bar for 1 h before thermal desorption 
and cryogenic focusing of the desorbed agents occurred. The substances were then 
separated on a GC column (Agilent Technologies, Santa Clara, US) and finally detected with 
a mass spectrometer (Agilent Technologies, Santa Clara, US). 
Provided filtrates were further prepared for GC-MS analysis by Nicole Scherer. GC-MS 
measurements and analysis of the chromatograms was performed by Nicole Scherer. The 
evaluation of this data was done by Benjamin Werner. 
 
2.2.2.7 Ejection force 
The impact of the filter attachment on the ejection force of the product solution from a syringe 
was determined using a Texture Analyzer XTplus device (Stable micro Systems, Godalming, 
UK). Pre-test speed was set to 5 mm/sec, test speed was 6 mm/sec (0.18 mL/min) and post-
speed was 10 mm/sec. Marketed products (anti-TNF-α IgG 1 40 mg/mL, Roferon® 3 Mio, 
Roferon® 9 Mio, NeoRecormon® 2000 IE) were analyzed. 27G ½” needles for attachment 
were supplied by the manufacturer for Roferon® 3 Mio, Roferon® 9 Mio and 
NeoRecormon® 2000 IE, whereas the anti-TNF-α IgG 1 product was already filled into 
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prefilled syringes with a staked-in needle. The product was repacked into glass syringes 
without a staked-in needle (BD Hypak SCF™, BD, Franklin Lakes, New Jersey, USA) to 
enable filter and 27G ½” needle (BD MicrolanceTM 3, Becton, Dickinson and Company 
Limited, Drogheda, Ireland) attachment. Controls represent the force to eject the protein 
solution from the glass syringe and the 27G ½” needle. Filters with a pore size of 0.2 µm and 
a diameter of 13 mm were attached on the luer cone of the syringe. 27G ½” needles were 
attached to the filter outlet and are later referred to as 27G needles.  
For the simulation of injection into subcutaneous tissue, injections were carried out into pig 
skin. The skin was at least 3 cm thick and the needles were inserted 1 cm into the skin. 
These experiments were performed with a 120 mg/mL monoclonal antibody solution filled in 
glass syringes. Either a 27G ½” needle or a filter and a 27G ½” needle were attached before 
ejection at a speed of 3 mm/s. 
 
 
2.3. Results 
2.3.1 Filter testing by filter manufacturers 
Information about the internal filter quality testing was obtained from the four filter 
manufacturers GE Healthcare, Merck Millipore, Pall GmbH and Sartorius AG. The collected 
information shows that quality criteria for filters are diverse and not every company was able 
to provide information on properties like particulates, extractables or product lot release 
criteria. Regarding biocompatibility all companies run tests according to ISO 10993, two run 
also 93/42/EEC and USP Class VI Biological tests for plastics. Title 21 Code of Federal 
Regulations, Section 210.3(b)(6) and 211.72 for non-fiber-releasing filters is carried out by 
one company. Production and packaging occur under clean room conditions according to 
several ISO forms or to ISO 9001. Two of the companies have internal limits regarding 
particulates. In one case the test method according to Annex A.2 of ISO 8536-11 is applied 
for infusion filters but not for other medical filters. The other company allows less than 50 
particles larger than 10 µm/unit. Visual inspections for product lot release are done by two 
companies. The units should be free of visible fibers and particles under normal plant 
lighting, respectively, should be free of injection molded particles and loose particles or fibers 
of sizes larger than 100 µm. One company determines extractables by UV and weighing, 
although it is not stated which extractables could be expected. Further, the filters are tested 
for the release of ammonium and heavy metal ions. Another company weighs the amount of 
non-volatile residues and analyzes them with FT-IR in adaption to Title 21 Code of Federal 
Regulations parts 176 and 177. However, this test is done for filter cartridges and not for 
infusion or syringe filters. 
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2.3.2 Filtration effectiveness 
The main aim of bedside filtration is to protect of the patients from any larger protein 
aggregates and protein particles. Hence, the filters should have the capability to diminish 
larger protein aggregates effectively. The suitability of several filters was tested by filtration of 
more than 19 different, highly relevant products. Protein solutions were measured in non-
stressed (Tables S4 and S6) and stressed (Table S5) conditions before and after filtration. 
MFI measurements showed for all cases the capacity of filters to diminish small micrometer 
particles. The particle counts of four differently stressed products are exemplarily presented 
in Figure 1. For harshly shaken, reconstituted Cerezyme® 200 Units (3.5 Units/kg) a 
reduction of the particle count from around 73,000 particles/mL to 2,686 particles/mL for one 
filter and to values even lower than 800 particles/mL for the other filters was achieved 
(Figure 1A). This corresponds to reduction factors of up to 894. For Mabthera® (1 mg/mL), 
which was stressed by end-over-end rotation in the original vial before dilution, the particle 
count was diminished from 4,535 particles/mL to less than 200 particles/mL, for four out of 
five filters (Figure 1B). End-over-end rotation stressed NeoRecormon® 2000 IE in prefilled 
syringes (Figure 1C) and Orthoclone® OKT 3 (1 mg/mL) in 5 mL ampoules had particle 
reduction factors of above 1,000. For Orthoclone® OKT 3 e.g. the particle burden decreased 
from 675,394 particles/mL to less than 100 particles/mL (Figure 1D). Note that numbers for 
the particle sizes 10 µm and 25 µm, which are mandatorily monitored by the pharmacopoeia 
[30], were either reduced to a minimum of a few particles/mL or were even entirely 
eliminated. Further numbers of the effective reduction of these two particle sizes with 
filtration can be found in Figure S2.  
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Figure 1. Particle count, as determined with MFI, is shown for shaken Cerezyme® 200 Units (3.5 Units/kg) (A) 
and end-over-end rotation stressed Mabthera® (1 mg/mL) (B), NeoRecormon® 2000 IE (C) and Orthoclone® OKT 
3 (1 mg/mL) (D). Non-filtered controls and filtered samples are displayed with the filters applied. The cumulative 
particle count/mL is shown for particles sizes of 1 µm, 2 µm, 5 µm, 10 µm and 25 µm. 
 
Table S4 and S5 list additional examples for non-stressed and stressed protein drug 
products displaying the high capability of filters to eliminate larger protein aggregates. Table 
S4 and S5 include DLS measurement data. In the majority of all cases the hydrodynamic 
radius of the proteins as well as the PdI remains virtually unaffected by filtration. Yet, in 
several cases like for Hylase 300®, NeoRecormon® 10000 IE or for stressed anti-TNF-α 
IgG 1 40 mg/mL, human growth hormone 0.8 mg/mL (Table S4 and S5) or Zenapax® (Figure 
3D) a reduction in the hydrodynamic radius after filtration could be observed. This 
demonstrated that reversible protein aggregates could be destroyed by filtration. In particular 
in the case of stressed proteins it was shown that the native hydrodynamic radius could be 
obtained after filtration.  
Further, two standard pharmacopoeia methods, LO and nephelometry were additionally 
carried out for several proteins (Table S6). LO measurements revealed a clear reduction of 
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the particle burden of the tested protein solutions and consequently confirmed the so far 
presented MFI results. Nephelometry data showed lower or similar values after filtration 
indicating the reduction of nanometer sized particles. In Figure 3 the data of a stressed 
Zenapax solution is exemplarily displayed graphically in order to confirm the observed 
results.  
 
 
Figure 3. Stressed Zenapax solution was analyzed with MFI (A), LO (B), nephelometry (C) and DLS (D). The 
cumulative particle count/mL is shown for particle sizes of 1 µm, 2 µm, 5 µm, 10 µm and 25 µm. Non-filtered 
controls and filtered samples are presented. 
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In order to test the effectiveness of 0.2 µm filters in the nanometer range NTA analysis was 
performed (Figure 4). The particle count of anti-TNF-α IgG 1 40 mg/mL was around 
200 million particles/mL of around 200 nm before filtration and it was reduced by at least 
25 % after filtration (Figure 4A). A more than 80 % particle burden reduction was achieved 
for NeoRecormon® 2000 IE after filtration. Also the particle mean size which was around 
324 nm was reduced to around 190 nm after filtration, corresponding well to the filter pore 
size of 200 nm (Figure 4B). The data illustrated that filtration was also effective in the 
nanometer range.  
 
 
Figure 4. The total particle count in millions/mL and the particle mean size for anti-TNF-α IgG 1 40 mg/mL (A) and 
NeoRecormon® 2000 IE (B) solutions are presented before and after filtration, as analyzed by NTA. 
 
Overall, the particle burden of non-stressed and stressed protein solutions can be effectively 
reduced in the nanometer and particularly in the micrometer range as demonstrated for more 
than 20 products. All filters were able to diminish the amount of larger protein aggregates in 
all cases. Regarding their capability to eliminate protein particles most of the investigated 
filters behaved similar except one filter. 
  
Chapter 2 
 
72 
2.3.3 Particle shedding from filters 
The particle shedding from filters was determined by filtering purified buffers. In order to 
identify possible factors leading to shedding from filters, buffers with different pH values and 
ionic strengths were applied. The presence or absence of surfactants was additionally tested. 
Apart from few exceptions it was observed that the filtration process led to lower particle 
counts (Table 3). For some samples the particle burden remained relatively unaffected by 
filtration which did not surprise, because already very low particle counts were measured in 
the buffer controls. However, filter shedding can occur in principle. In particular the Whatman 
PVDF 13 filter led to a higher particle burden in several test solutions after filtration. An 
explanation for this could be its packaging. The Whatman PVDF 13 filter was delivered in a 
plain paper box as a non-sterile bulk product, whereas both Millipore filters were sold as non-
sterile bulks within a plastic bag and a box as secondary packaging. In contrast, the Pall 
Acrodisc filter could be obtained as a single, sterile packaged filter. Single, sterile packaging 
was not available for all filters with a similar filtration area and with the same diameter. An 
impact of the pH value, the presence of a surfactant, the ionic strength (data not shown) or 
filter preflushing (data not shown) on the particle load of the solution could not be detected. 
For a few cases it was shown that the particle burden of the filters varied strongly within the 
same filter batch as indicated by standard deviations. Overall, particle shedding from filters 
can be neglected when adequate packaging is applied. As single, sterile packed filters are 
the target, particle shedding is considered as a controllable, uncritical aspect. 
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Table 3. Shedding behavior of two PES and two PVDF filters with a pore size of 0.2 µm and a diameter of 13 mm 
was analyzed using MFI and LO 
For each method the total particle count/mL (particles ≥ 1 µm) is stated. 
 
 
Buffer Filter Name MFI 
≥ 1 µm/mL 
LO 
≥ 1 µm/mL 
Acetate buffer pH 3.8  
ionic strength 154 mM  
without 0.1 % polysorbate 80 
Control 192 ± 201 34 ± 43 
Pall Acrodisc 22 ± 0 3 ± 1 
Millipore PES 13 59 ± 84 16 ± 14 
Millipore PVDF 13 67 ± 22 10 ± 12 
Whatman PVDF 
13 229 ± 141 271 ± 46 
Acetate buffer pH 3.8  
ionic strength 154 mM  
with 0.1 % polysorbate 80 
Control 22 ± 22 24 ± 19 
Pall Acrodisc 81 ± 78 18 ± 6 
Millipore PES 13 44 ± 38 16 ± 6 
Millipore PVDF 13 22 ± 0 8 ± 2 
Whatman PVDF 
13 392 ± 201 390 ± 184 
Phosphate buffer pH 6.2 
ionic strength 154 mM  
without 0.1 % polysorbate 80 
Control 185 ± 194 52 ± 64 
Pall Acrodisc 118 ± 34 17 ± 15 
Millipore PES 13 22 ± 0 23 ± 20 
Millipore PVDF 13 44 ± 22 4 ± 3 
Whatman PVDF 
13 44 ± 38 40 ± 24 
Phosphate buffer pH 6.2 
ionic strength 154 mM  
with 0.1 % polysorbate 80 
Control 192 ± 257 144 ± 221 
Pall Acrodisc 89 ± 38 24 ± 8 
Millipore PES 13 96 ± 90 6 ± 6 
Millipore PVDF 13 89 ± 117 7 ± 11 
Whatman PVDF 
13 1,428 ± 955 527 ± 35 
Phosphate buffer pH 8.0 
ionic strength 154 mM  
without 0.1 % polysorbate 80 
Control 22 ± 0 182 ± 25 
Pall Acrodisc 37 ± 46 20 ± 5 
Millipore PES 13 104 ± 46 15 ± 9 
Millipore PVDF 13 111 ± 97 40 ± 42 
Whatman PVDF 
13 118 ± 110 159 ± 37 
Phosphate buffer pH 8.0 
ionic strength 154 mM  
with 0.1 % polysorbate 80 
Control 81 ± 34 95 ± 60 
Pall Acrodisc 74 ± 71 17 ± 4 
Millipore PES 13 44 ± 22 26 ± 22 
Millipore PVDF 13 111 ± 80 9 ± 3 
Whatman PVDF 
13 429 ± 278 236 ± 98 
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2.3.4 Protein adsorption 
Protein drug products have a broad concentration range from a few µg/mL up to 
concentrations beyond 100 mg/mL. In particular for highly potent drugs in the lower 
concentration range like cytokines or hormones it is of substantial importance not to lose any 
protein because of adsorption to the filter membrane or housing. The filters which were used 
were all defined as low protein binding filters by the manufacturers. The adsorption behavior 
of several protein drug products and protein solutions, formulated according to products on 
the market, covering a broad concentration range and different protein classes were filtered 
with various filters (Table 7). Protein loss due to adsorption could be neglected for the 13 mm 
Pall Acrodisc filter with a filtration area of 1 cm2. In the majority of all investigated samples 
protein adsorption was also not noted for filters with a diameter of 25 mm or 28 mm 
(Table 7). The best results were achieved with the Pall PharmAssure filter. However, in some 
cases slight protein losses of around 4 µg for NeoRecormon® 10000 IE and Cerezyme® 200 
Units as well as up to 25 µg/mL for human growth hormone were observed.  
Overall, protein recovery after filtration was very high in the majority of all cases. Protein 
adsorption on the filter membrane will be negligible e.g. for high dosed antibodies, but in 
particular for low concentrated products protein adsorption should be checked as it can 
occur.  
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Table 7. P
rotein adsorption w
as as determ
ined by H
P
-S
E
C
 
The area under the curve [%
] is show
n for different proteins before and after filtration w
ith various filters. n.a. = not analyzed. 
  
Product 
Before Filtration 
Pall 
Acrodisc 
Pall 
Pharm
Assure 
Pall 
AEF 
anti-TN
F-α IgG
 1 (1 m
g/m
L) 
100 ± 0.38 
100.7 ± 0.35 
100.67 ± 0.18 
100.87 ± 0.19 
M
abthera
® 100 m
g (1.5 m
g/m
L)  
100 ± 1.25 
99.6 ± 1.2 
99.62 ± 1.55 
98.59 ± 0.78 
M
abthera
® 100 m
g (1.5 m
g/m
L) - stir stress 
100 ± 1.61 
98.78 ± 1.29 
99.34 ± 2.52 
98.36 ± 1.58 
Beriglobin
® 
100 ± 0.95 
99.71 ± 0.71 
99.84 ± 0.92 
n.a. 
H
um
an G
row
th H
orm
one (0.8 m
g/m
L) 
100 ± 0.95 
n.a. 
99.72 ± 1.03 
100.91 ± 1.33 
H
um
an G
row
th H
orm
one (0.8 m
g/m
L) - stir stress 
100 ± 2.27 
n.a. 
102.45 ± 3.83 
99.42 ± 1.18 
Erythropoietin (84 µg/m
L) 
100 ± 0.99 
100.59 ± 0.59 
100.78 ± 1.88 
n.a. 
Erythropoietin (84 µg/m
)L - stir stress 
100 ± 0.93 
99.12 ± 0.83 
99.16 ± 0.81 
n.a. 
H
ylase
® „D
essau“ 300 I.E
. 
100 ± 1.78 
99.59  ± 3.47 
n.a. 
n.a. 
U
rokinase H
S m
edac 500 000 I.E. 
(50 000 I.E./m
L) 
100 ± 0.42 
99.29 ± 0.34 
n.a. 
n.a. 
Bioclate
TM Antihem
ophilic Factor 
(recom
binant) 250 
100 ± 0.39 
99.16 ± 0.39 (supplied filter needle) 
O
rthoclone
® O
KT 3 (1 m
g/m
L) 
100 ± 1.52 
100.91 ± 0.93 
n.a. 
n.a. 
N
eoR
ecorm
on
® 10000 IE 
100 ± 3.03 
95.26 ± 3.15 
n.a. 
n.a. 
 
Product 
Before 
Filtration 
Pall 
Pharm
Assure 
Pall 
AEF 
M
illipore 
PES 
W
hatm
an 
PES 
Sartorius 
PES 
M
illipore 
PVDF 
W
hatm
an 
PVDF 
Erythropoietin (84 µg/m
L)  
stir stress 
100 ± 3.63 
101.24 ± 5.18 
98.26 ± 
3.12 
101.13 ± 
2.51 
99.34 ±  
1.5 
98.76 ± 
3.36 
96.13 ± 
3.56 
96.17 ± 
4.70 
M
abthera
® 100 m
g  
(4 m
g/m
L) 
100 ± 0.64 
100.17 ± 0.31 
99.94 ± 
0.56 
100.27 ± 
0.28 
99.98 ± 
0.36 
99.77 ± 
0.20 
100.44 ± 
0.46 
100.17 ± 
0.65 
C
erezym
e
® 200 U
nits 
(2.5 U
/kg) 
100 ± 1.66 
100.07 ± 0.54 
99.09 ± 
1.35 
100.21 ± 
1.78 
97.09 ± 
1.44 
99.16 ± 
0.90 
100.82 ± 
2.11 
91.03 ± 
0.93 
U
rokinase 100 000 H
S  
(2 000 I.E./m
L) 
100 ± 0.38 
98.73 ± 0.51 
99.19 ± 
0.67 
98.76 ± 
0.47 
99.25 ± 
1.28 
n.a. 
n.a. 
n.a. 
H
um
an G
row
th H
orm
one 
(0.8 m
g/m
L) 
100 ± 0.30 
101.18 ± 3.48 
96.88 ± 
2.16 
97.12 ± 
1.13 
97.75 ± 
1.86 
99.67 ± 
0.82 
98.82 ± 
1.94 
96.92 ± 
1.69 
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2.3.5 Hold-up volume 
Depending on the filter housing design and the filter size different volumes of protein drug 
solution remain in the filter. These so called hold-up volumes have to be of small volume in 
order to assure that the loss of protein drug product is minimized in all cases. For products 
applied in larger volumes of e.g. ≥ 5 mL a small excess to account for a potential loss in a 
filter could be considered. For small volume products (≤ 2 mL) the losses would not be 
acceptable.  
Here, eight filters, one with a diameter of 13 mm, six with 25 mm and one with 28 mm (see 
Table 2) were investigated regarding their hold-up volumes. Generally, rather high hold-up 
volumes were found. For the smallest filter, the Pall Acrodisc filter with a diameter of 13 mm, 
approximately 16.3 % of the initial volume remained in the filter after the filtration process 
(Table 8). For filters with 25 mm or 28 mm diameter the hold-up volumes were in the range of 
23 % to 60.5 % of the initial volume.  
 
Table 8. Overview of the initial volume, the volume after filtration, the hold-up volume, the hold-up volume after 
1 mL air purge and the declared hold-up volume after 1 mL air purge for eight filters  
 
 Acro-
disc 
Pharm-
Assure 
AEF M-PES M-
PVDF 
W-PES W-
PVDF 
S-PES 
Initial Volume [µL] 1,000 2,000 2,000 2,000 2,000 2,000 2,000 2,000 
Volume after 
filtration [µL] 
837 ± 
25 
1,320 ± 
30 
1,220 
± 30 
1,490 
± 30 
790 ± 
10 
1,550 ± 
30 
1,540 ± 
50 
1,150 ± 
20 
Hold-up volume 
(= remaining volume 
in the filter) [µL] 
163 ± 
25 
680 ± 
30 
780 ± 
30 
510 ± 
30 
1,210 ± 
10 
460 ± 
30 
460 ± 
50 
850 ± 
20 
Hold-up volume after 
1 mL air purge [µL] 
76 ± 32 270 ± 
20 
370 ± 
30 
220 ± 
10 
1,070 ± 
10 
160 ± 
50 
270 ± 
60 
320 ± 
50 
Hold-up volume after 
1 mL air purge as 
declared by the 
manufacturer [µL] 
≤ 28 50 700 < 100 < 100 not 
stated 
not 
stated 
100 - 
150 
 
13 mm diameter filter: Acrodisc = Pall Acrodisc  
25 mm diameter filters: PharmAssure = Pall PharmAssure; AEF = Pall AEF; M-PES= Millipore PES; M-PVDF = 
Millipore PVDF; W-PES = Whatman PES; W-PVDF = Whatman PVDF 
28 mm diameter filter: S-PES = Sartorius PES 
 
In order to reduce the hold-up volume filter manufacturers instruct a 1 mL air purge which is 
however not applicable during drug administration. Even though such an air purge reduced 
the hold-up volumes of all investigated filters, the loss of solution is still too high for small 
volume products and did not coincide with the hold-up volumes declared by the 
manufacturers (Table 8). 
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2.3.6 Protein denaturation 
During the filtration process protein solutions are exposed to a small filter pore size and the 
filter surface which presents a shear and interfacial stress for proteins. This stress might 
theoretically lead to protein unfolding, although practically all pharmaceutical protein drug 
products are sterile filtered at least once, typically at least twice, during the course of their 
manufacturing. CD and FT-IR measurements were carried out to confirm common 
knowledge that filtration does not impact the protein structure and to make sure that filtration, 
which was applied here, did not cause atypical alterations in the secondary structure of the 
protein. CD spectra were recorded for four model proteins before and after filtration. CD 
spectra of human growth hormone are exemplarily displayed (Figure 5B). FT-IR spectra were 
additionally taken for anti-TNF-α IgG 1 (Figure 5A). The results showed that filtration did not 
cause any changes in the secondary structure of the analyzed proteins.  
 
Figure 5. FT-IR spectra of non-stressed and stressed anti-TNF-α IgG 1 40 mg/mL solutions (A) as well as the CD 
spectra of human growth hormone (B) are displayed. 
 
2.3.7 Leachables 
The existence and quantity of leachables in filtrates was determined by ICP-OES, RP-HPLC 
and GC-MS after flushing various filters with highly purified water or a 0.9 % sodium chloride 
solution pH 4 with 0.1 % polysorbate 80.  
With ICP-OES more than 20 metal ions were monitored in filtrates, but no toxic heavy metals 
were detected. Filtrates were analyzed for ultraviolet active leachables using RP-HPLC at 
four wavelengths. Leachables were only detected in five out of seven filters at 214 nm, 
245 nm and 280 nm, but not at 330 nm. While three filters showed each ≤ 5 peaks, two filters 
had multiple peaks. All these measured impurities were on a low level. Chromatograms of 
three filters are shown in Figure S6 to display the differences between filters and the low 
amount of leachables. By analyzing seven filters with GC-MS, more than 60 aromatic and 
aliphatic leachables were identified in total. As observed with RP-HPLC, differences in the 
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quantity of leachables were detected. Three filters showed 6 to 12 peaks, one filter 15 peaks 
and three filters 22 to 28 peaks after filtering the solution which contained the surfactant. A 
lower number of peaks were visible in the highly purified water filtrates. The concentration of 
the detected peaks was in general far below 1 ppm, which represents the reporting threshold 
by the U.S. Food and Drug Administration [31]. The substances neodecanoic acid, 
dodecanoic acid, 1-dodecanol, 11-methyldodecanol and another not clearly identified one, 
which could be a polymer chain with several phenyl derivates were in some cases above 
1 ppm. 1-dodecanol and dodecanoic acid are frequently found as extractables and their 
safety hazard is considered as low [32]. Values and risk assessments were not found in the 
literature for neodecanoic acid and 11-methyldodecanol. However, taking the structural 
similarity of those two substances into account, it is assumed that their classification is similar 
to their structural derivates. 
 
2.3.8 Ejection force 
The inclusion of a filter into the process of the preparation or administration of the protein 
drug product should not lead to major handling problems due to high ejection forces caused 
by the filter resistance. A moderate ejection force with an attached filter, particularly for high 
dosed and viscous protein formulations is needed. For bedside filtration filters with a pore 
size of 0.2 µm, a small diameter like 13 mm and a low hold-up volume are required. Although 
a direct application of filtration for the injection of drugs with volumes below 1 mL is so far 
practically not possible, due to the high hold-up volumes of the filters, it should be tested, if 
drug injection at reasonable forces below 20 N is generally practicable.  
The ejection force of marketed drug products filled in prefilled syringes was determined at a 
speed of 0.18 mL/s. anti-TNF-α IgG 1 40 mg/mL filled into prefilled syringes with staked-in 
27G needles showed values of around 6.2 N. The same IgG 1 with a 0.2 µm filter (13 mm 
diameter) and a 27G needle showed values of about 8.7 N (Figure S7). For Roferon® 3 Mio 
8.5 N without a filter and 10.4 N with a 0.2 µm filter were necessary (Figure S7). For 
Roferon® 9 Mio similar values with 9 N and 11.6 N, respectively, were obtained (data not 
shown). NeoRecormon® 2000 IE had an ejection force of 5.4 N without and 7 N with a 0.2 µm 
filter (data not shown). The injection of a protein solution into a patient is supposed to require 
higher forces. A 120 mg/mL concentrated monoclonal antibody was injected at a speed of 
0.9 mL/min into pig skin. Easy to inject values of 7.8 N were achieved for the high dosed 
monoclonal antibody with a 27G needle and of 13.5 N with a 0.2 µm filter and a 27G needle 
(data not shown). All these measured values are even at high speed well below the critical 
force of 20 N and are easy to inject. 
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2.4. Discussion 
Bedside filtration could be a straightforward measure to guard patients from potential 
immunogenicity risks associated with protein aggregates above 0.2 µm in size. Protein 
aggregation is a broadly accepted factor regarding unwanted immune responses [13] and 
immune reactions can be reduced by diminishing protein aggregates from the drug product 
[15]. Bedside filtration is already performed for approximately 16 % of biopharmaceuticals 
[22].  
In this study comprehensive data regarding the efficiency of filtration is presented. 
Furthermore, critical aspects such as filter cleanliness or protein loss are evaluated. In the 
end, recommendations for future application of bedside filtration are given. 
 
2.4.1 Filtration efficiency 
For drug product solutions from several protein classes with different molecular weights and 
protein concentrations, it was shown with several filters that protein aggregates ≥ 1 µm can 
effectively be diminished with filtration. Even enormous particle burden above one million 
particles (≥ 1 µm)/mL could be reduced to values below a few hundreds of particles/mL. 
Differently stressed protein samples demonstrated further the capabilities of the investigated 
filters to diminish the particle count significantly. The total particle count was substantially 
reduced for all investigated samples, also for products with low particle counts before 
filtration. Particles ≥ 10 µm or ≥ 25 µm were completely eliminated or remained at numbers 
well below 100 particles/mL. DLS, nephelometry and NTA measurements further showed 
filtration effects also in the nanometer range, when using a 0.2 µm filter. The reduction of 
those small particles is of course not as effective as for the micrometer particles. However, it 
cannot be the intention of the filtration concept to get rid of protein aggregates below 0.2 µm. 
Moreover, for the quantification of these small particles HP-SEC studies are more 
appropriate. Reducing a very high number of protein particles might theoretically lead to 
lower protein concentrations. However, HP-SEC revealed no differences between non-
stressed and stressed samples indicating that the amount of lost protein is too low to be 
detected. These findings are in agreement with literature [33]. Another study demonstrated 
for stressed proteins as well that protein loss is in the range of a few µg/mL and might not be 
measureable in all cases [34].  
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2.4.2 Filter cleanliness 
Concerning the filter cleanliness the number of downstream particles and the concentration 
of leachables is important. From a previous study [27], we were alert that under certain 
conditions filter could even contribute to a higher particle load in the filtrate instead of 
reducing it. It was therefore tested in this study, if filters from various suppliers shed particles 
and if parameters, such as pH, ionic strength, filter preflushing or presence of a surfactant, 
would have an impact on the potential shedding behavior. Generally, the detected particle 
burden was extremely low in the non-filtered controls and in the filtered samples. In the 
majority of all investigated cases no shedding to such an extent as reported was observed 
[27]. However, variances between different filters exist. One of the tested filters showed 
stronger shedding behavior and could not be chosen for the purpose of bedside filtration. 
This specific filter was not single sterile packed, which explains the particle release from this 
filter. The shedding behavior was not influenced by pH, ionic strength, presence of a 
surfactant or filter preflushing. Regarding their shedding behavior the majority of the tested 
filters could be used for bedside filtration, although most of them are not yet specified by their 
manufacturers for this purpose but for in vitro, non-clinical use only. Filter companies take 
already several quality assurance measures in order to provide clean filters. Further, filters 
are generally manufactured and packaged under clean room conditions according to ISO 
norms. Internal limits for larger particles exist as well. However, testing for particles in the low 
micrometer range or for extractables is not routinely performed and should become a 
standard procedure for medical filters.  
Our rather small investigation about leachables in the tested filters revealed overall a low 
level of impurities by RP-HPLC and GC-MS. No adverse effects of these low concentrated 
leachables are expected, based on the negative biocompatibility tests of the filters performed 
by the manufacturers. It was also shown that the amount of detected leachables differed 
between the filters. To be on the safe side, it would be recommendable that manufacturers 
evaluate their filters systematically for extractables, which is currently not the case for all 
medical filters.  
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2.4.3 Protein loss 
Protein can be lost during filtration either due to adsorption of protein to the filter surface or 
due to the hold-up volume of the filter. 
Protein adsorption is a complex process with several factors like buffer, pH, temperature, 
charge or polarity playing a role [35, 36]. Further, the dilution media, the membrane and even 
the manufacturing process of the membrane can have an impact on the adsorption of protein 
to the filter surface [37, 38]. Adsorption of proteins to the filter surface was not observed for 
the majority of the investigated proteins. However, in some cases lower protein 
concentrations were measured after filtration. These losses were in the range of around 
4 µg/mL for NeoRecormon® 10000 IE and Cerezyme® 200 Units and up to 25 µg/mL for 
human growth hormone (0.8 mg/mL). Protein adsorption might therefore be of importance for 
very low concentrated drugs in the µg/mL range, but not for higher concentrated products like 
monoclonal antibodies [38].   
Another reason to lose protein during the application of bedside filtration is the hold-up 
volume of the filter. A loss of 16.3 % after filtration of 1 mL solution was already measured for 
the investigated 13 mm diameter filter. The loss was even higher for 25 mm and 28 mm 
diameter filters. An air purge as instructed by the manufacturer can reduce the hold-up 
volume. But this is not applicable during drug administration because injected air poses the 
risk of air embolism. Besides the hold-up volumes are still too high for small volume drug 
products. It is of utmost importance that filter manufacturers develop filter designs in a way 
that the hold-up volumes are dramatically reduced for small filters with low filtration areas. A 
reliable low hold-up volume is in particular necessary for a correct dosing of the drug and to 
keep potential overfill volumes at a minimum. The hold-up volume is less critical for infusions, 
because the dosing error is far less and clinically less relevant. Further, infusion sets are 
often flushed with a saline to avoid drug loss due to the void volume of the system [39].  
 
2.4.4 Protein structure and ejection force 
It was the purpose of our studies to confirm that no structural changes of the protein occur 
during bedside filtration. Our exemplary tests on four proteins showed that filtration in the 
process of drug preparation or administration did not alter the protein structure, as expected, 
because sterile filtration is a routine operation unit carried out in the course of aseptic 
manufacturing of each biotech drug. 
In a last step it was further checked, whether the addition of a filter would disturb the proper 
handling and a smooth drug administration. It was demonstrated with marketed products that 
easy to inject forces of below 20 N can be achieved with a 0.2 µm and 13 mm diameter filter 
at high speed [40]. Hence, a direct application of bedside filtration for drugs with volumes 
less than 1 - 2 mL is possible once filters with low hold-up volumes are on the market.  
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2.4.5 Expansion of bedside filtration - suggestions on how to proceed  
The question which is arising now is how to implement bedside filtration of 
biopharmaceuticals on a more routine basis as its establishment will take time. Filtration 
should be first considered for products which already need several handling steps until the 
injection takes place. In particular lyophilisates need a multiple step process with adding the 
solvent, dissolution of the powder, inspection after dissolution, aspiration into the 
administration syringe, change of the needle and dose adjustment before administration. A 
filter could be easily integrated in such a procedure without much additional effort. This is 
supported by the fact that 56 % of all lyophilisates with a filtration recommendation by the 
manufacturer are filtered during drug preparation [22]. Further, an easy implementation of 
filtration would also be possible for drugs stored in multi-dose or mono-dose vials, because 
at least the transfer into the administration syringe would be necessary anyway. A routine 
usage of filters should also be considered in infusion settings. In a later stage the concept of 
bedside filtration could also be applied to small dosage forms, but redesigned filters are 
needed as discussed before. For the identification of the most urgent products for the 
expansion of bedside filtration the prevalence and clinical effects of anti-drug antibodies for a 
specific product should be considered. Further, the particle burden of the product as well as 
the stability data of the product provide information whether the product tends to form protein 
aggregates over its shelf life and should be a candidate for bedside filtration. Safety, not 
convenience should be the ultimate factor to decide on the preparation and administration 
routine. 
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2.5. Conclusion 
The presented data show the benefit of bedside filtration for a wide range of protein classes 
and concentrations. In stressed and non-stressed protein drug products it was demonstrated 
that filtration is a powerful tool to eliminate larger protein aggregates. Other technical aspects 
regarding bedside filtration were critically assessed. The results showed no indication against 
the usage of filters. Filter cleanliness regarding particle shedding from filters was overall 
good, but variances exist. Several leachables, although on a low level, were detected by RP-
HPLC and GC-MS. They have to be further assessed and limited. Protein adsorption on the 
filter surface is not relevant for high dosed proteins, but should be considered for low µg/mL 
dosed drugs. The major loss of protein can be traced back to the hold-up volume of the 
filters. Protein denaturation caused by filtration was not detected and the filter impact on the 
ejection force is small.  
Although the investigated filters performed well, the filter industry has to address two major 
topics. First, a global quality testing for filters for clinical use should be established. As seen 
in the study, filter quality might vary regarding filter cleanliness in respect of particulates and 
extractables within and between batches. It is of utmost importance that a constant filter 
quality can be assured. Second, filter housings have to be adjusted for the usage of filters for 
small volume drugs.  
In summary, a broader application of bedside filtration is recommended as an immediate and 
potential measure to improve patient safety. 
 
 
Disclaimer 
The majority of the investigated products derived from the market. Almost all of the analyzed 
products were expired at the time of analysis. This allows studying an extreme condition. The 
data is by no means appropriate or intended to describe the actual quality of a particular drug 
product on the market. 
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Figure S2. The cumulative particle count/mL for the particle sizes 10 µm and 25 µm, as measured by MFI, is 
shown for Beriglobin (240 ± 235, respectively, 25 ± 43 particles/mL for 10 µm; 0 particles for 25 µm after filtration) 
(A), Anakinra (0 particles after filtration) (B), end-over-end stressed Erypo 4000 (7 ± 13 particles/mL for 10 µm; 
0 particles for 25 µm after filtration) (C) and for non-stressed (17 ± 24, respectively, 34 ± 34 particles/mL for 
10 µm; 0 particles for 25 µm after filtration) and stir stressed (0 particles after filtration) Human Serum Albumin 
(D). Non-filtered controls and filtered samples are presented with the used filters. 
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 Table S4. M
arketed drug products and proteins w
ith form
ulations according to products on the m
arket w
ere analyzed w
ith M
FI and D
LS
 before and after filtration w
ith the stated 
filters. For M
FI analysis the cum
ulative particle count/m
L for particles ≥ 1 µm
, 2 µm
 and 5 µm
 is displayed 
Protein 
Filter nam
e 
M
FI 
≥ 1 µm
/m
L 
M
FI 
≥ 2 µm
/m
L 
M
FI 
≥ 5 µm
/m
L 
DLS 
Z-Average 
[d.nm
] 
DLS 
Polydispersity 
Index 
anti-TN
F-α IgG
 1 
(1 m
g/m
L) 
C
ontrol 
4,333 ± 169 
1,582 ± 125 
198 ± 40 
10.97 ± 0.52 
0.15 ± 0.05 
Pall Pharm
Assure 
233 ± 68 
129 ± 68 
0 ± 0 
10.80 ± 0.13 
0.12 ± 0.02 
Pall AEF 
1026 ± 90 
304 ± 105 
70 ± 41 
11.30 ± 0.32 
0.17 ± 0.04 
anti-TN
F-α IgG
 1 
(40 m
g/m
L) 
C
ontrol 
330,279 ± 19,038 
143,247 ± 5,800 
220,807 ± 561 
15.45 ± 0.28 
0.16 ± 0.03 
Pall Acrodisc 
789 ± 319 
275 ± 41 
80 ± 53 
14.68  ± 0.45 
0.04 ± 0.01 
Kineret ® 100 m
g 
 
C
ontrol 
206,992 ± 2,049 
110,004 ± 2,490 
27,632 ± 2,057 
n.a. 
n.a. 
Pall Acrodisc 
200 ± 40 
94 ± 54 
12 ± 21 
n.a. 
n.a. 
Beriglobin
® 
 
C
ontrol 
306,683 ± 24,932 
158,388 ± 15,198 
43,192 ± 5,499 
18.45 ± 0.85 
0.34 ± 0.03 
Pall Acrodisc 
4,333 ± 2,665 
3,118 ± 2,149 
1,132 ± 905 
18.84 ± 1.53 
0.37 ± 0.08 
Pall Pharm
Assure 
1,695 ± 638 
804 ± 214 
210 ± 57 
17.97 ± 0.57 
0.32 ± 0.02 
Bioclate
TM 
Antihem
ophilic Factor 
(recom
binant) 250 
C
ontrol 
204,117 ± 2,471 
70,750 ± 2,424 
8,434 ± 542 
22.23 ± 3.05 
0.70 ± 0.07 
 Filter needle 
177,943 ± 3,936 
63,090 ± 3,117 
7,285 ± 682 
20.39 ± 1.77 
0.78 ± 0.07 
Bioclate
TM 
Antihem
ophilic Factor 
(recom
binant) 250 
C
ontrol 
123,243 ± 3,312 
31,392 ± 166 
782 ± 189 
17.71 ± 0.47 
0.67 ± 0.02 
 Pall Acrodisc 
134 ± 168 
61 ± 76 
24 ± 42 
18 ± 0.12 
0.64 ± 0.05 
Erythropoietin  
(84 µg/m
L) 
C
ontrol 
841 ± 177 
448 ± 46 
174 ± 36 
7.92 ± 0.49 
0.24 ± 0.01 
Pall Pharm
Assure 
355 ± 145 
132 ± 80 
17 ± 29 
8.51 ± 0.21 
0.25 ± 0.01 
Pall AEF 
502 ± 271 
148 ± 107 
33 ± 38 
8.52 ± 0.19 
0.25 ± 0.01 
Erypo
® 4000 
 
C
ontrol 
69,060 ± 2,047 
19,395 ± 506 
1,520 ± 166 
n.a. 
n.a. 
Pall Acrodisc 
542 ± 217 
254 ± 125 
30 ± 28 
n.a. 
n.a. 
H
elixate
® 250 
 
C
ontrol 
1,477,020 ± 
219,228 
615,949 ± 98,533 
92,360 ± 13,901 
n.a. 
n.a. 
Filter needle 
495,301 ± 19,596 
264,502 ± 12,137 
72,057 ± 4,866 
n.a. 
n.a. 
H
um
an G
row
th 
H
orm
one 
(0.8 m
g/m
L) 
C
ontrol 
36,894 ± 1,068 
19,699 ± 579 
6,702 ± 875 
84.89 ± 82.27 
0.56 ± 0.34 
Pall Pharm
Assure 
380 ± 174 
172 ± 42 
60 ± 39 
33.87 ± 27.71 
0.83 ± 0.20 
Pall AEF 
257 ± 111 
137 ± 97 
34 ± 30 
78.41 ± 84.48 
0.73 ± 0.21 
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Table S4 continued 
Protein 
Filter nam
e 
M
FI 
≥ 1 µm
/m
L 
M
FI 
≥ 2 µm
/m
L 
M
FI 
≥ 5 µm
/m
L 
DLS 
Z-Average 
[d.nm
] 
DLS 
Polydispersity 
Index 
Album
in (H
um
an) 
U
.S.P. Albutein
® 
25 %
 solution 
C
ontrol 
4,241 ± 48 
2,121 ± 308 
558 ± 17 
15.72 ± 0.86 
0.53 ± 0.00 
Pall Pharm
Assure 
722 ± 72 
285 ± 23 
50 ± 71 
16.68 ± 1.09 
0.55 ± 0.00 
Pall AEF 
974 ± 118 
202 ± 67 
78 ± 19 
15.91 ± 0.54 
0.52 ± 0.01 
H
ylase
® „D
essau“ 
300 I.E. 
C
ontrol 
36,145 ± 2,246 
13,723 ± 1,630 
2,244 ± 409 
290.13 ± 34.25 
0.89 ± 0.19 
Pall Acrodisc 
224 ± 166 
112 ± 166 
67 ± 89 
25.41 ± 1.31 
0.97 ± 0.05 
C
erezym
e
®
 200 U
nits 
(3.5 U
/kg) 
C
ontrol 
1,672 ± 83 
761 ± 61 
324 ± 14 
69.81 ± 10.65 
0.21 ± 0.05 
Pall Acrodisc 
130 ± 78 
60 ± 40 
17 ± 30 
15.55 ± 1.50 
0.58 ± 0.15 
IV set control 
1,974 ± 349 
885± 213 
177 ± 16 
50.71 ± 8.55 
0.28 ± 0.20 
IV set + Acrodisc
* 
176 ± 133 
76 ± 66 
34 ± 38 
25.32 ± 11.18 
0.55 ± 0.38 
IV set + I.V.Star 
334 ± 74 
163 ± 53 
68 ± 29 
16.46 ± 0.68 
0.68 ± 0.03 
Intron A
® Injection 
1 M
io 
C
ontrol 
83,448  ± 2,866 
37,844 ± 1,618 
6,156 ± 890 
n.a. 
n.a. 
Pall Acrodisc 
768 ± 1,071 
350 ± 521 
68 ± 90 
n.a. 
n.a. 
M
abthera
® 100 m
g 
(1.5 m
g/m
L) 
C
ontrol 
2,531 ± 360 
937 ± 72 
256 ± 70 
13.24 ± 3.25 
0.13 ± 0.03 
Pall Acrodisc 
207 ± 194 
137 ± 96 
33 ± 27 
16.61 ± 4.85 
0.14 ± 0.04 
Pall Pharm
Assure 
349 ± 213 
101 ± 92 
15 ± 29 
13.17 ± 2.86 
0.15 ± 0.07 
Pall AEF 
670 ± 136 
197 ± 20 
18 ± 32 
16.30 ± 4.57 
0.15 ± 0.06 
M
inirin
® parenteral 
(4 µg/1 m
L) 
C
ontrol 
8,034 ± 808 
2,195 ± 65 
256 ± 0 
n.a. 
n.a. 
Pall Acrodisc 
121 ± 119 
0 ± 0 
0 ± 0 
n.a. 
n.a. 
N
eoR
ecorm
on
®  
10000 IE 
C
ontrol 
25,113 ± 4,224 
9,372 ± 1,867 
1,314 ± 205 
188.12 ± 13.95 
0.25 ± 0.02 
Pall Acrodisc 
313 ± 96 
139 ± 55 
0 ± 0 
137.73 ± 4.60 
0.21 ± 0.02 
O
rthoclone
® O
KT 3 
(1 m
g/m
L) 
C
ontrol 
249,946 ± 29,704 
155,293 ± 10,932 
42,034 ± 1,875 
11.57 ± 0.10 
0.09 ± 0.02 
Pall Acrodisc 
43 ± 39 
17 ± 29 
0 ± 0 
11.3 ± 0.1 
0.06 ± 0.02 
R
ebif  ® 22 µg 
Injection solution 
C
ontrol 
678,557 ± 
313,801 
330,744 ± 
144,249 
75,281 ± 22,819 
n.a. 
n.a. 
Pall Acrodisc 
214 ± 170 
102 ± 122 
11 ± 20 
n.a. 
n.a. 
U
rokinase H
S m
edac 
500 000 I.E. 
(50 000 I.E./m
L) 
C
ontrol 
2,390 ± 767 
852 ± 57 
60 ± 26 
9.52 ± 0.44 
0.32 ± 0.04 
 Pall Acrodisc 
177 ± 82 
48 ± 14 
0 ± 0 
10.97 ± 1.73 
0.37 ± 0.06 
n.a. = not analyzed; * Acrodisc = P
all A
crodisc 
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 Table S5. M
arketed drug products and proteins w
ith form
ulations according to products on the m
arket w
ere exposed to different kinds of stress as stated 
A
fterw
ards the products w
ere analyzed w
ith M
FI and D
LS
 before and after filtration w
ith the listed filters. For M
FI analysis the cum
ulative particle count/m
L for particles ≥ 1 µm
, 
2 µm
 and 5 µm
 is displayed. 
Protein 
Filter nam
e 
M
FI 
≥ 1 µm
/m
L 
M
FI 
≥ 2 µm
/m
L 
M
FI 
≥ 5 µm
/m
L 
DLS 
Z-Average 
[d.nm
] 
DLS 
Polydispersity 
Index 
anti-TN
F-α IgG
 1 
(40 m
g/m
L) 
stir stress 
C
ontrol 
461,215 ± 19,417 
163,096 ± 10,238 
24,084 ± 610 
36.22 ± 1.96 
0.39 ± 0.02 
 Pall Acrodisc 
 
942 ± 1064 
 
520 ± 652 
 
50 ± 66 
 
17.96 ± 0.45 
 
0.29 ± 0.02 
anti-TN
F-α IgG
 1 
(1 m
g/m
L) 
stir stress 
C
ontrol 
7,465 ± 568 
2,778 ± 305 
360 ± 122 
11.65 ± 0.53 
0.24 ± 0.07 
Pall Pharm
Assure 
102 ± 1 
17 ± 29 
0 ± 0 
12.48 ± 0.61 
0.28 ± 0.06 
Pall AEF 
513 ± 160 
183 ± 80 
52 ± 27 
12.27 ± 0.89 
0.26 ± 0.09 
Erythropoietin  
(84 µg/m
L) 
stir stress 
C
ontrol 
913 ± 238 
411 ± 17 
173 ± 43 
7.81 ± 0.08 
0.23 ± 0.00 
Pall Pharm
Assure 
344 ± 42 
107 ± 15 
25 ± 25 
8.87 ± 0.34 
0.28 ± 0.04 
Pall AEF 
271 ± 89 
74 ± 25 
16 ± 28 
8.48 ± 0.87 
0.29 ± 0.07 
Erypo
® 4000 
end-over-end 
C
ontrol 
30,171 ± 1,475 
8,963 ± 424 
2,820 ± 258 
n.a. 
n.a. 
Pall Acrodisc 
222 ± 365 
96 ± 148 
22 ± 22 
n.a. 
n.a. 
H
um
an G
row
th 
H
orm
one (0.8 m
g/m
L) 
stir stress 
C
ontrol 
68,733 ± 569 
30,048 ± 80 
7,508 ± 287 
311.73 ± 122.5 
0.73 ± 0.15 
Pall Pharm
Assure 
635 ± 391 
348 ± 249 
119 ± 78 
75.43 ± 25.44 
0.85 ± 0.19 
Pall AEF 
606 ± 293 
277 ± 89 
79 ± 70 
74.25 ± 23.40 
0.95 ± 0.07 
Album
in (H
um
an) 
U
.S.P. Albutein
® 25 %
 
solution - stir stress 
C
ontrol 
159,940 ± 12,737 
93,632 ± 10,472 
30,121 ± 4,392 
15.28 ± 0.34 
0.52 ± 0.02 
Pall Pharm
Assure 
371 ± 233 
112 ± 70 
11 ± 19 
15.58 ± 1.33 
0.53 ± 0.02 
Pall AEF 
565 ± 337 
194 ± 93 
34 ± 48 
14.98 ± 0.12 
0.53 ± 0.02 
M
abthera
® 100 m
g 
(1.5 m
g/m
L) 
stir stress 
C
ontrol 
9,001 ± 472 
2,406 ± 147 
232 ± 117 
13.23 ± 0.50 
0.34 ± 0.05 
Pall Acrodisc 
317 ± 320 
103 ± 89 
17 ± 15 
18.95 ± 3.74 
0.24 ± 0.05 
Pall Pharm
Assure 
149 ± 57 
75 ± 43 
0 ± 0 
11.01 ± 0.08 
0.08 ± 0.03 
Pall AEF 
211 ± 90 
87 ± 82 
35 ± 39 
18.35 ± 0.44 
0.23 ± 0.01 
M
abthera
® 100 m
g  
1 m
g/m
L 
shake stress 
C
ontrol 
18,052 ± 885 
6,636 ± 491 
614 ± 143 
n.a. 
n.a. 
 Pall Acrodisc 
1,324 ± 795 
333 ± 89 
59 ± 34 
n.a. 
n.a. 
 n.a. = not analyzed
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Table S6. S
everal m
arketed drug products and proteins w
ith form
ulations according to products on the m
arket w
ere analyzed w
ith LO
, nephelom
etry and D
LS
 before and after 
filtration w
ith the indicated filters 
For LO
 analysis the total particle count/m
L (particles ≥ 1 µm
) is show
n. 
Protein 
Filter nam
e 
LO 
≥ 1 µm
/m
L 
Nephelom
etry 
[FNU] 
DLS 
Z-Average [d.nm
] 
DLS 
Polydispersity Index 
anti-TN
F-α IgG
 1 
(1 m
g/m
L) 
C
ontrol 
2,500 ± 179 
0.66 ± 0.07 
10.82 ± 0.29 
0.14 ± 0.04 
Pall Acrodisc 
194 ± 45 
0.56 ± 0.08 
10.70 ± 0.15 
0.12 ± 0.01 
Erythropoietin  
(84 µg/m
L) 
C
ontrol 
403 ± 179 
0.43 ± 0.03 
7.88 ± 0.16 
0.22 ± 0.02 
Pall Acrodisc 
31 ± 31 
0.34 ± 0.09 
7.95 ± 0.15 
0.22 ± 0.01 
R
eteplase  
(1 m
g/m
L) 
C
ontrol 
15,495 ± 482 
0.85 ± 0.02 
446.1 ± 179.05 
0.18 ± 0.02 
Pall Acrodisc 
736 ± 666 
0.36 ± 0.02 
3.18 ± 6.37 
0.32 ± 0.03 
H
um
an G
row
th H
orm
one 
(0.8 m
g/m
L) 
control 
28,707 ± 3,073 
2.26 ± 0.07 
86.56 ± 47.06 
0.66 ± 0.12 
Pall Pharm
Assure 
14,508 ± 1,505 
2.03 ± 0.34 
20.76 ± 4.87 
0.71 ± 0.09 
Pall AEF 
13,415 ± 1,935 
1.61 ± 0.45 
18.08 ± 12.49 
0.58 ± 0.11 
M
illipore P
ES
 
11,426 ± 2,795 
1.47 ± 0.29 
17.97 ± 14.62 
0.79 ± 0.12 
W
hatm
an PES 
14,313 ± 3,155 
1.60 ± 0.12 
33.25 ± 7.21 
0.51 ± 0.12 
Sartorius PES 
17,385 ± 2,526 
2.04 ± 0.46 
56.92 ± 27.29 
0.64 ± 0.17 
M
illipore P
VD
F 
13,525 ± 3,342 
1.2 ± 0.19 
35.7 ± 25.47 
0.64 ± 0.13 
W
hatm
an PVD
F 
15,866 ± 2,982 
1.64 ± 0.06 
16.49 ± 8.39 
0.65 ± 0.19 
C
erezym
e
®
 200 U
nits 
(2.5 U
/kg) 
control 
5,932 ± 481 
1.14 ± 0.02 
364.73 ± 99.90 
0.48 ± 0.04 
Pall Pharm
Assure 
727 ± 237 
0.85 ± 0.11 
22.75 ± 8.84 
0.78 ± 0.21 
Pall AEF 
401 ± 140 
0.81 ± 0.07 
25.49 ± 7.86 
0.78 ± 0.13 
M
illipore P
ES
 
606 ± 82 
0.70 ± 0.16 
21.84 ± 8.89 
0.76 ± 0.21 
W
hatm
an PES 
647 ± 195 
0.8 ± 0.09 
18.25 ± 0.88 
0.68 ± 0.03 
Sartorius PES 
2,890 ± 686 
0.78 ± 0.11 
15.69 ± 1.64 
0.58 ± 0.11 
M
illipore P
VD
F 
887 ± 162 
0.86 ± 0.06 
22.67 ± 6.96 
0.51 ± 0.31 
W
hatm
an PVD
F 
619 ± 105 
0.80 ± 0.05 
28.55 ± 2.61 
0.86 ± 0.04 
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Figure S6. RP-HPLC chromatogramms of an isotonic sodium chloride solution with a pH 4 and 0.1 % 
polysorbate 80 at 245 nm are presented before filtration (A) and after filtration with three different PES filters (B) 
to (D).  
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Figure S7. The ejection force at a speed of 0.18 mL/s is measured for an anti-TNF-α IgG 1 40 mg/mL and 
Roferon® 3 Mio solution without (control) or with (filtered) an attached filter (Pall Acrodisc) and 27G needles. 
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Abstract 
Purpose: The particle counts and the nature of particles of three different antivascular 
endothelial growth factor agents (VEGF) in different containers in a laboratory setting were 
compared. 
 
Methods: Original prefilled ranibizumab glass syringes, original vials with aflibercept, and 
repacked ready-to-use plastic syringes with bevacizumab from a compounding pharmacy 
and a compounding company (CC) were analyzed. Particle counts and size distributions 
were quantified by different particle characterization methods (nephelometry, light 
obscuration, Micro-Flow Imaging, nanotracking analysis, resonant mass measurement). 
Using high-performance size-exclusion chromatography (HP-SEC), levels of protein drug 
monomer and soluble aggregates were determined. 
 
Results: Nearly all samples showed similar product quality. Light obscuration and Micro-Flow 
Imaging showed a 4-fold to 9-fold higher total particle count in compounding company 
bevacizumab (other samples up to 42,000 particles/mL). Nanotracking analysis revealed 
highest values for compounding company bevacizumab (6,375 million particles/mL). All 
containers showed similar amounts of silicone oil microdroplets. Ranibizumab showed lowest 
particle count of all tested agents with only one monomer peak in HP-SEC. Repackaged 
bevacizumab from different suppliers showed varying product quality.  
 
Conclusion: All three tested agents are available in similar quality regarding particulate purity 
and silicone oil microdroplet count. Repackaging can have a major impact on the quality.  
 
 
Disclaimer 
Owing to the limited number of samples and the need to dilute 20 fold for analysis, the 
statistical value of the data is limited.  
 
 
Keywords  
aflibercept, bevacizumab, contamination, intraocular pressure, protein particles, ranibizumab, 
silicone oil 
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3.1. Introduction 
Intravitreal antivascular endothelial growth factor (VEGF) agents, including ranibizumab 
(Lucentis; Genentech, San Francisco, CA), bevacizumab (Avastin; Genentech) and 
aflibercept (Eylea; Regeneron Pharmaceuticals, Inc, Tarrytown, NY), are used for years to 
treat several kinds of retinal vascular disorders.1-3 Short-term and transient intraocular 
pressure (IOP) rise is well known to occur after intravitreal injection and is easy to explain 
because of injection of the fluid volume into the vitreous with the different anti-VEGF agents.4, 
5 Long-term or sustained IOP rise has a more difficult mechanism and has been reported 
clinically in several case reports and case series. Bakri et al6  first reported sustained IOP 
rise after ranibizumab injections requiring medical treatment in a small series of four patients 
and Kahook et al reported similar findings in six patients.7 Several studies with different 
number of patients followed reporting prevalence of long-term IOP rise after treatment with 
ranibizumab, bevacizumab, or aflibercept injections.7-20 
Recent retrospective analysis of the VIEW 1 and 2 data of 2,457 patients showed significant 
higher IOP elevation in ranibizumab than in aflibercept injected eyes.21 This study showed for 
the first time in a high number of patients a statistically significant IOP elevation difference 
between these two agents. Notably all studies evaluating IOP elevations after anti-VEGF 
injections are limited because of the retrospective design of the analysis.  
Several mechanisms have been proposed to explain clinically significant IOP elevation after 
anti-VEGF treatment. Such mechanisms include mechanical trauma to the trabecular 
meshwork from repeated injection-related IOP spikes and a decrease in aqueous outflow 
because of VEGF blockade, as potentially mediated by inhibition of nitric oxide synthesis, or 
inflammation or obstruction by high molecular weight protein aggregates or silicone 
microdroplets.22-24 Because of the different size of molecules (bevacizumab has a molecular 
weight of 149 kDa, aflibercept of 115 kDa, and ranibizumab of 48 kDa), it has been assumed 
that the agents can accumulate in the trabecular meshwork especially after long-term 
repeated administration and cause either direct obstruction or indirect change of the outflow 
facility. Other proposed mechanisms postulate outflow obstruction by protein aggregates 
and/or silicone oil droplets from the syringes or needles used.24-26 Liu et al reported both 
protein aggregates and particles ≥ 1 µm in repackaged bevacizumab obtained from three 
external compounding pharmacies in the United States.26 
All three agents are currently prepared and distributed in different containers. Ranibizumab 
comes in two possible injection containers. First, there is a single-dose vial, which is drawn 
into a syringe immediately before injection. Second, since 2013, there is a prefilled syringe 
available in the European Union, which has been approved also by the U.S. Food and Drug 
Administration (FDA) in 2016. Currently, mainly the prefilled syringe is used in central 
Europe. 27, 28 Aflibercept is only delivered in a single-dose vial, which is drawn into a syringe 
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immediately before injection. The use of bevacizumab as intravitreal agent is off-label. 
Bevacizumab is therefore only available from compounding pharmacies as an agent drawn 
from a larger vial and then usually filled into multiple syringes, which are stored in a 
refrigerator at 2°C to 8°C before use.26 Theoretically, this compounding, refilling, inadvertent 
freeze and thaw processes carries an increased risk for aggregate and particle generation.  
Liu et al quantified levels of subvisible particles and protein aggregates in repackaged 
bevacizumab syringes obtained from compounding pharmacies, as well as in samples of 
bevacizumab and ranibizumab vials tested in controlled laboratory experiments.25 The ready-
to-use prefilled ranibizumab was not available at the time of Liu’s publication. 
Aim of this study was to add further laboratory data on levels of subvisible particles and 
protein aggregates in a new prefilled ranibizumab syringe product and in the aflibercept 
product and to compare it to samples of bevacizumab delivered from a compounding 
pharmacy and from a compounding company. 
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3.2. Materials and Methods 
3.2.1 Materials 
The products of interest were bevacizumab 25 mg/mL, repackaged by the central pharmacy 
of the University Hospital Duesseldorf in 1 mL Braun syringes with a volume of 150 µL (8 
units; Avastin Roche 3.75 mg; batch No. B8008H10) (bevacizumab D), bevacizumab 25 
mg/mL, repackaged by BA.Herstellung GmbH & Co. KG in a Braun micro-fine insulin syringe 
U100 with a 30G staked-in needle with a volume of 50 µL (16 units; Avastin Roche 3.75 mg; 
batch No. 060117APO) (bevacizumab F), original aflibercept 40 mg/mL supplied in a vial and 
with a 5 μm filter needle (6 units; EYLEA 40 mg/mL injection solution in a vial, Bayer; batch 
No. 54269C) and original ranibizumab 10 mg/mL in a siliconized glass syringe (6 units; 
Lucentis 10 mg/mL injection solution in a prefilled syringe; Novartis; batch No. S2050C). All 
units were packed in shock absorbing containers with cooling packs until arrival at the 
laboratory of the Department of Pharmacy, Pharmaceutical Technology and 
Biopharmaceutics at the Ludwig-Maximilians-University in Munich. Upon arrival all products 
were visually inspected for any damages. No damages and no signs of freezing were 
detected. Samples were stored light protected at 6°C in the middle of a refrigerator to prevent 
any impact of light or freeze-thawing effects until direct analysis. 
 
3.2.2 Sample Preparation 
All steps like extracting the protein solution from the product container, sample dilution, or 
aliquoting was carried out under a laminar flow hood according to aseptic handling. For the 
simulation of a real application, all products were prepared according to the manufacturer 
instructions. An exception of this was that the whole syringe content was used instead of 
disposing some of the protein solution as instructed to avoid wasting product volume, which 
was required for analysis. Briefly, aflibercept solution was aspirated from the vial with the 
enclosed 18G x 1 ½ BD Blunt Fill Needle – Filter (Becton, Dickinson and Company Limited, 
Franklin Lakes, NJ) into a BD 1 mL syringe with Luer-Lok Tip (Becton, Dickinson and 
Company Limited). The filter needle was removed. The following procedure was now the 
same as for the other two products, bevacizumab D and ranibizumab. A 30G ½” BD 
Microlance 3 (Becton, Dickinson and Company Limited, Drogheda, Ireland) was attached to 
the syringe and the protein solution was expelled into a 50 mL Greiner tube. The repackaged 
bevacizumab F was stored in Braun micro-fine insulin syringes U100 with a staked-in needle. 
In this case, the product was directly expelled into the tube. All aliquots of the same product 
were pooled in one tube. For analysis, the pooled samples were diluted 1:20 in the 
appropriate formulation buffer. The buffers were filtered before with a medical 
polyethersulfone filter with a pore size of 0.2 µm (Pall PharmAssure; Pall GmBH, Dreieich, 
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Germany) before the addition of the concentrated protein solution. The samples were 
analyzed within three days after dilution. The presented data show the calculated results for 
nondiluted samples except for nephelometry where the results of the diluted samples are 
presented. Particle analysis was performed on calibrated equipment. Duke Standards and 
Count-Cal Particle Size Standards were used (both Thermo Scientific, Fremont, CA).  
  
3.2.3 Methods 
3.2.3.1 Nephelometry 
A Nephla turbidimeter (Dr. Lange, Düsseldorf, Germany) was used to determine the turbidity 
of the samples. At an angle of 90°, scattered light from a laser with a wavelength of 860 nm 
is detected. Triplicate measurements were performed and presented in the form of formazin 
nephelometric units (FNU).  
 
3.2.3.2 Light Obscuration 
Light obscuration was performed by using a SVSS-C device from PAMAS GmbH and the 
software PAMAS PMA Program V 2.1.2.0 (Rutesheim, Germany) for the quantification of 
particles in the subvisible and visible particle range. The system cleanliness was tested 
before each sample by measuring the particle content of highly purified water. Each sample 
run was carried out in triplicates of 0.3 mL after a prerun of 0.4 mL. Each sample was 
analyzed in triplicates resulting in a total of nine single runs. The speed for the aspiration of 
the solution was set to 10 mL/minute.  
 
3.2.3.3 Micro-Flow Imaging 
A Micro-Flow Imaging DPA 4100 device (BrightWELL Technologies Inc, Ottawa, Canada) 
with a 100 µm flow cell in the operation mode high magnification was used. The software MFI 
Particle Analyzer V6.9.7.2 was applied for analysis. The flow cell was flushed with highly 
purified water and flow cell cleanliness was checked between each run. The cell was flushed 
with 0.5 mL of the corresponding buffer to optimize illumination, which ensures a correct 
system thresholding, before each analysis. Next, the cell was loaded with 0.3 mL before 0.65 
mL of the sample was analyzed at a flow rate of 0.1 mL/minute. Triplicate measurements 
were performed. 
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3.2.3.4 Nanotracking Analysis 
A NanoSight LM20 (NanoSight, Amesbury, United Kingdom) with the software NTA 2.3 was 
used for capturing the particle movement in the nanometer range for 60 seconds. The 
camera shutter and gain were set to 1,497 and 680, respectively. The sample cell was 
flushed with highly purified water before it was loaded air bubble free with 0.5 mL sample. 
Between each analysis of the triplicate, 0.1 mL sample was loaded into the cell. Loading was 
performed with a 1 mL Terumo Syringe without needle (Terumo (Philippines) Corporation, 
Laguna, Philippines). During video capture, no flow was applied. 
 
3.2.3.5 Resonant Mass Measurement 
For the differentiation of protein and silicone oil particles in a particle size range from 300 nm 
to 5 µm resonant mass measurement with a Hi-Q Micro Sensor was carried out (Affinity 
Biosensors LLC, Santa Barbara, CA). Before the sample was loaded for 40 seconds, the 
sensor was flushed with highly purified water. Next, in the automatic limit of detection mode, 
the limit of detection was determined three times before calculating the mean value. The 
mean value was then used for the measurement. Analysis was stopped either after the 
volume reached 150 nL or 10 minutes. The manual stop needed to be performed because of 
very low particle counts in the samples leading to a wrongly recognized analysis volume. The 
density of protein particles was set to 1.32 g/mL and for silicone oil to 0.97 g/mL. The 
software ParticleLab V 1.9 (Affinity Biosensors LLC) was used for analysis. Each product 
was measured three times. 
 
3.2.3.6 High-Performance Size-Exclusion Chromatography 
For the evaluation of the relative amount of soluble protein species, size-exclusion 
chromatography (HP-SEC) was carried out. A flow of 0.5 mL/minute with a mobile phase 
consisting of 300 mM sodium chloride and 50 mM phosphate pH 7 in highly purified water 
was applied on a TSKgel 3000SWXL column (Tosoh Bioscience GmbH, Stuttgart, Germany). 
Samples were centrifuged before analysis for 10 minutes at 14,000 rpm. Twenty-five 
microliters of the diluted protein solution were injected. Each product was run six times. 
Analysis was carried out on a Waters 2695 Alliance Separation Module (Waters Corporation, 
Milford, MA) with a Waters 2487 Dual λ Absorbance Detector for UV absorbance at 280 nm. 
Data analysis was carried out with Chromeleon V6.8.  
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3.3. Results 
3.3.1 Nephelometry 
The determination of the opalescence of the buffer and protein solutions showed for all 
samples very low values (Figure 1). The addition of the protein solutions to the 
corresponding filtered placebo buffers led to a slight increase of the turbidity. One reason for 
the slightly lower opalescence value for the diluted ranibizumab samples in comparison with 
the other three products is the lower concentration of ranibizumab by a factor of 2.5 and four 
to bevacizumab and aflibercept, respectively. Overall the samples were clear and no 
particles visible. 
 
 
Figure 1. Nephelometry data for buffers and diluted (1:20) protein solutions. 
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3.3.2 Light Obscuration and Micro-Flow Imaging 
The particle burden in the subvisible range was measured with light obscuration and Micro-
Flow Imaging (Table 1). The filtered placebo buffer solutions contained only a minor amount 
of particles (< 1,100 particles [≥ 1 µm]/mL), whereas all protein solutions, except 
bevacizumab F, showed a (calculated) particle level in a range of around 36,000 to 42,000 
particles (≥1 µm)/mL. Bevacizumab F displayed particle counts by a factor of at least four 
(light obscuration) and nine (Micro-Flow Imaging) higher than the other samples. 
Ranibizumab had the overall lowest particle count. The difference in the solutions with and 
without protein clearly demonstrated the presence of many small protein and silicone oil 
particles in the product solutions. Particles larger than 10 µm as well as 25 µm were on a low 
level, if existing at all. 
 
 
Table 1. The Total Particle Count (Particles ≥ 1 µm, Calculated After Measuring Samples With 1:20 Dilution) of 
Each Sample as Determined by Light Obscuration and Micro-Flow Imaging is listed  
 
 Light Obscuration Micro-Flow Imaging 
particles/mL ≥ particles/mL ≥ 
1 µm 10 µm 25 µm 1 µm 10 µm 25 µm 
Bevacizumab 
D buffer 
546 ± 7 13 ± 6 7 ± 5 54 ± 23 0 0 
Bevacizumab 
D 
41,733 ± 
9,374 
622 ± 212 82 ± 122 42,848 ± 
12,097 
535 ± 463 0 
Bevacizumab 
F buffer 
81 ± 6 3 ± 3 0 498 ± 58 7 ± 13 0 
Bevacizumab 
F 
182,919 ± 
2,168 
2,126 ± 
151 
37 ± 46 414,308 ± 
40,781 
2,663 ± 
3,107 
0 
Aflibercept 
buffer 
1049 ± 41 6 ± 4 1 ± 1 255 ± 47 0 0 
Aflibercept 36,096 ± 
5,356 
163 ± 100 7 ± 13 44,299 ± 
4,244 
271 ± 470 0 
Ranibizumab 
buffer 
1,093 ± 95 5 ± 1 0 121 ± 70 0 0 
Ranibizumab 37,755 ± 
14,715 
570 ± 490 82 ± 90 19,815 ± 
9,358 
267 ± 463 0 
 
The table further contains the particle numbers of interest regarding the USP requirements (particles ≥ 10 µm and 
particles ≥ 25 µm). 
 
  
Chapter 3 
 
104 
3.3.3 Nanotracking Analysis  
Measuring submicrometer particles with nanotracking analysis revealed a particle level of up 
to 102 million particles/mL for all placebo buffers (Figure 2). In comparison, highly purified 
water had a particle count of around 12 million particles/mL. In the protein samples, however, 
hundreds of millions of particles in the low nanometer range were detected. The highest 
value with 6,375 million particle/mL was obtained for bevacizumab F, followed by aflibercept 
with 4,082 million particles/mL. The high particle count observed for aflibercept can be 
attributed to the highest protein concentration. Bevacizumab D showed less than half the 
number and ranibizumab showed about one fourth of the number of submicroparticles 
compared with aflibercept. The mean particle size for all drug samples was around 184 nm ± 
21 nm. Aflibercept and ranibizumab nanoparticles had a similar mean particle diameter of 
163 nm ± 10 nm and 171 nm ± 35 nm, whereas bevacizumab D and bevacizumab F particles 
showed a broader distribution and a larger mean value of 192 nm ± 62 nm and 
209 nm ± 11 nm, respectively. 
 
 
Figure 2. The total (calculated) particle count/ml of all nanometer particles is displayed for each sample as 
determined by nanotracking analysis. 
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3.3.4 Resonant Mass Measurement 
For the differentiation of silicone oil and protein particles, resonant mass measurement was 
performed (Figure 3). Overall, the particle burden of all solutions was very low and near the 
detection limit because of the high cleanliness of the samples. For comparison, highly 
purified water had a particle burden of around 50,000 particles (≥ 0.3 µm)/ml and a buffer 
showed values of 400,000 particles (≥ 0.3 µm)/mL. In all cases, silicone oil droplets were 
detected beside protein particles. The particle numbers were similar for bevacizumab D, 
bevacizumab F and aflibercept; ranibizumab showed a much smaller overall particle number. 
For bevacizumab D, bevacizumab F and aflibercept, a relatively small amount of silicone oil 
in comparison with the amount of protein particles was found. Silicone oil droplets are more 
dominant for ranibizumab, which is stored in a siliconized glass syringe and has an overall 
lower protein content.  
 
 
Figure 3. The (calculated) cumulative particle count/mL of silicone oil and protein particles is shown as 
determined by resonant mass measurement. 
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3.3.5 High-Performance Size-Exclusion Chromatography 
Bevacizumab D and F showed similar shares of soluble protein species as detected with HP-
SEC (Figure 4). One peak represented the monomer, whereas the other ones represented 
dimers and higher molecular weight protein species. Tiny amounts of higher molecular 
weight protein species made a percentage of around 0.1%, whereas the monomer 
accounted for around 98.2% and the dimers for roughly 1.7%. Two peaks were found for 
aflibercept, representing the monomer and higher molecular species with a share of 98.8% 
and 1.2%, respectively. For ranibizumab, only a monomer peak was detected. 
 
 
Figure 4. Determination of the relative amount of protein species for different anti-VEGF drugs with HP-SEC. 
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3.4. Discussion 
Intravitreal injection of anti-VEGF drugs can lead to an increased long-term IOP.4, 5, 7-20  
Several mechanisms to explain this phenomenon including the possibility that protein 
aggregates and silicone oil microdroplets are responsible for the IOP elevation are 
discussed.22-24 Protein aggregates can be formed by various pathways, including 
temperature, light, freeze-thawing or shaking during drug transportation and handling or just 
by long-term storage.25, 29 The major source for silicone oil particles is the primary packaging 
container of the drug substance. Other sources could be silicone oil coated stoppers, the 
syringe used for drug aspiration or the needles used for withdrawing or injection of the drug. 
Obstruction of the outflow pathway by particulate matter with IOP elevation is a well-known 
phenomenon in experimental glaucoma models.30 
To the best knowledge of the authors, this is the first study directly comparing subvisible 
particle numbers and type in all three clinically used anti-VEGF drugs in the current 
application form. In this study, the level and nature of the particles found in anti-VEGF drugs 
for intravitreal injection were identified and quantified. 
The diluted samples showed no sign of visible particles before analysis, which was confirmed 
by low nephelometry data (Figure 1) and overall moderate-to-low particle counts for all 
products except bevacizumab F (Table 1). Eventually, the high particle count in 
bevacizumab F in comparison with the agents could be explained by the primary packaging 
material. For expelling the protein solution an external 30G needle was attached to the 
syringe for all agents beside bevacizumab F. Bevacizumab F was supplied with a staked-in 
needle syringe. In another intravitreal injection study, intravitreal silicone oil droplets were 
more often detected with staked-in needle syringes than with luer cone syringes with an 
attached needle. The explanation of the authors was that a 50 µL residual space is present in 
the needle hub for attached needles. For staked-in needles this space is missing. In this 
space, silicone oil, which was scratched off the syringe barrel during ejection, can 
accumulate and is not injected into the eye, whereas it is in the staked-in needle syringe.31 
This hypothesis is supported by observations during preparation of this study. The loss of 
volume was higher for bevacizumab D; whereas in case of bevacizumab F, the complete 
small volume of 50 µL could be expelled. Other factors playing a role in the higher particle 
count of bevacizumab F could be the product itself or handling during storage, repackaging, 
or transportation. For ranibizumab one should keep in mind that it has a 2.5, respectively, 4 
fold lower protein concentration than the other products and the overall lower particle counts 
can in part be explained by that. Despite moderate-to-low particle counts in three out of four 
products, it is notable that all investigated products would theoretically not meet the 
specifications by U.S. Pharmacopeial Convention reference standard (USP) 789 (Table 1).32 
USP 789 deals with the foreign particulate matter in ophthalmic solutions and requires a 
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particle count below 50 particles/mL ≥ 10 µm, 5 particles/mL ≥ 25 µm and 2 particles/mL ≥ 50 
µm,32 respectively. It has to be mentioned that our measurements were performed according 
to USP 787, not according to USP 788 (as it is normally required in USP 789).32-34 USP 787 
differs from USP 788 mainly by the analyzed volume. USP 787 is designed for therapeutic 
protein injections with low volumes and can be performed with 0.2 mL to 0.5 mL, whereas 
USP 788 would require a volume of 25 mL. The particle number limits are the same for USP 
787 and USP 788.33, 34 The filtered aflibercept shows the best values regarding these 
requirements, although it would not meet them. Similar findings were already reported by 
Palmer et al and Yannuzzi et al.35, 36 They found in repackaged as well as in original 
bevacizumab particle counts higher than the limits set by the pharmacopoeia.36 A future 
solution to reduce particle numbers and to fulfill the requirements by the USP might be to 
filter the protein solutions before administration with a lower pore size filter (e.g., 0.2 µm).37 
Further, a batch to batch variation cannot be excluded because all our samples derived from 
one batch. Such a variation is possible as several other reports show.25, 35, 36, 38 Particle levels 
do not only vary between different compounders but may even vary between syringes 
produced from the same original vial content.25, 26, 36 Analyzed samples from this study were 
taken from standard clinical settings and therefore reflect real live anti-VEGF samples for 
injections in patients.  
So far only Micro-Flow Imaging data are published to quantify silicone oil and protein 
particles in ophthalmic preparations.25 A drawback of this method is that a reliable 
differentiation is only possible at particle sizes over 5 µm. Because smaller particles might 
have an effect on the trabecular meshwork, resonant mass measurement was applied. With 
this technique, also the nanometer range can be analyzed. The analysis revealed millions of 
nanometer-ranged silicone oil and protein particles (Figure 3). But, overall the samples 
contain a low amount of silicone oil and the absolute amount is similar for all four products in 
the study. The total particle number measured with resonant mass measurement is clearly 
lower for ranibizumab. The contribution of silicone oil microdroplets to the overall particle 
level in repackaged bevacizumab samples has been shown several times.25, 38 It was 
observed that the amount of silicone oil has not changed much over the investigated period 
of several weeks for nearly all tested samples.25, 36, 38 Nevertheless, the particle burden in 
repackaged bevacizumab increased over time,25, 36 suggesting protein aggregation, beside 
silicone oil as cause for the particle elevation.36 Otherwise, bevacizumab seems to be stable 
for several weeks in repackaged syringes.25, 36, 38, 39  
Nanotracking analysis measurements revealed a high amount of nanosized particles 
(Figure 2) and confirmed the overall particle number trends gained by light obscuration and 
MFI (Table 1).  
For the identification of the amount of soluble protein aggregates HP-SEC was carried out 
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(Figure 4). Overall the data correlate well with the findings for the insoluble particles. In 
accordance with literature, bevacizumab contains a small percentage of higher molecular 
weight species. The investigated bevacizumab samples had an amount of roughly 1.8%, 
whereas others detected a value of 1.56%38 or even higher.25, 40 Besides the monomer peak, 
a protein dimer peak was observed as well for aflibercept in a low concentration of 1.2% of 
the total protein concentration. The higher molecular species peak was so far not described 
in literature.41 The detection of only the ranibizumab monomer peak with HP-SEC was in 
accordance with literature.40  
Several authors have postulated mechanisms explaining long-term IOP elevation after 
repeated anti-VEGF injections.6, 7, 10, 25 Most mechanisms refer to mechanic or 
postinflammatory occlusion of the trabecular meshwork outflow pathway. None of these 
mechanisms have been proved so far, possibly reasons are multifactorial. Direct toxic effects 
have been examined as well; but even in much higher doses than clinically used, there is no 
toxic effect of anti-VEGF agents in laboratory setting.42 
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3.5. Conclusion 
Summarizing, the product quality of the repackaged bevacizumab D, the aflibercept vial, and 
the new siliconized glass syringe ranibizumab is overall similar. Repackaged bevacizumab F 
shows a much higher particulate burden, particularly when the standard method of light 
obscuration is applied. This might be due to the fact that a staked-in needle syringe was 
used in contrast to the other products, but also other reasons cannot be excluded. 
Ranibizumab displays in the majority of the applied analytical methods the highest quality 
with regard to protein-based submicron particles. However, one should keep in mind that 
protein concentration in ranibizumab is the lowest one. At least with the new syringe-
packaged ranibizumab product, differences to aflibercept like they were hypothesized in the 
VIEW 1 and 2 study could no longer be correlated with high particle burden in future use. 
Further, it can be stated that repackaging in general does not lead to inferior quality 
regarding particulate levels compared with “original” products. But already with only two 
repackaged bevacizumab products in hand, relevant differences could be detected. With only 
one batch of repackaged bevacizumab F at disposal, it is impossible to judge the cause for 
its inferior performance in comparison with the other investigated samples. When it comes to 
larger, two digit micrometer-sized particles application of a filter (needle) like for aflibercept 
appears helpful, although such a filter does not reduce smaller particles. 
In summary, it is important to make clear that none of the investigated three agents stood out 
in terms of particulate impurity. We found high numbers of submicron particles with different 
analytical methods. The relevance of such particles is still unclear, nor do we have 
specifications, or an industry standard for quantifying them. Therefore caution has to be 
applied before drawing conclusions. Yet, in the context of the ophthalmic use of protein drug 
products and the clinical experience with elevated IOP, it appears urgent to put more effort 
into research correlating these factors.  
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Abstract 
Prefilled syringes are a popular choice for the delivery of biopharmaceuticals. However, glass 
syringes might not be the optimal primary packaging material for all biopharmaceuticals. 
There is evidence that the necessary lubricant silicone oil in glass syringes can interact with 
proteins and can be shed from the surface into the product solution. In the last years, 
polymer based syringes were developed which are free of silicone oil. Despite the several 
advantages however, a major shortcoming of these polymer systems is their relatively high 
gas permeability, which might be a limitation for the storage of oxygen sensitive 
biopharmaceuticals. So far, no long-term protein stability studies regarding such polymer 
systems have been published. In this study, two therapeutic proteins were stored in glass 
syringes and in silicone oil free polymer syringes made out of cyclic olefin polymer. In 
addition, polymer syringes stored in nitrogen filled aluminum pouches or covered with 
oxygen-tight labels were included. Similar chemical protein stability was achieved at 4 °C for 
all different primary packaging materials. However, in contrast to the polymer syringes, high 
particle counts were observed in the glass syringes. Polymer syringes stored in nitrogen filled 
aluminum pouches presented a promising alternative for the storage of biopharmaceuticals 
as they do not expose patients to silicone oil and silicone oil-protein aggregates. 
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4.1. Introduction 
The number of prefilled syringes (PFS) as primary packaging for biopharmaceuticals has 
increased in the last years as many biopharmaceuticals are injected subcutaneously and 
make up for most of the top 10 US best selling drugs [1-3]. As a consequence PFS have a 
potential to grow by around 90 % up to 6.7 billion units in 2020. The wide spread usage of 
PFS is based on several benefits like enabling an easy and quick administration. Further, 
PFS offer an increased safety due to direct labeling and dosing as well as a reduction of 
needle stick injuries. Other PFS advantages include reduced contamination risks and 
minimized overfills [1, 2, 4]. However, downsides of commonly used type I borosilicate glass 
PFS exist as well [1, 2, 5]. Disadvantages of glass are breakage, delamination or pH shifts 
due to the leaching of alkali metals [2, 5]. Tungsten traces are introduced into the syringe 
when forming the fluid path with a tungsten pin. Due to high temperatures during syringe 
manufacturing tungsten oxides react with glass forming tungsten polyanions. Those 
polyanions are able to induce protein aggregation in certain cases [1, 2, 6-8]. Another major 
issue is that glass syringes need silicone oil for functionality. Several studies show that 
silicone oil alone or in combination with stresses like agitation or shaking can lead to protein 
aggregation [9-14]. Typically 0.2 - 1 mg medical grade silicone oil is used for the lubrication 
of the syringe barrel by spray-on technology [3, 4]. In the last years attempts were made to 
minimize the issues associated with silicone oil by optimizing the siliconization processes. 
Baked-on or cross linked siliconization techniques led to lower silicone oil levels and reduced 
silicone oil migration into the drug solution [2-4]. However, a silicone oil free glass syringe is 
not yet on the market. Since siliconization of the syringe barrel is still necessary, syringe 
manufacturers investigated other materials for silicone oil sensitive biopharmaceuticals. As 
alternative to glass syringes polymer syringes made of cyclic olefin polymers (COP) or cyclic 
olefin copolymers (COC) aroused the interest of the main syringe manufacturers [2]. 
Currently, two companies offer silicone oil free syringe systems based on COP material, 
other available polymer syringe systems still need silicone oil for lubrication. West 
Pharmaceutical Services developed a silicone oil free syringe system with Crystal Zenith® 
from Daikyo Seiko with FluroTec® coated stoppers. Terumo Corporation offers a silicone oil 
free COP syringe system called PLAJEXTM syringe with i-coatingTM coated stoppers [2, 15]. 
Outside of Japan these polymer syringes are still rarely used, but the interest in these 
polymer syringes increases [16]. Whilst breakage and delamination of glass syringes are 
reasons for frequent recalls, these two issues can be neglected with polymer syringes [5, 16, 
17]. Further, the polymer syringes show a high transparency, enabling visual inspection, a 
low impurity and extractable profile, a high moisture barrier, a broad chemical resistance and 
can be sterilized by steam or e-beam sterilization [17-20]. It is also proven that the polymer is 
safe and biocompatible and can be used for medical packaging [15]. The tungsten free and 
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glue free manufacturing process and the absence of silicone oil is more important for the 
storage of biopharmaceuticals [21, 22]. In comparison to siliconized polymer and glass 
syringes, lower particle counts in silicone oil free polymer syringes were detected in two 
studies, in which protein solutions were exposed to shaking for up to one week [15, 23]. 
However, no report about the development of particle count in protein filled silicone oil free 
polymer syringes over a longer storage period without artificial stress exists. Moreover, 
protein adsorption is reported to be lower for the polymer than for glass [20]. Despite these 
advantages polymer syringes have a major shortcoming. The material itself possesses 
relatively weak gas barrier properties [15, 24]. This might limit its usage as primary 
packaging material for oxygen sensitive pharmaceuticals [24, 25]. Various options are 
available to handle the oxygen permeability of the polymer syringes. First, oxygen absorbers 
could be placed in a packaging blister to control residual oxygen [16, 26]. Second, polymer 
layers with high oxygen barrier properties can be incorporated into the COP syringe body 
resulting in multilayer syringes. This approach will not be feasible in the near future due to 
high costs and low available quantities, which cannot sufficiently guarantee a wide market 
distribution. Therefore, the storage of a COP syringe in a gas tight aluminum pouch, which 
would also offer protection against light, might be an inexpensive alternative. The pouch 
could be filled with nitrogen as performed in this study. Next, labeling of the syringe is 
required anyway, hence oxygen-tight labels could be used as another rather cheap option. It 
should further be considered that oxygen permeation might have such a low impact on the 
stability of some proteins that none of these modifications are necessary. For the first time, in 
this study two highly relevant therapeutic proteins were stored in five different syringe 
systems evaluating the suitability of the polymer syringes for the long-term storage of 
biopharmaceuticals. Their chemical and physical stability was determined at three different 
temperatures during a period of up to 48 weeks.  
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4.2. Materials and Methods 
4.2.1 Materials 
Sodium chloride pure and glacial acetic acid 100 % were purchased from Bernd Kraft GmbH 
(Duisburg, Germany). Di-sodium hydrogen phosphate dihydrate p. A., sodium dihydrogen 
phosphate dehydrate p. A. and L-Arginine base pure Ph.Eur., USP were acquired from 
AppliChem GmbH (Darmstadt, Germany). Sodium acetate, 99 %, anhydrous, p. A. was used 
from Grüssing GmbH (Filsum, Germany). Trisodium citrate, anhydrous, 99 % was purchased 
from Alfa Aesar GmbH & Co KG (Karlsruhe, Germany). Citric acid monohydrate AnalaR 
Normapur® derived from VWR BDH Prolabo® (Leuven, Belgium). Polysorbate 80 was 
obtained from Fluka® Analytical (Buchs, Switzerland). Glycine ReagentPlus® ≥99 (TLC) was 
purchased from Sigma Life Sciences (Taufkirchen, Germany) and mannitol was obtained 
from Boehringer Ingelheim (Ingelheim, Germany). Hydrochloric acid, fuming 37 % and 
sodium hydroxide 32 % were obtained from Brenntag GmbH (Mühlheim an der Ruhr, 
Germany). Highly purified water was used for the preparation of buffers and mobile phases 
or for system cleanliness checks.  
The following steps were carried out according to aseptic manufacturing rules and under a 
laminar air flow system. A monoclonal antibody (mAb) with a concentration of 1 mg/mL was 
formulated in a buffer containing NaCl (105.5 mM), NaH2PO4 x 2 H2O (5.5 mM), Na2HPO4 
x 2 H2O (8.6 mM), sodium citrate (1.2 mM), citric acid x H2O (6 mM), mannitol (6.6 mM) and 
0.1 % polysorbate 80 at a pH of 5.2. The buffer for a highly potent cytokine, which was used 
in a concentration of 84 µg/mL, had a pH of 7.2 and comprised NaCl (75 mM), 
NaH2PO4 x 2 H2O (7.5 mM), Na2HPO4 x 2 H2O (12.5 mM), glycine (66.6 mM) and 0.03 % 
polysorbate 80. Used protein solutions and buffers were 0.2 µm filtered. 1 mL protein solution 
was filled into siliconized BD Hypak SCF™ (BD, Franklin Lakes, New Jersey, USA) or Gx 
RTF® (Gerresheimer Bünde GmbH, Bünde, Germany) glass syringes or silicone oil free 
cyclic olefin polymer (COP) syringes (Daikyo Crystal Zenith® Polymer Ready-to-Use 
syringes, West Pharmaceutical Services, Inc., Lionville, PA, USA). COP syringes were used 
as supplied and stored as follows. Version A (COP-Open): no further measures taken; 
Version B (COP-Pouch): storage of the COP syringes in nitrogen (≥ 90 %) filled aluminum 
pouches (Drylok 3000, Advantek GmbH, Freiburg, Germany); Version C (COP-Label): 
labeling of the COP syringes with a high oxygen barrier property label (Ceramix® CPT 001 
SiOx-coated PET, Tovenca, Ebmatingen, Switzerland). The syringes were individually 
stoppered by hand. Hereby, after filling 1 mL, trapped air was eliminated through the fluid 
path. Through this approach a large headspace could be avoided to allow studying the direct 
impact of the syringe barrel on protein stability without the additional influence of an air 
bubble. FluroTec® stoppers (West Pharmaceutical Services, Inc., Lionville, PA, USA) were 
used for all setups. The setups were stored at 4 °C and 25 °C for 48 weeks and at 40 °C and 
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at 75 % relative humidity for 24 weeks. For the analysis the syringe content was ejected like 
during a drug administration and the contents of five syringes were pooled. Four of these 
pools of each syringe packaging configuration and condition were analyzed with different 
methods. The results are presented as mean ± standard deviation. 
 
4.2.2 Methods 
4.2.2.1 Visible particles 
Syringes were inspected for visible particles before liquid ejection in front of a matt black and 
white plate with a light source as described in the European Pharmacopoeia method. 
 
4.2.2.2 Dynamic Light Scattering (DLS) 
DLS was carried out with a Zetasizer APS (Malvern Instruments, Worcestershire, UK) to 
determine the particle size and size distribution in the nanometer range. 200 µL protein 
solution were measured in duplicates at 20 °C. For each packaging configuration four pools 
were analyzed in duplicates resulting in a total of eight measurements per syringe packaging 
configuration. Z-Average value states the particle size and the particle size distribution is 
represented by the Polydispersity Index. 
 
4.2.2.3 Micro-Flow ImagingTM (MFI) 
To evaluate the particle count a Micro-Flow Imaging DPA 4100 device (BrightWELL 
Technologies Inc., Ottawa, Canada) with a 100 µm flow cell in the operation mode “high 
magnification” was used. The MFITM Particle Analyzer V6.9.7.2 software was applied for the 
analysis. Highly purified water was used for flow cell cleaning. Between each run the flow cell 
cleanliness was checked. The “optimize illumination” process, which ensures a correct 
system threshold, was carried out before each sample run by flushing the flow cell with 
0.5 mL of the appropriate protein solution buffer. Prior to the analysis of 0.65 mL sample for 
particle count and characterization the cell was flushed with 0.35 mL sample. A flow rate of 
0.1 mL/min was applied for the sample run. Four pools of each syringe packaging 
configuration were measured. For the system calibration Duke StandardsTM (10 µm) and 
Count-CalTM (5 µm) Particle Size Standards (both Thermo Scientific, Fremont, CA, USA) 
were used. 
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4.2.2.4 Chromatography Methods 
Mobile phases were prepared with highly purified water or were purchased in HPLC grade 
and 0.2 µm filtered. All samples were centrifuged at 14,000 rpm for 10 min before analysis. 
Three different high-performance liquid chromatography systems (HPLC) were used. The 
absorbance of the mAb was monitored at 280 nm using a Waters 2695 Alliance Separation 
Module (Waters Corporation, Milford, MA, USA) with a Waters 2487 Dual λ Absorbance 
Detector. A Dionex Summit system with an ASI 100 autosampler, a RF 2000 Fluorescence 
(extinction: 295 nm; emission: 343 nm for the cytokine) and a UVD170U detector (280 nm for 
the mAb) (all Thermo Fisher Scientific GmbH, Idstein, Germany) were used for both proteins. 
A Dionex Ultimate 3000 system with a fluorescence detector with the same wavelengths as 
stated before was used for the cytokine analysis. Data analysis was carried out with 
Chromeleon V6.8. Each pool was injected twice resulting in a total of eight runs per syringe 
setup and condition. 
 
4.2.2.4.1 High-Performance Size Exclusion Chromatography (HP-SEC) 
The amount of soluble protein species such as native, fragmented or aggregated protein was 
determined with HP-SEC.   
Cytokine: The mobile phase consisted of 300 mM sodium chloride and 50 mM phosphate 
pH 7 in highly purified water. A flow rate of 0.5 mL/min was applied and a TSKgel® 
3000SWXL column was used (Tosoh Bioscience GmbH, Stuttgart, Germany). Run time was 
30 min. 
mAb: A buffer with 20 mM phosphate and 150 mM sodium chloride at a pH of 7.5 was used 
as mobile phase. Separation was performed for 1 h on a SuperoseTM 6, 10/300 GL column 
(GE Healthcare, Uppsala, Sweden) with a 0.5 ml/min flow rate.  
 
4.2.2.4.2 High-Performance Ion-Exchange Chromatography (HP-IEX) 
Chemical modifications of the proteins were detected by HP-IEX. 
Cytokine: A 20 mM Tris buffer pH 7.5 (mobile phase A) and mobile phase A plus 500 mM 
sodium chloride pH 7.5 (mobile phase B) were used. A constant gradient from 5 % to 40 % B 
over a time range of 50 min, followed for 2 min at 100 % B and a reduction to 5 % B over 
2 min, which was kept for 5 min, was applied with a flow rate of 0.5 mL/min. A YMC BioPro 
QA column (YMC, Kyoto, Japan) was used. 
mAb: A 10 mM phosphate buffer pH 7.5 as mobile phase A and mobile phase A plus 0.5 M 
sodium chloride pH 5.5 as mobile phase B were used. Using a ProPacTM WCX-10G (BioLCTM 
Guard, 4 x 50 mm) and a ProPacTM WCX-10 (BioLCTM Analytical, 4 x 250 mm) (both Thermo 
Fisher Scientific, Rockford, USA) column for separation with a flow rate of 1 mL/min, the 
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share of B was increased from 6 % to 16 % within 20 min before 100 % was reached within 
2 min. 100 % B was kept constant for 4 min before it was reduced again to 6 % within 2 min. 
 
4.2.2.4.3 Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) – Cytokine 
only 
RP-HPLC was used to determine the share of chemically modified cytokine. Mobile Phase A 
consisted of 90 % highly purified water, 10 % HPLC grade acetonitrile (Acetonitrile, 
HiPerSolv CHROMANORM® Super gradient for HPLC, VWR BDH Prolabo® Chemicals, 
Ismaning, Germany) and 0.1 % trifluoroacetic acid (w/w) (Trifluoroacetic acid, reagent grade 
99 %, Sigma-Aldrich Chemie Gmbh, Munich, Germany) whereas mobile phase B was made 
up of 100 % HPLC grade acetonitrile and 0.1 % trifluoroacetic acid (w/w). Separation was 
achieved by using a YMC-Pack C4 (250 x 4.6 mml.D. S-5µm, 30 nm) column (YMC, Kyoto, 
Japan) at a flow rate of 0.5 mL/min with the following flow gradient: from 2 min to 25 min a 
linear gradient from 0 % to 100 % B, followed by 5 min 100 % B and within 1 min back to 0 % 
B. The column oven temperature was set to 37 °C. 
 
4.2.2.4.3 Protein A Chromatography – mAb only 
mAb oxidation was monitored by Protein A Chromatography. Mobile phase A contained 
20 mM phosphate with a pH of 7.4, whereas mobile phase B comprised additional 150 mM 
sodium chloride at a pH of 2.9. From 3 min to 23 min the share of B was increased from 0 % 
to 40 %, and then to 100 % B within 5 min and kept constant for 10 min. Column equilibration 
with A was performed before and after the increase of B. A Poros A column (2.1 mm x 30 
mm, Applied Biosystems, Framingham, MA, USA) and a flow rate of 0.5 mL/min were 
employed for separation.  
 
4.2.2.5 Oxygen quantification 
The concentration of soluble oxygen within the stored protein solution in the syringes was 
monitored using a Microx 4 stand-alone fiber optic oxygen meter (PreSens Precision Sensing 
GmbH, Regensburg, Germany). The tip cap of the syringe was removed and the sensor was 
inserted via the syringe bore into the protein solution, before the measurement was started. 
For each syringe packaging configuration twelve measurements were performed. The device 
was further used to measure the oxygen content in the nitrogen filled aluminum pouches. 
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4.2.2.6 Inductively Coupled Plasma Optical Emission Spectrometry (ICP-OES) – Cytokine 
only 
To analyze traces of tungsten in glass syringes a Varian Vista RL CCD simultaneous ICP 
AES Vista RL radial device from Varian (nowadays Agilent Technologies, Santa Clara, CA, 
USA) was applied. 3 mL protein solution were mixed with 0.24 mL 69 % nitric acid and 
double distilled water was added to a final volume of 8 mL before thermal treatment. System 
calibration was performed with a tungsten standard from Merck KGaA (Darmstadt, 
Germany). 2 to 3 emission wavelengths were chosen for each element. Each sample was 
analyzed in triplicates resulting in a mean value of twelve independent measurements for a 
single syringe setup. The following instrument settings were applied: performance: 1.2 kW; 
nebulizer pressure: 185 kPa; pump speed: 17 rpm; plasma flow: 13.5 l/min; auxiliary 
flow: 1.5 l/min; sample uptake time: 31 s; instrument stabilization time: 46 s; measurement 
time: 9 s. The maximum percentage variance is 5 % and the minimum correlation coefficient 
is 0.995. 
Samples were measured by Jaroslava Obel from the analytical division of the Department of 
Chemistry and Pharmacy at the Ludwig-Maximilians-Universität Munich. Method 
development was done in close collaboration between Jaroslava Obel and Benjamin Werner. 
 
4.2.2.7 Liquid Chromatography-Mass Spectrometry (LC-MS) 
LC-MS was performed to identify protein modifications like molecular oxidation of the two 
proteins. The formulation buffer of both proteins was exchanged for a 25 mM phosphate 
buffer pH 7.25 via centrifugation at 14,000 rpm for 12 min using Amicon® ultra-0.5 centrifugal 
filter devices (Millipore Corp. Bedford, MA, USA). This step was repeated twice. DL-
Dithiothreitol (DL-Dithiothreitol (≥98% (HPLC), ≥99.0% (titration), Sigma-Aldrich Corporation, 
St. Louis, MO, USA) was added resulting in a final concentration of 10 mM in the mAb 
solution. Before LC-MS analysis the solution was again centrifuged at 14,000 rpm for 5 min. 
For the deglycosylation of the cytokine the enzyme PNGase F was applied overnight at room 
temperature and DL-Dithiothreitol (10 mM final concentration) was added directly before the 
analysis. LC-MS analysis was carried out on an Agilent 1200 series LC system and an 
Agilent 6520 Quadrupole Time-Of-Flight system (Agilent Technologies, Santa Clara, CA, 
USA). Analysis was performed as described by Okbazghi et al. [27]. 
Sample preparation was performed by Benjamin Werner. Together with Ishan Shah 
(Department Pharmaceutical Chemistry, University of Kansas, KS, USA) the samples were 
run on the LC-MS device. 
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4.2.2.8 4-(aminomethyl) benzenesulfonic acid (ABS) assay 
For the detection of tyrosine and phenylalanine oxidation an ABS assay was carried out. 
ABS was synthesized as described by Sharov et al. [28]. The cytokine was concentrated and 
dialyzed against a 100 mM phosphate buffer pH 8.8 using Amicon® ultra-0.5 centrifugal filter 
devices (Millipore Corp. Bedford, MA, USA). The concentrated cytokine solution as well as 
the mAb solution were mixed with K3Fe(CN)6 (Potassium ferricyanide(III), powder, <10 
micron, 99+%, A.C.S. reagent, Sigma-Aldrich Corporation, St. Louis, MO, USA) in a ratio of 
1:15 and a final ABS concentration of 10 mM. 100 mM phosphate buffer pH 8.8 was added 
to ensure reaction conditions. As a positive control protein solutions were stressed with 
10 mM 2,2-azobis(2-methylpropionamidine) dihydrochloride (Sigma-Aldrich Corporation, St. 
Louis, MO, USA) for 3 h at 37 °C. The benzoxazole fluorescence of the ABS-derivatized 
protein samples was quantified using a SpectraMax Gemini XS plate reader (Molecular 
Devices, Sunnyvale, CA) and the software SoftMax® Pro 4.8. The compounds were excited 
at a wavelength of 360 nm and the emission maximum at 520 nm was used for the analysis. 
Measurements were carried out in triplicate for the mAb solutions, whereas the cytokine 
samples were measured once. 
Rupesh Bommana and Christian Schöneich (both Department Pharmaceutical Chemistry, 
University of Kansas, KS, USA) helped to establish the assay for the cytokine and the mAb. 
 
4.2.2.9 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
To detect protein fragments and aggregates non-reducing, denaturing SDS-PAGE was 
performed. NuPage® Novex® 4 - 12 % Bis-Tris protein gels, NuPage® MOPS SDS Running 
Buffer (20x) and Mark12TM Unstained Standard were used for the cytokine. NuPage® Novex® 
3 - 8 % Tris-Acetate protein gels, NuPAGE® Tris-Acetate SDS Running Buffer (20x) and 
HiMarkTM Unstained Protein Standard were applied for the mAb. Further, NuPage® LDS 
Sample buffer (4x), SilverXpress® Silver Staining Kit (all substances, Novex® by Life 
Technologies, Carlsbad, CA, USA), glacial acetic acid 100 % and methanol (Methanol HPLC 
grade, Fisher Scientific UK, Loughborough, UK) were used for the analysis. mAb was diluted 
with LDS Sample Buffer (4x) to a concentration of 37.5 µg/mL, whereas the cytokine had a 
final concentration of 67.2 µg/mL. Samples were denatured at 90 °C for 5 min. 12 µL of each 
sample were loaded per lane. Markers were prepared according to manufacturer 
instructions. Gels were run in a XCell SureLockTM Mini-Cell Electrophoresis System (Novex® 
by Life Technologies, Carlsbad, CA, USA) with the corresponding running buffers at a 
constant voltage of 200 V (cytokine) or 150 V (mAb) using a Bio-Rad PowerPac 200 (Bio-
Rad Laboratories, Hercules, CA, USA). Proteins were stained with the SilverXpress® Silver 
Staining Kit according to manufacturer instructions.  
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4.3. Results 
Taking the lower gas barrier properties of COP into consideration, COP syringes with no 
measures (COP-Open), COP syringes stored in nitrogen filled aluminum pouches (COP-
Pouch) and COP syringes with an oxygen-tight label (COP-Label) were compared to two 
commonly used, siliconized glass syringes (BD Hypak SCF™ and Gx RTF®). The physical 
and chemical stability of a mAb and a cytokine stored in these five packaging configurations 
was evaluated by visual inspection, MFI, DLS, HP-SEC, SDS-PAGE, HP-IEX, Protein A 
Chromatography, RP-HPLC, ABS assay, ICP-OES and LC-MS at 4 °C and 25 °C for 
48 weeks and at 40 °C for 24 weeks. The dissolved oxygen concentration of the protein 
solutions within the syringes was determined as well. The results are presented in the 
following first for the mAb for the three temperatures 4 °C, 25 °C and 40 °C and then in the 
same order for the cytokine. The sections have all the following structure: each starts with 
the results of the physical protein stability, followed by the oxygen quantification and 
continues with the results of the methods detecting chemical degradation.  
 
The protein solutions within the syringes were inspected for visible particles. In the whole 
study period no visible particles were detected for both proteins at all storage conditions.  
 
4.3.1 Results of the mAb stored at 4 °C 
Subvisible particle counting was performed with MFI. For the mAB solution the glass 
syringes showed overall higher particle counts compared to the COP syringes. Hereby, BD 
Hypak SCF™ syringes had a starting value of 6,440 particles/mL, followed by Gx RTF® 
syringes with 3,224 particles/mL, whereas the COP syringes had a particle burden of 
531 particles/mL for the mAb (Figure 1A). At 4°C the particle count increased over storage 
time for all syringes to values of 7,339 particles/mL for BD Hypak SCF™, 4,330 particles/mL 
for Gx RTF®, 1,336 particles/mL for COP-Open, 2,087 particles/mL for COP-Pouch and 
1,113 particles/mL for COP-Label syringes (Figure 1A). DLS showed no increase in the 
hydrodynamic radius of the protein (data not shown). The monomer content was slightly 
reduced after 48 weeks with the highest loss observed in the BD Hypak SCF™ syringes with 
3.6 %, whereas only 2.6 % of monomer content were lost in COP syringes (data not shown) 
as assessed by HP-SEC. SDS-PAGE revealed no differences between the syringe 
packaging configurations (data not shown). Oxygen quantification, Protein A 
Chromatography, ABS assay and LC-MS were applied to detect in particular oxidative 
protein modifications due to a possible impact of the oxygen barrier property of the syringe 
barrel material. First, the dissolved oxygen content was measured in the protein solution 
within the syringe before expelling the solution. The oxygen saturation was between 19 % 
and 20.5 % for all packaging configurations at the beginning (Figure 1B). The amount of 
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dissolved oxygen remained similar for glass, COP-Open and COP-Label syringes over a 
period of 48 weeks. In contrast, the amount of dissolved oxygen was reduced to around 
14.4 % in the COP-Pouch syringes (Figure 1B). HP-IEX revealed a rise of the amount of 
non-native species from around 10.9 % to around 15.46 % for all syringe packaging 
configurations after 48 weeks (Figure 1C). With Protein A Chromatography and the ABS 
assay no oxidation was observed (Figure 1D and 1E). In contrast to the other methods, 
which detected no or only low oxidative modifications, LC-MS analysis revealed that already 
20 % of the mAb were oxidized at the beginning of the study (Figure 1F). The relative 
amount of oxidized protein increased steadily to 28.2 % for both glass syringes. All COP 
syringes showed higher amounts of oxidized protein with 33.7 % for COP-Open and 37.6 % 
for COP-Label syringes. COP-Pouch syringes had only 31.4 % of oxidized species. 
Oxidation occurred in the heavy chains and no changes were observed in the light chains. 
The mean mass difference between the native and oxidized species for the samples stored 
up to 1 year was 15.77 Da. This indicated that besides a methionine oxidation with a mass 
difference of + 16 Da a tyrosine oxidation product with a mass of tyrosine + 14 Da was 
present.  
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Figure 1: The results of six methods characterizing the mAb solution stored at 4°C for 48 weeks within five 
different syringe packaging configurations are displayed. The total particle count/mL (particles/mL ≥ 1 µm) was 
obtained by MFI (A). The oxygen saturation of the protein solution within the syringe setups is shown in (B)*. 
Chemical or oxygen specific modifications were determined and quantified with HP-IEX (C), Protein A 
Chromatography (D), ABS assay (E) and LC-MS (F). Oxidation of the mAb (Native + 16) was detected by LC-MS. 
*The COP-Pouch 24 week value is not shown as it turned out to be an artifact.  
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4.3.2 Results of the mAb stored at 25 °C 
At a storage temperature of 25 °C the subvisible particle count showed in general slightly 
higher values for the mAb after 48 weeks than at 4 °C. Only the particle count in COP-Label 
syringes was lower with 899 particles/mL (Figure 2A). No changes were observed with DLS 
(data not shown). Monomer recovery, as determined with HP-SEC, was lower in glass 
syringes than in COP syringes (data not shown). Only after 48 weeks fragmentation of the 
mAb was observed for all syringe systems with approximately 1.5 %. The occurrence of a 
slight fragmentation was confirmed by SDS-PAGE (data not shown). The measurements of 
dissolved oxygen content led to similar results as described for 4 °C. COP-Pouch syringes 
showed an oxygen saturation of around 15.1 %, whereas the other syringe packaging 
configurations had at least values of 18.4 % (Figure 2B). A 4.2 fold higher amount of non-
native protein in comparison to the beginning was detected by HP-IEX for all syringe systems 
(Figure 2C). Methionine oxidation was detected with Protein A Chromatography (Figure 2D). 
Hereby, the highest amount of oxidized methionine with around 2 % was measured in the 
COP-Open and COP-Label syringes. To a lower extent the oxidation was also observed in 
the other syringe packaging configurations with the COP-Pouch syringe performing nearly as 
good as the BD Hypak SCF™ (0.32 % vs. 0.16 %). An increase in the fluorescence signal by 
the ABS assay, indicating a higher level of tyrosine and phenylalanine oxidation was not 
observed (Figure 2E). Major changes in the amount of oxidized protein became visible 
applying LC-MS analysis (Figure 2F). Roughly 41 % of the mAb in glass syringes and 48 % 
of the mAb in COP-Pouch syringes were oxidized in the heavy chain after 48 weeks. For 
COP-Open and COP-Label syringes 49.4 % of the mAb showed a single oxidation and 34 % 
of the mAb were even oxidized twice. As observed at 4 °C the native and oxidized species 
were separated by a mean value of 15.83 Da indicating the presence of oxidized tyrosine 
+ 14 Da. However, after 48 weeks for COP-Open and COP-Label syringes a mass difference 
of around 17.4 Da was obtained indicating a shift towards an oxidized tyrosine + 18 Da 
molecule. The mean mass difference between the single and double oxidized mAb was 
around 1 Da higher than between the native and single oxidized mAb. Oxidized methionine, 
also detected with Protein A Chromatography, and an oxidized tyrosine + 18 Da derivate 
were dominating. 
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Figure 2: mAb stability at 25 °C for 48 weeks was assessed in five different syringe packaging configurations. 
MFI measurements revealed the total particle count/mL (particles/mL ≥ 1 µm) (A), whilst the determined amount 
of dissolved oxygen is shown in (B). HP-IEX (C), Protein A Chromatography (D), ABS assay (E) or LC-MS (F) 
were applied to evaluate the amount of modified protein species. Single and double oxidations of the mAb 
(Native + 16 and Native + 32, respectively) were detected by LC-MS. 
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4.3.3 Results of the mAb stored at 40 °C 
Storing the mAb at 40 °C for 24 weeks, as an accelerated stress study, confirmed the results 
obtained at lower temperatures and longer storage time. In detail, the particle count doubled 
for BD Hypak SCF™ syringes to 13,069 particles/mL, whereas the particle numbers of the 
other syringe packaging configurations were similar to those observed at 25 °C after 
48 weeks (Figure 3A). DLS showed no changes in the hydrodynamic radius of the protein 
(data not shown). mAb fragmentation was already detected after 12 weeks with around 3 % 
in all cases but slight differences between the syringe packaging configurations were visible. 
After 24 weeks the lowest amount of fragmentation was observed for COP-Pouch syringes 
(3.86 %), followed by Gx RTF® (3.95 %), BD Hypak SCF™ (4.08 %), COP-Label syringes 
(4.08 %) and finally COP-Open syringes with 4.38 %. Protein recovery was slightly higher for 
COP syringes in comparison to glass (data not shown). No differences between the syringe 
systems were detected by SDS-PAGE (data not shown). Dissolved oxygen level remained 
similar for all syringe packaging configurations except for COP-Pouch syringes (19.1 % vs. 
5.1 %) and COP-Label syringes (19.1 % vs. 15.3 %) (Figure 3B). Chemical modifications of 
the mAb occurred as identified with HP-IEX (Figure 3C). A 6.34 fold increase of the ratio of 
native to oxidized mAb was noted for COP-Open syringes. In contrast, COP-Pouch syringes 
had a ratio of 5.86 %, followed by BD Hypak SCF™ (5.91 %), COP-Label (5.96 %) and Gx 
RTF® (6.0 %) syringes. After a storage time of 24 weeks methionine oxidation was detectable 
in all syringe systems (Figure 3D). However, the extent was very low in glass syringes 
(< 1 %) and in COP-Pouch syringes (1.7 %). In contrast, 9.2 % and 6.6 % of the mAb 
showed methionine oxidation in COP-Open and COP-Label syringes. The ABS assay also 
indicated oxidation of tyrosine and phenylalanine over the storage time of 24 weeks 
(Figure 3E). The data correlated with results obtained by Protein A Chromatography. LC-MS 
revealed that after 24 weeks the highest amount of native mAb could be found in glass 
syringes with around 37.5 %, followed by COP-Pouch syringes with 24 % (Figure 3F). COP-
Open and COP-Label syringes showed the lowest performance with 90.7 % mAb oxidized. 
Single oxidation was predominant in all packaging configurations except for COP-Open and 
COP-Label syringes after 24 weeks of storage. In these two cases the share of double 
oxidized protein, which occurred in all types of syringes besides single oxidation, made up for 
56 %. The mass difference between the native and single oxidized mAb increased with 
storage time and was principally caused by methionine sulfoxide formation in glass syringes 
and tyrosine oxidation for the three COP syringe packaging configurations. Whilst in glass 
and COP-Pouch syringes a reduction of the mass difference between single and double 
oxidation was observed over time, the values for COP-Open and COP-Label syringes 
remained nearly constant. All packaging configurations except the Gx RTF® showed values 
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between 16.6 Da and 16.95 Da for the double oxidation indicating that more methionine than 
tyrosine oxidized after 24 weeks. 
Figure 4 displays mass spectra obtained for the mAb at the different points in time of storage 
at 40 °C in COP-Open syringes. Besides a varying ratio of mAb to mAb + 16 Da to 
mAb + 32 Da similar mass spectra were obtained for the other packaging configurations. 
Mass spectra of mAb stored at 4 °C and 25 °C differed from the shown ones by higher 
shares of native and single oxidized protein and only for COP-Open and COP-Label syringes 
double oxidized peaks were observed. 
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Figure 3: For the mAb stored at 40 °C for 24 weeks in five different syringe packaging configurations the following 
is shown: the total particle count/mL (particles/mL ≥ 1 µm), the dissolved oxygen content and chemical 
modifications, as assessed by MFI (A), Microx 4 stand-alone fiber optic oxygen meter (B), HP-IEX (C), Protein A 
Chromatography (D), ABS assay (E) and LC-MS (F). Single and double oxidations of the mAb (Native + 16 and 
Native + 32, respectively) were detected by LC-MS. 
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Figure 4: The mass spectra of mAb solution stored in COP-Open syringes at 40 °C over time are displayed. The 
full mAb mass spectrum with an additional magnification of the light chain (marked with a frame) is presented in 
(A). (B) to (E) show an enlarged view of the heavy chain at the investigated time points of 0, 4, 12 and 24 weeks. 
The native and oxidized protein species are indicated. 
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Table 1 provides an overview of the chemical and physical modifications of the mAb over 
storage time at the three temperatures. 
 
Table 1: Summary of the mAb changes within the five different packaging configurations over a storage period of 
up to 48 weeks and at 4 °C, 25 °C and 40 °C as detected with various techniques  
 
 BD Hypak SCF™ Gx RTF® COP-
Open 
COP-
Pouch 
COP-
Label 
 
4 °C 
Visual O O O O O 
MFI* + + + + + 
DLS O O O O O 
HP-SEC O O O O O 
SDS-PAGE O O O O O 
HP-IEX + + + + + 
Protein A 
Chromatography 
O O O O O 
ABS O O O O O 
LC-MS O/+ O/+ + O/+ + 
 
25 °C 
Visual O O O O O 
MFI* + + + + + 
DLS O O O O O 
HP-SEC O/+ O/+ O/+ O/+ O/+ 
SDS-PAGE + + + + + 
HP-IEX +/++ +/++ +/++ +/++ +/++ 
Protein A 
Chromatography 
O/+ O/+ + O/+ + 
ABS O O O O O 
LC-MS + + ++ + ++ 
 
40 °C 
Visual O O O O O 
MFI* ++ + + + + 
DLS O O O O O 
HP-SEC + + + + + 
SDS-PAGE ++ ++ ++ ++ ++ 
HP-IEX ++ ++ ++ ++ ++ 
Protein A 
Chromatography 
O/+ O/+ ++ + ++ 
ABS O O + O/+ + 
LC-MS +/++ +/++ ++ ++ ++ 
 
O = no or minor changes; + = changes; ++ = major changes  
* = Highest particle count measured in BD Hypak SCF™ > Gx RTF® >> COP (in general)  
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4.3.4 Results of the cytokine stored at 4 °C 
Similar as observed for the mAb the particle burden of the cytokine solution in glass syringes 
was higher than in COP syringes from the beginning. BD Hypak SCF™ syringes had the 
highest particle number with 6,776 particles/mL, followed by Gx RTF® syringes with 
2,155 particles/mL, whereas in COP syringes 545 particles/mL were detected (Figure 5A). 
The storage time influenced the number of particles slightly at 4°C. Higher particle numbers 
where obtained for Gx RTF® (2,666 particles/mL) and for COP-Open syringes 
(1,444 particles/mL) (Figure 5A). The protein size, as determined with DLS, was not altered 
(data not shown). Only the monomer was detected by HP-SEC and SDS-PAGE (data not 
shown). Similar to the described observations for the mAb, the amount of dissolved oxygen 
was with 14.4 % the lowest in COP-Pouch syringes, whilst the other syringe packaging 
configurations showed values above 20 % (Figure 5B). After 24 weeks the share of chemical 
modified protein ranged between 0.5 % and 0.62 % for the cytokine as monitored by HP-IEX 
(Figure 5C). With RP-HPLC no altered protein was detected (data not shown). The ABS 
assay also showed no additional oxidation in comparison to the beginning (data not shown). 
Glycosylated cytokine displayed a high heterogeneity in LC-MS analysis (data not shown). In 
order to reduce the heterogeneity N-glycans were removed with PNGase F to allow focusing 
on the O-glycoforms. O-glycoforms with a composition of NeuAc1Hex1HexNAc1 and 
NeuAc2Hex1HexNAc1 were obtained [29], where the latter had a higher prevalence. Peaks 
with a 16 Da higher mass were observed for the major isoform. LC-MS analysis revealed that 
approximately 25.5 % of the NeuAc2Hex1HexNAc1 isoform were already oxidized at the 
beginning (Figure 5D). The share of oxidized cytokine remained stable for all syringe 
systems but one. COP-Label syringes displayed an oxidation rate of 40 % after 48 weeks. 
Approximately 5 % of the main isoform showed an O-acetylation of probably a sialic acid, 
identified due to a mass increase of 42 Da [29]. Oxidation was also observed for the 
NeuAc1Hex1HexNAc1 molecule. A low percentage of approximately 1.2 % of the main isoform 
showed dehydration of aspartic acid. To evaluate any oxidation caused by tungsten ICP-
OES was carried out for the glass syringes. After 48 weeks a tungsten concentration of 
0.06 ± 0.02 µg/mL for BD Hypak SCF™ and of 0.58 ± 0.08 µg/mL for Gx RTF® was 
measured.  
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Figure 5: Cytokine stability at 4 °C for 48 weeks in five different syringe packaging configurations was 
determined. The total particle count/mL (particles/mL ≥ 1 µm) was determined by MFI (A). The dissolved oxygen 
content was measured with a Microx 4 stand-alone fiber optic oxygen meter (B)*. The amount of chemically 
modified protein species was analyzed with HP-IEX (C) and LC-MS (D). Acetylation (+ 42 Da), oxidation 
(+ 16 Da) and dehydration (- 18 Da) were detected by LC-MS. *The COP-Pouch 24 week value is not presented, 
because it turned out as an artifact.  
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4.3.5 Results of the cytokine stored at 25 °C 
At a storage temperature of 25 °C the particle burden of the cytokine solutions were in a 
similar range at the beginning and at the end of the study (Figure 6A). An increase was only 
observed for Gx RTF® syringes were the particle number rose from 2,155 particles/mL to 
3,854 particles/mL (Figure 6A). DLS and HP-SEC showed no to minor changes during the 
storage time (data not shown). In HP-SEC aggregate formation with a small fraction of 
around 0.3 % was detected for all syringe packaging configurations only after a 48 weeks 
storage time. In contrast, no aggregate formation was observed by SDS-PAGE (data not 
shown). The same pattern, as described before, was gained by measuring the dissolved 
oxygen concentration. The lowest value was obtained for COP-Pouch syringes (data not 
shown). The share of chemical modified protein was around 0.35 % for all packaging 
conditions after week 24 (Figure 6B). However, after 48 weeks slight differences between 
glass and polymer syringes were noted by HP-IEX. COP-Open and COP-Label syringes had 
the highest amount of chemical modified protein with 1.16 % and respectively 1.17 %. The 
lowest share was detected in BD Hypak SCF™ syringes with 0.96 %, followed by COP-
Pouch syringes (1 %) and Gx RTF® syringes (1.14 %). With RP-HPLC the differences were 
more distinctive than with HP-IEX (Figure 6C). Before week 12 no modifications were 
obtained. Until week 24 only hydrophilic changes were observed, whereas after 48 weeks 
both, hydrophilic and hydrophobic changes were detected. RP-HPLC confirmed the results 
obtained by HP-IEX, as COP-Open and COP-Label syringes had a total share of modified 
protein species of 1.90 % and 1.81 %, respectively. Glass syringes performed similar 
(1.48 % BD Hypak SCF™ and 1.46 % Gx RTF®) and COP-Pouch syringes showed the best 
results with 1.36 % regarding the share of modified protein species. An increase of tyrosine 
and phenylalanine oxidation was not detected by the ABS assay (data not shown). LC-MS 
confirmed the results from the other analyses that the amount of oxidized cytokine was the 
highest in COP-Open and COP-Label syringes (48.0 % and 51.3 %) (Figure 6D). COP-
Pouch syringes had a value of 31.2 % of oxidized cytokine. The lowest share of oxidized 
protein was obtained in glass syringes with approximately 24 %. The amount of acetylated 
cytokine was slightly reduced from around 6 % at week 0 to a range between 4.8 % and 
3.6 % after 48 weeks depending on the amount of oxidized protein. An increase in the 
dehydration of the aspartic acid in a range from 0.1 % to 0.6 % over 48 weeks was observed. 
The percentage change refers to the main isoform NeuAc2Hex1HexNAc1. The tungsten 
concentration in BD Hypak SCF™ syringes was 0.06 ± 0 µg/mL and in Gx RTF® syringes 
0.59 ± 0.16 µg/mL, similar to the values obtained at 4 °C.  
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Figure 6: For the cytokine stored at 25 °C for up to 48 weeks in five different packaging configurations data 
obtained by MFI (A), HP-IEX (B), RP-HPLC (C) and LC-MS (D) are shown. Acetylation (+ 42 Da), oxidation 
(+ 16 Da) and dehydration (- 18 Da) were detected by LC-MS. 
 
 
4.3.6 Results of the cytokine stored at 40 °C 
The storage of the cytokine at 40 °C led to severe modifications of the protein. First, the 
particle count in COP syringes remained constant over the study period (Figure 7A). On the 
contrary, the amount of particles in glass syringes significantly increased from 
6,776 particles/mL to 11,632 particles/mL in BD Hypak SCF™ syringes and from 
2,155 particles/mL to 6,078 particles/mL in Gx RTF® syringes (Figure 7A). Whilst DLS 
measurements showed little changes over storage time, aggregation was observed from 
week 12 onwards by HP-SEC (data not shown). At the end the highest share of aggregates 
in the recovered protein was found for COP-Open syringes (6.4 %). 5.3 % of cytokine 
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aggregates were formed in Gx RTF® and COP-Label syringes. In BD Hypak SCF™ and 
COP-Pouch syringes the aggregate level of the recovered protein was at 4.9 %. Besides 
noting the formation of aggregates, protein loss of up to 45 % of the original protein 
concentration after 24 weeks was documented as well. In contrast to HP-SEC, aggregation 
was detected by SDS-PAGE already after 4 weeks (data not shown). Dissolved oxygen 
concentration was again the lowest in COP-Pouch syringes (10.0 %) (Figure 7B). HP-IEX 
revealed that the best performances regarding chemical modifications were achieved by 
COP-Pouch (10.4 %) and COP-Label (11.7 %) syringes (Figure 7C). COP-Open syringes 
showed the highest share of altered protein with 18.3 %, followed by glass syringes with 
15.0 % to 15.5 %. The results were confirmed by RP-HPLC measurements (Figure 7D). 
Whilst during the first 12 weeks only hydrophilic changes were observed at a level below 
5 %, high amounts of hydrophilic and hydrophobic changes were obtained after 24 weeks. In 
total 28.5 % of the cytokine stored in COP-Open syringes and only 18.1 % of the cytokine 
stored in COP-Pouch syringes showed chemical modifications. The two glass and the COP-
Label syringes were in the range of these values. Although the fluorescence intensity in the 
ABS assay increased for samples which were stored for 12 or 24 weeks, it was not possible 
to clearly state, if tyrosine and phenylalanine oxidation occurred because the starting values 
were too high (Figure 7E). LC-MS provided additional evidence that COP-Pouch syringes 
were the most suitable packaging condition for the cytokine at 40 °C (Figure 7F). Around 
63 % of the main isoform persisted after 24 weeks. The share of oxidized protein remained 
constant for the whole time at around 25 %, whereas the share of cytokine with a reduced 
molecular weight of 18 Da increased over time from 1.4 % to 8.9 %. In contrast, COP-Label 
syringes, performing in HP-IEX and RP-HPLC measurements nearly as good as COP-Pouch 
syringes, showed with LC-MS similar results as COP-Open syringes. Approximately 43 % of 
the main isoform and nearly the same amount of oxidized species were detected. Glass 
syringes preserved around 56 % native cytokine and only a 4 % to 5 % increase of oxidized 
species was observed. Further dehydration of the cytokine by at least 7.5 % and 
deacetylation with values of up to 3 % was observed in all packaging configurations.  
The cytokine degradation progress over storage time as determined with LC-MS is depicted 
in Figure 8.  
No tungsten was observed in BD Hypak SCF™ syringes, whereas in Gx RTF® syringes a 
concentration of 0.66 ± 0.22 µg/mL was found. 
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Figure 7: For the cytokine stored at 40 °C for up to 24 weeks in five different packaging configurations the MFI 
results (total particle count/mL ≥ 1 µm) are shown in (A), whilst the amount of dissolved oxygen content is 
displayed in (B). Chemical modifications were determined with HP-IEX (C) and RP-HPLC (D). Specific oxidation 
processes were analyzed with the ABS assay (E) and LC-MS (F). Acetylation (+ 42 Da), oxidation (+ 16 Da) and 
dehydration (- 18 Da) were detected by LC-MS. 
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Figure 8: N-deglycosylated cytokine was analyzed with LC-MS. The mass spectrum of the cytokine shows two 
major isoforms (A). These isoforms are enlarged in (B). The molecular changes of the main isoform over storage 
time at 40 °C in COP-Open syringes are visualized in (B) to (E). Major peaks are labeled with the cause of the 
mass difference besides the native protein.  
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Table 2 summarizes the changes of the cytokine detected with all methods over storage time 
at all temperatures. 
 
Table 2: Overview of the share of cytokine modifications as detected with various methods over the storage time 
in the five different packaging configurations 
 
 BD Hypak SCF™ Gx RTF® COP-
Open 
COP-
Pouch 
COP-
Label 
 
4 °C 
Visual O O O O O 
MFI* O O O O O 
DLS O O O O O 
HP-SEC O O O O O 
SDS-PAGE O O O O O 
HP-IEX O/+ O/+ O/+ O/+ O/+ 
RP-HPLC O O O O O 
ABS O O O O O 
LC-MS O O O O O/+ 
 
25 °C 
Visual O O O O O 
MFI* O/+ + O O O 
DLS O O O O O 
HP-SEC O/+ O/+ O/+ O/+ O/+ 
SDS-PAGE O O O O O 
HP-IEX + + + + + 
RP-HPLC O/+ O/+ O/+ O/+ O/+ 
ABS O O O O O 
LC-MS O O +/++ O +/++ 
 
40 °C 
Visual O O O O O 
MFI* ++ ++ O O O 
DLS O/+ O/+ O O O 
HP-SEC ++ ++ ++ ++ ++ 
SDS-PAGE ++ ++ ++ ++ ++ 
HP-IEX ++ ++ ++ +/++ +/++ 
RP-HPLC ++ ++ ++ +/++ +/++ 
ABS O/+ O/+ O/+ O/+ O/+ 
LC-MS + + ++ O/+ ++ 
 
O = no or minor changes; + = changes; ++ = major changes 
* = Highest particle count measured in BD Hypak SCF™ > Gx RTF® >> COP (in general)  
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4.4. Discussion 
In this study the suitability of silicone oil free polymer syringes made out of COP for the long-
term storage of biopharmaceuticals was evaluated. The impact of the oxygen barrier 
properties of COP in comparison to glass as syringe barrel material on the physical and 
chemical stability of two highly relevant therapeutic proteins was assessed. Two secondary 
packaging concepts to reduce the COP permeability were included in the study as well.  
First, the particle concentration within different packaging conditions is discussed. 
Afterwards, the impact of the packaging material on the amount of dissolved oxygen is 
commented on. Finally, the protein stability as determined using all methods, in particular 
with LC-MS, is discussed, starting with the mAb.  
 
Throughout the storage period the particle count showed for all packaging and storage 
conditions the highest level in glass syringes with values between 3,200 to 
13,100 particles/mL, whereas the particle concentration in COP syringes ranged between 
200 and 2,100 particles/mL. The elevated particle number in glass syringes could be 
explained by the presence of silicone oil. The distinctions between the two glass systems are 
based on the different amounts of silicone oil and siliconization techniques which were 
applied by the two manufacturers [3]. Overall, our findings are in agreement with other 
studies investigating silicone oil free syringe systems and syringe systems containing silicone 
oil [15, 23]. Particles that formed during the storage period of up to 48 weeks can consist of 
silicone oil microdroplets, protein particles or a combination of both. With the majority of 
particles having sizes of less than 5 µm, a clear identification of these particles using MFI 
was not possible. However, at the beginning the differences in the particle counts between 
glass and COP syringes can be attributed to silicone oil microdroplets. 
 
In all cases an oxygen saturation of around 20 % within the protein solutions was detected at 
the beginning as expected. In contrast to the other packaging configurations, which remained 
constant, COP-Pouch syringes showed a maximum value of approximately 15 % oxygen at 
the end points of all storage conditions. The reason for the reduced value is that COP 
syringes possess a low oxygen barrier property and oxygen from within the syringe 
exchanged with nitrogen from the nitrogen filled aluminum pouch. Similar experiences have 
been made before, e.g. for COP vials [24]. Two other studies took advantage from the COP 
permeability and used oxygen absorbers within the secondary packaging to control the 
oxygen level during product storage [16, 26]. Both studies were able to show that the amount 
of oxidized methionine was reduced in a system consisting of an oxygen absorber and COP 
syringes [16, 26].  
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HP-IEX showed for all syringe packaging configurations an increase of chemical modified 
mAb species by a factor of around 1.4 at 4 °C and around 4.2 at 25 °C. At 40 °C minor 
differences between the packaging configurations were detectable with a factor of modified 
protein within the range from 5.85 to 6.34. Whilst differences between the syringe packaging 
configurations were minor in HP-IEX measurements and changes were not assignable to 
oxidation processes alone, other techniques not only showed major differences between the 
systems, but also that these changes were clearly caused by oxidation.  
Protein A Chromatography was used to monitor the oxidation of methionine in the Fc region 
of the mAb, because an oxidation of these methionines resulting in a different binding affinity 
to Protein A [30, 31]. Methionine oxidation was low at 25 °C (max. 0.85 %) and at most 
around twice as high at 40 °C for glass syringes and COP-Pouch syringes. Whereas at 25 °C 
COP-Open and COP-Label syringes performed similar with around 2 % methionine sulfoxide 
formation, a major difference, not only with regard to the other packaging configurations, but 
also between COP-Open (6.6 %) and COP-Label (9.2 %) syringes, was noted using Protein 
A Chromatography at 40 °C. The lower detected amount of methionine sulfoxide formation in 
COP-Pouch syringes is in good agreement with two reports which use an oxygen absorber 
within the secondary packaging to prevent methionine oxidation [16, 26]. 
The data correlated well with LC-MS data, because oxidations were detected in all cases by 
LC-MS only in the heavy chains of the mAb, as it was observed by Protein A 
Chromatography, but not in the light chains. Moreover, based on the proposed tyrosine 
oxidation mechanisms with tyrosine + 14 Da, + 16 Da and + 18 Da products (see Steinmann 
et al. [32]), it was possible to conclude whether tyrosine or methionine was oxidized the 
most. Intact mass spectrometry revealed that a combination of tyrosine + 14 Da and 
methionine oxidation was predominant at 4 °C. Similar results were obtained at 25 °C and 
40 °C for glass and COP-Pouch syringes for the single oxidation, whereas tyrosine + 18 Da 
products were more distinctive for the second oxidation. Tyrosine + 18 Da oxidations were 
more prevalent for COP-Open and COP-Label syringes for both oxidations in particular at 
40 °C. Further, the LC-MS data showed at all temperatures the highest amount of native 
mAb in the following order: Gx RTF® ~ BD Hypak SCF™ > COP-Pouch > COP-Open ~ COP-
Label syringes.  
The data obtained by HP-IEX, Protein A Chromatography and LC-MS, showing that COP-
Open syringes protected the mAb less from oxidation, was further supported by the ABS 
assay. After 12 and 24 weeks tyrosine and/or phenylalanine oxidation was detected in COP-
Open and COP-Label syringes to a similar extent, whereas for COP-Pouch and Gx RTF® 
syringes the fluorescence intensity increase occurred to a lower degree or not at all (BD 
Hypak SCF™). Bommana et al. have shown with LC-MS that a quantitative correlation exists 
between the amount of oxidized tyrosine and phenylalanine products and methionine 
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sulfoxide [33]. Based on the results from Bommana et al. it can be stated that there is a 
strong correlation regarding the mAb oxidation status between the data obtained with ABS 
and Protein A Chromatography for the syringe systems in the present study.  
Overall, the low performance of COP-Open syringes for the long-term storage of the 
investigated mAb was confirmed by several methods.  
 
Regarding the cytokine only minor changes were observed over the storage period and were 
comparable for all syringe packaging configurations at 4 °C and 25 °C except for LC-MS. The 
amount of oxidized cytokine was increased in COP-Open and COP-Label syringes at 25 °C 
and even at 4 °C for COP-Label syringes. At 25 °C only a slightly higher amount (max. 
0.55 %) of chemically modified protein was detected by RP-HPLC for COP-Open and COP-
Label syringes in comparison to the other three syringe packaging configurations. Otherwise 
no major differences have been noticed between the configurations. At 40 °C major changes 
were observed for all techniques. Strikingly, COP-Pouch syringes performed best in all 
cases, even better than glass, whereas COP-Open syringes performed worst of all 
packaging variants in all but one method. Comparable results were obtained from the two 
glass and COP-Label packaging configurations with BD Hypak SCF™ showing overall 
slightly better results than Gx RTF® and COP-Label syringes. The reason for the slightly 
higher amount of chemically modified cytokine in Gx RTF® syringes in comparison to BD 
Hypak SCF™ syringes might be the presence of low amounts of tungsten. LC-MS showed 
major changes of the main isoform of the cytokine. The increase of the oxidized species was 
related to an oxidation of a methionine or a carbohydrate [34]. Deacetylation, a temperature 
dependent progress [35], of O-acetylated sialic acid was observed with increasing storage 
time and in particular at high temperature. In accordance with deacetylation, a strong 
increase of proteins losing a molecular mass of 18 Da was observed at 40 °C. This could be 
attributed to a dehydration of aspartate [36]. The cytokine amino acid sequence also includes 
an aspartate-serine motif which promotes dehydration of aspartate [36]. This chemical 
degradation is again temperature dependent [36, 37]. The findings of the study were 
consequently in good agreement with literature [36, 37]. 
 
Overall, the present study shows that different air bubble free syringe packaging 
configurations filled with mAb and cytokine solutions displayed at 4 °C a similar suitability for 
the long-term storage of biopharmaceuticals. We did not investigate the stability of proteins in 
these syringe packaging configurations with an air headspace for three reasons. First, the 
main goal was to assess the direct impact of the syringe barrel material and the gas barrier 
properties of the material. Second, vacuum stoppering resulting only in a tiny air bubble is 
applied anyway when using FluroTec® coated stoppers in conjunction with silicone oil free 
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COP syringes [2]. Third, the negative impact of an air bubble within syringes on the protein 
stability was already demonstrated several times [9, 15, 38]. Based on our own study with 
vials (Chapter 5), it could be stated that the impact of the primary packaging material on the 
protein stability was leveled out when a headspace was present (data not shown).  
 
 
4.5. Conclusion 
Two different syringe barrel materials, glass and COP, were compared in their suitability for 
the long-term storage of biopharmaceuticals. Two siliconized glass syringes and three 
silicone oil free COP syringe packaging configurations, including labeling or storage in 
nitrogen filled aluminum pouches, were investigated. At the typical storage temperature for 
biopharmaceuticals at 4 °C, chemical modifications between the five different syringe 
packaging configurations were comparable. However, regarding the particle burden 
significant differences existed. The particle level was significantly lower in COP syringes and 
did not increase as severely as in glass syringes over the storage period. The data further 
showed that silicone oil free COP syringes stored in nitrogen filled aluminum pouches could 
be used as a straightforward and efficient alternative for siliconized glass syringes for the 
long-term storage of biopharmaceuticals. Without such secondary packaging concepts the 
oxidation of sensitive proteins would restrict the use of COP syringes. The usage of silicone 
oil free COP syringes should be considered in the future to avoid the exposure of patients to 
measurable levels of silicone oil particles and their associated harmful consequences. 
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Abstract 
Glass vials are commonly used as primary packaging material for injectable drugs. A well-
known issue with glass vials is the occurrence of glass delamination in particular in liquid 
formulations. Despite several different approaches to get hold of the problem, it is so far not 
possible to entirely exclude the formation of glass flakes over time. In plastic vials this 
phenomenon cannot occur. Different plastic vials are available on the market. However, the 
suitability of plastic vials for the long-term storage of biopharmaceuticals has not been 
investigated in detail so far. In this study, the stability of two for therapeutic use highly 
relevant biopharmaceuticals was assessed in monolayer and multilayer plastic vials in 
comparison to glass vials. The container material had an impact on the protein stability even 
at 4 °C. Glass vials were able to preserve the product quality best. For the plastic materials 
multilayer vials should be preferred over monolayer vials. 
 
 
Keywords 
COP, cyclic olefin polymer, CZ-resin, Multishell®, vial, plastic, protein stability, oxidation, 
protein particle, protein aggregates 
 
 
Abbreviations 
ABS, 4-(aminomethyl) benzenesulfonic acid; COP, cyclic olefin polymer; DLS, Dynamic Light 
Scattering; HP-IEX, High-Performance Ion-Exchange Chromatography; HPLC, High-
Performance Liquid Chromatography; HP-SEC, High-Performance Size Exclusion 
Chromatography; LC-MS, Liquid Chromatography-Mass Spectrometry; mAb, monoclonal 
antibody; MFI, Micro-Flow Imaging; RP-HPLC, Reversed-Phase High-Performance Liquid 
Chromatography; SDS-PAGE, Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis. 
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5.1. Introduction 
Vials are commonly used containers as primary packaging systems for liquid and lyophilized 
injectable drugs [1-4]. In the last decades the material of choice for these vials or other 
containers such as ampoules or prefilled syringes has been borosilicate glass type I [1, 3-8]. 
Glass offers several advantages like chemical durability, transparency, ease of sterilization 
and low production costs [2, 3]. The chemical resistance of glass is influenced by the share 
of alkali oxides, the manufacturing process, sterilization and the interaction with the drug 
formulation [2, 3, 5, 6, 9-12]. As pH values, buffer components or salts can have a strong 
impact on the glass durability, drug container compatibility tests are necessary in particular 
with liquid drugs [4-6, 10-13]. All these factors have also an impact on visible particle 
formation for products stored in glass vials [4, 6-11]. The presence of particles in injectable 
drugs is considered as a health hazard and belongs to the top 10 reasons for recalls [2, 3, 5, 
6, 8-12]. These particles are associated with adverse effects like acting as an adjuvant on the 
immunogenicity of biopharmaceuticals or causing a capillary obstruction resulting in 
embolism [11, 12, 14-16]. Regarding the side effects of particles and the high costs of a 
recall, this issue attracted the attention of authorities and the pharmaceutical 
industry [3, 11, 12].  
So far two major particle groups which are caused by the vial material have been identified. 
They either consist of aluminum or silica. This can be explained by the typical composition of 
type I borosilicate glass, which contains around 81 % silicon dioxide, 13 % boric oxide, 
4 % sodium oxide and 2 % aluminum oxide [1]. The elution of aluminum depends on the type 
of buffer, but not all buffers are able to form aluminum precipitates. In particular phosphate 
buffers have the capability to elute and interact with aluminum to form white particles at 
neutral pH [4, 7, 8]. Silica particles are generated through a process called delamination. In 
glass vials delamination frequently occurs at the vial bottom or shoulder as these regions are 
exposed to higher temperatures during their manufacturing process and are therefore 
enriched in silica with a simultaneous accumulation of alkali oxides at the glass surface [1, 2, 
5, 6, 12, 13]. This altered glass composition is later prone to undesired glass flake formation 
[1, 13]. Ammonium sulfate treatment can reduce the amount of alkali ions [1, 13]. However, it 
might provoke a different effect as its extraction of cations alters the glass structure and 
therefore triggers the formation of glass flakes [5, 13]. Reducing the conversion temperature 
during the vial manufacturing process seems to be a more promising approach to diminish 
the delamination frequency [1]. In general delamination is a slow process and occurs 
predominantly at higher temperatures [1, 6, 10, 11, 13]. In order to circumvent the time 
dependent appearance of glass flakes, the shelf life of some products has to be reduced. 
This in turn, already contributed to acute supply shortages of certain medicines [12]. To 
mitigate these bottlenecks, the U.S. Food and Drug Administration allowed the temporary 
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usage of filters for a handful of life-saving drugs in the past. However, in these cases it had to 
be demonstrated that the filter did not alter the drug and that the filtration was effectively 
eliminating the particles [17].  
 
Plastic vials might be an alternative for glass vials in particular for liquid formulations with 
high pH values, buffers like phosphate and chelating agents like citrate [6, 9, 12, 13]. 
Delamination is not an issue for plastic vials made out of cyclic olefin polymers (COP). 
Compared to glass, the material properties of these polymer resins show a higher breaking 
and chemical resistance in a broad pH range preventing unwanted pH shifts [5, 6, 18-21]. 
Visual inspection is possible due the glass-like clarity of the material [18-20, 22]. Moreover, 
these resins possess low levels of impurities and extractables and a high moisture barrier 
and they can be sterilized by various sterilization techniques such as steam or e-beam [18-
20, 22-26]. Due to the hydrophobicity of the material, electrostatic interactions between drug 
and container could be reduced [19]. Besides, protein adsorption is lower in polymer 
containers for certain proteins compared to glass vials [23, 27]. COP can be considered as 
biocompatible and safe for its usage as primary packaging material for drug products [18-20].  
However, a major disadvantage of these polymers over glass is their permeability for gases 
like oxygen [28, 29]. This shortcoming might exclude COP based materials as primary 
packaging containers for oxygen sensitive biopharmaceuticals [23, 29, 30]. A solution to 
increase the gas barrier properties of COP is the incorporation of a layer with lower oxygen 
permeability rates, like polyamide, between two COP layers [31, 32]. This approach is found 
in Multishell® vials from Gerresheimer Bünde GmbH (Bünde, Germany) [33]. The Multishell® 
vials use the layer composition COP/polyamide/COP [33]. Up to date, literature on the 
performance of COP monolayer and COP/polyamide/COP multilayer plastic vials for the 
long-term storage of drugs, in particular of biopharmaceuticals, is scarce [19]. Another 
approach to obtain COP vials with a higher gas barrier is to coat the interior vial wall with a 
layer of silicon dioxide [34].  
 
In this study two plastic vial types were compared with commonly used glass vials and were 
evaluated for the first time for their suitability to store biopharmaceuticals. To this end, two for 
therapeutic use highly relevant proteins were filled into three vial types and the chemical and 
physical stability of the proteins was assessed after storage at three different temperatures 
for up to 48 weeks. 
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5.2. Materials and Methods 
5.2.1 Materials 
Di-sodium hydrogen phosphate dihydrate p. A., sodium dihydrogen phosphate dehydrate p. 
A. and L-Arginine base pure Ph.Eur., USP were purchased from AppliChem GmbH 
(Darmstadt, Germany). Sodium acetate, 99 %, anhydrous, p. A. was obtained from Grüssing 
GmbH (Filsum, Germany). Trisodium citrate, anhydrous, 99 % derived from Alfa Aesar 
GmbH & Co KG (Karlsruhe, Germany). Citric acid monohydrate AnalaR Normapur® was 
purchased from VWR BDH Prolabo® (Leuven, Belgium). Sodium chloride pure and glacial 
acetic acid 100 % were ordered from Bernd Kraft GmbH (Duisburg, Germany). 
Polysorbate 80 was purchased from Fluka® Analytical (Buchs, Switzerland). Glycine 
ReagentPlus® ≥99 (TLC) was obtained from Sigma Life Sciences (Taufkirchen, Germany) 
and mannitol derived from Boehringer Ingelheim (Ingelheim, Germany). DL-Dithiothreitol 
(≥98% (HPLC), ≥99.0% (titration), 2,2-azobis(2-methylpropionamidine) dihydrochloride and 
potassium ferricyanide(III), powder, <10 micron, 99+%, A.C.S. reagent derived from Sigma-
Aldrich Corporation, St. Louis, MO, USA. Hydrochloric acid, fuming 37 % and sodium 
hydroxide 32 % were purchased from Brenntag GmbH (Mühlheim an der Ruhr, Germany). 
For the preparation of buffers and mobile phases or for system cleanliness checks highly 
purified water was applied.  
The preparation of protein solutions and the filling and closing of vials was performed under a 
laminar air flow system and in compliance with aseptic manufacturing rules. Two protein 
solutions, one with an IgG 1 monoclonal antibody (mAb) with a concentration of 1 mg/mL and 
the other one with a low dosed cytokine (84 µg/mL) were used in this study. The buffer 
composition of the mAb was NaCl (105.5 mM), NaH2PO4 x 2 H2O (5.5 mM), Na2HPO4 
x 2 H2O (8.6 mM), sodium citrate (1.2 mM), citric acid x H2O (6 mM), mannitol (6.6 mM) and 
0.1 % polysorbate 80. The cytokine was formulated in NaCl (75 mM), NaH2PO4 x 2 H2O 
(7.5 mM), Na2HPO4 x 2 H2O (12.5 mM), glycine (66.6 mM) and 0.03 % polysorbate 80. The 
mAb formulation had a pH value of 5.2, whereas the cytokine solution had a pH of 7.2. All 
protein and buffer solutions were 0.2 µm filtered before usage.  
The 2R vials of interest, glass vials from Schott AG (Mainz, Germany), cyclic olefin polymer 
vials from West Pharmaceutical Services, Inc. (Lionville, PA, USA) and Multishell® vials from 
Gerresheimer Bünde GmbH (Bünde, Germany), had different sizes and diameters. Hence, to 
ensure a similar headspace to solution ratio the vials had different fill volumes. Glass vials 
were filled with 2.0 mL, COP vials with 1.17 mL and Multishell® vials with 2.2 mL protein 
solution. All vials were closed with FluroTec® coated stoppers and sealed with Flip-Off® seals 
(both West Pharmaceutical Services, Inc., Lionville, PA, USA). Protein stability in these vials 
was assessed at 4 °C and 25 °C for 48 weeks and at 40 °C and at 75 % relative humidity for 
24 weeks. For the analysis the content of several vials from each vial type was pooled. In 
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particular, the solutions of two glass vials, four COP vials and three Multishell® vials were 
mixed. At the end, four pools of each vial material and condition existed. Every pool was 
measured with the following methods. The results are presented as mean ± standard 
deviation. 
 
5.2.2 Methods 
5.2.2.1 Visible particles 
Examination for visible particles in the vials was performed in front of a matt black and white 
plate with a light source as described in the European Pharmacopoeia method.  
 
5.2.2.2 Dynamic Light Scattering (DLS) 
The particle size and size distribution in the nanometer range was determined using a 
Zetasizer APS device (Malvern Instruments, Worcestershire, UK). Four pools of each of the 
three vial materials were measured in duplicates at 20 °C resulting in a total of eight 
measurements. The particle size is given by the Z-average values and the particle size 
distribution is depicted by the polydispersity index. 
 
5.2.2.3 Micro-Flow ImagingTM (MFI) 
Micrometer particles were analyzed and quantified using a 100 µm flow cell in the “high 
magnification” operation mode on a Micro-Flow Imaging DPA 4100 device (BrightWELL 
Technologies Inc., Ottawa, Canada). For the analysis the software MFITM Particle Analyzer 
V6.9.7.2 was used. Flow cell cleaning and cleanliness check were performed with highly 
purified water. Before each run the command “optimize illumination” was carried out in order 
to ensure a correct threshold of the system. During this process the flow cell was flushed with 
0.5 mL of the corresponding protein solution buffer. In total 1 mL sample was used for the 
analysis. 0.35 mL were used to flush the flow cell before 0.65 mL of the sample were 
analyzed. Analysis was performed at a flow rate of 0.1 mL/min. For each vial material and 
condition four pools were measured. Duke StandardsTM (10 µm) and Count-CalTM (5 µm) 
Particle Size Standards (both Thermo Scientific, Fremont, CA, USA) were applied for the 
system calibration. 
 
5.2.2.4 Chromatography Methods 
Before chromatography analysis was carried out all samples were centrifuged for 10 min at 
14,000 rpm. The mobile phases were filtered with a 0.2 µm filter and prepared in HPLC 
grade medium or with highly purified water. High-performance liquid chromatography (HPLC) 
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was performed on systems from Waters Corporation (Milford, MA, USA) or Thermo Fisher 
Scientific GmbH (Idstein, Germany) using the software Chromeleon V6.8 (Thermo Fisher 
Scientific GmbH, Idstein, Germany). A Waters 2695 Alliance Separation Module with a 
Waters 2487 Dual λ Absorbance Detector at 280 nm was applied for monitoring the 
absorbance of the mAb. For mAb and cytokine analysis a Dionex Summit system with a 
UVD170U detector and a RF 2000 Fluorescence detector were applied. The mAb was 
measured with the UVD170U detector at 280 nm. The RF 2000 Fluorescence detector was 
operated for the cytokine extinction at 295 nm and for its emission at 343 nm. Moreover, a 
Dionex Ultimate 3000 system was employed to analyze the cytokine with a fluorescence 
detector (extinction: 295 nm; emission 343 nm). In total eight runs of each vial material and 
condition were analyzed as each pool was injected twice. 
 
5.2.2.4.1 High-Performance Size Exclusion Chromatography (HP-SEC) 
Soluble monomer, fragment or aggregate species of the proteins were quantified with HP-
SEC. The cytokine species were separated for 30 min with a flow rate of 0.5 mL/min on a 
TSKgel® 3000SWXL column (Tosoh Bioscience GmbH, Stuttgart, Germany). The mobile 
phase contained 300 mM sodium chloride and 50 mM phosphate pH 7 in highly purified 
water. For the separation of the mAb a mobile phase comprising 20 mM phosphate and 
150 mM sodium chloride at a pH of 7.5 and a SuperoseTM 6, 10/300 GL column (GE 
Healthcare, Uppsala, Sweden) were applied. Run time was 1 h with a flow rate of 
0.5 mL/min.  
 
5.2.2.4.2 High-Performance Ion-Exchange Chromatography (HP-IEX) 
HP-IEX was used to detect chemical modifications of the proteins. Cytokine analysis was 
carried out on a YMC BioPro QA column (YMC, Kyoto, Japan) with a flow rate of 0.5 mL/min. 
The mobile phases consisted of 20 mM Tris buffer pH 7.5 (mobile phase A) and of 20 mM 
Tris and 500 mM sodium chloride pH 7.5 (mobile phase B). Over a period of 50 min a 
constant gradient from 5 % to 40 % of B was applied. For the next 2 min 100 % B and then 
back to 5 % B within 2 min were programmed, before the gradient was kept constant for 
5 min at a 95:5 ratio of A to B. The mAb was analyzed at a flow rate of 1 mL/min on a 
ProPacTM WCX-10G column (BioLCTM Guard, 4 x 50 mm) and a ProPacTM WCX-10 column 
(BioLCTM Analytical, 4 x 250 mm) (both Thermo Fisher Scientific, Rockford, USA). The 
gradient consisted of mobile phase A (10 mM phosphate buffer pH 7.5) and mobile phase B 
(mobile phase A plus 0.5 M sodium chloride pH 5.5). At the beginning the amount of A was 
reduced from 94 % to 84 % within 20 min before 100 % B were reached within 2 min. 
100 % B remained for 4 min before the share of A increased again to 94 % within 2 min. 
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5.2.2.4.3 Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) 
Chemical modifications of the cytokine were analyzed with RP-HPLC. Mobile Phase A was 
made up of 90 % highly purified water, 10 % HPLC grade acetonitrile (Acetonitrile, HiPerSolv 
CHROMANORM® Super gradient for HPLC, VWR BDH Prolabo® Chemicals, Ismaning, 
Germany) and 0.1 % trifluoroacetic acid (w/w) (Trifluoroacetic acid, reagent grade 99 %, 
Sigma-Aldrich Chemie GmbH, Munich, Germany). Mobile phase B comprised 100 % HPLC 
grade acetonitrile and 0.1 % trifluoroacetic acid (w/w). A YMC-Pack C4 (250 x 4.6 mml.D. S-
5µm, 30 nm) column (YMC, Kyoto, Japan) was operated with a gradient at a temperature of 
37 °C and a flow rate of 0.5 mL/min for separation. The gradient was programmed as 
followed: the amount of B increased linearly from 0 % to 100 % during the run time from 
2 min to 25 min. 100 % B was kept constant for 5 min, before the share of B dropped to 0 % 
within 1 min. 
 
5.2.2.4.4 Protein A Chromatography 
Protein A Chromatography was used to monitor the methionine oxidation of the mAb. 
Separation was carried out on a Poros A column (2.1 mm x 30 mm, Applied Biosystems, 
Framingham, MA, USA). A flow rate of 0.5 mL/min with a gradient was applied. The gradient 
started after 3 min with a rise of B (20 mM phosphate and 150 mM sodium chloride at a pH 
of 2.9) to 40 % from 100 % A (20 mM phosphate with a pH of 7.4) within 20 min. In the next 
5 min the share of B further increased to 100 % and remained constant for 10 min before A 
was increased to 100 % for 2 min.  
 
5.2.2.5 Liquid Chromatography-Mass Spectrometry (LC-MS) 
LC-MS was carried out to detect molecular changes in the proteins. Amicon® ultra-0.5 
centrifugal filter devices (Millipore Corp. Bedford, MA, USA) were applied to dialyze the 
proteins into a 25 mM phosphate buffer pH 7.25. The buffer was exchanged for the 25 mM 
phosphate buffer twice. DL-Dithiothreitol was added to the mAb samples in a final 
concentration of 10 mM. Next, mAb samples were centrifuged before analysis. Cytokine was 
exposed overnight at room temperature to PNGase F for deglycosylation. As for the mAb 
solution DL-Dithiothreitol was added in a final concentration of 10 mM directly before 
analysis. Cytokine samples were centrifuged as well. The devices Agilent 1200 series LC 
system and Agilent 6520 Quadrupole Time-Of-Flight system (Agilent Technologies, Santa 
Clara, CA, USA) were applied for the analysis. The method was performed according to 
Okbazghi et al. [35]. 
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Benjamin Werner prepared the samples and run the samples together with Ishan Shah 
(Department Pharmaceutical Chemistry, University of Kansas, KS, USA) on the LC-MS 
device.  
5.2.2.6 4-(aminomethyl) benzenesulfonic acid (ABS) assay 
An ABS assay was applied to determine the occurrence of tyrosine and phenylalanine 
oxidation. To concentrate and dialyze the cytokine into a 100 mM phosphate buffer with a 
pH of 8.8 Amicon® ultra-0.5 centrifugal filter devices (Millipore Corp. Bedford, MA, USA) were 
used. In a ratio of 1:15 the concentrated cytokine solution and the mAb solution were each 
mixed with K3Fe(CN)6 and ABS, which had a final concentration of 10 mM. Basic reaction 
conditions were achieved by adding 100 mM phosphate buffer pH 8.8. Protein solutions were 
further exposed to 10 mM 2,2-azobis(2-methylpropionamidine) dihydrochloride for 3 h at 
37 °C to serve as positive controls. With an excitation wavelength of 360 nm and an emission 
maximum at 520 nm the fluorescence intensity of the ABS-derivatized protein samples was 
measured using a SpectraMax Gemini XS plate reader (Molecular Devices, Sunnyvale, CA) 
and the software SoftMax® Pro 4.8. As cytokine samples had to be concentrated only single 
measurements were possible, whereas the mAb samples were analyzed in triplicates.  
Assistance in the establishment of the ABS assay was received from Rupesh Bommana and 
Christian Schöneich (both Department Pharmaceutical Chemistry, University of Kansas, KS, 
USA).  
 
5.2.2.7 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
A non-reducing, denaturing SDS-PAGE was carried out to detect protein fragments or 
aggregates. For the cytokine NuPage® Novex® 4 - 12 % Bis-Tris protein gels, NuPage® 
MOPS SDS Running Buffer (20x) and Mark12TM Unstained Standard were applied. Whereas 
NuPage® Novex® 3 - 8 % Tris-Acetate protein gels, NuPAGE® Tris-Acetate SDS Running 
Buffer (20x) and HiMarkTM Unstained Protein Standard were used for the mAb. For the 
analysis the following substances were further used: NuPage® LDS Sample buffer (4x), 
SilverXpress® Silver Staining Kit (all substances, Novex® by Life Technologies, Carlsbad, CA, 
USA), glacial acetic acid 100 % and methanol (Methanol HPLC grade, Fisher Scientific UK, 
Loughborough, UK). LDS Sample Buffer (4x) was used to dilute the mAb to a concentration 
of 37.5 µg/mL. The cytokine was diluted to a concentration of 67.2 µg/mL with the LDS 
Sample Buffer (4x). Denaturing occurred at 90 °C for 5 min. In each lane 12 µL sample were 
loaded. Markers were prepared as recommended by the manufacturer. A XCell SureLockTM 
Mini-Cell Electrophoresis System (Novex® by Life Technologies, Carlsbad, CA, USA) was 
applied to run the gels in the appropriate running buffers at a constant voltage of 200 V 
(cytokine) or 150 V (mAb) using a Bio-Rad PowerPac 200 (Bio-Rad Laboratories, Hercules, 
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CA, USA). Staining of the proteins occurred with the SilverXpress® Silver Staining Kit and 
accordingly to manufacturer specifications.  
 
5.2.2.8 Oxygen quantification 
Glass and plastic vials were closed with FluroTec® coated stoppers and sealed with Flip-Off® 
seals under nitrogen atmosphere. The vials were stored in oxygen (≥ 75 %) filled aluminum 
pouches (Drylok 3000, Advantek GmbH, Freiburg, Germany) at 4 °C and 40 °C for 24 weeks. 
Oxygen concentration in the aluminum pouch and in the vials was measured with a Microx 4 
stand-alone fiber optic oxygen meter (PreSens Precision Sensing GmbH, Regensburg, 
Germany). For each vial material and condition twelve measurements were taken.  
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5.3. Results 
The usage of monolayer and multilayer plastic vials for the long-term storage of 
biopharmaceuticals has not been described so far. In this study, the physical and chemical 
stability of a mAb and a cytokine stored in COP monolayer (COP) and COP/polyamide/COP 
multilayer (Multishell®) vials were compared to commonly used glass vials. Protein stability 
was assessed by visual inspection, MFI, DLS, HP-SEC, SDS-PAGE, HP-IEX, Protein A 
Chromatography, RP-HPLC, ABS assay, and LC-MS at 4 °C and 25 °C for 48 weeks and at 
40 °C for 24 weeks. The results of the different methods, first for the mAb at the three 
temperatures 4 °C, 25 ° and 40 °C and then for the cytokine were presented in the order as 
listed above. 
 
Before further analysis a visible inspection of the vials was performed. No visible particles 
were detected in any of the vials for both proteins independent of the storage period and 
condition. The particle sizes 10 µm and 25 µm, according to the specifications of the 
pharmacopoeia were monitored as well for both proteins, besides the total particle count 
(particles ≥ 1 µm). The number of particles with sizes of 10 µm and 25 µm was in the range 
of 0 to 50 particles/mL for the mAb and the cytokine at all storage conditions. 
 
 
5.3.1 Results of the mAb stored at 4 °C 
The particle burden of the vials at the starting point for the mAb was 1,050 particles/mL in 
glass vials, 908 particles/mL in COP vials and 604 particles/mL in Multishell® vials as 
determined by MFI. Over the storage period of 48 weeks at 4 °C the particle number nearly 
doubled to 2,010 particles/mL in glass vials and slightly increased to 1,077 particles/mL in 
COP vials, whereas in Multishell® vials the particle count was 551 particles/mL (Figure 1A). 
No changes in the hydrodynamic radius were detected by DLS (data not shown). With HP-
SEC only monomer was detected (Figure 1B) and no additional bands were observed by 
SDS-PAGE (data not shown). HP-IEX displayed for all vial types an increase of chemically 
modified protein by a factor of around 1.4 (Figure 1C). Protein A Chromatography 
(Figure 1D) and ABS assay (Figure 1E), both with the capability to detect oxidation 
processes, showed no changes in the amount of oxidized species. However, LC-MS 
revealed that oxidation occurred over time (Figure 1F). At the beginning of the study the mAb 
was already oxidized by 18 %. Depending on the vial type the oxidation of the mAb 
increased differently within 48 weeks. mAb stored in glass vials showed with 29.6 % the 
lowest amount of oxidized protein, whereas the plastic vials performed equally regarding the 
share of oxidized mAb with 37.8 % in the COP vial and 37.1 % in the Multishell® vial. Further, 
only the heavy chains of the mAb were oxidized as analyzed by LC-MS. In general, during 
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the storage period the oxidation process led to a mean mass difference between the native 
and oxidized mAb of 15.72 Da. Based on results by Steinmann et al., who found that tyrosine 
oxidation products with + 14 Da, + 16 Da and + 18 Da do exist [36], it can be concluded that 
the observed mass difference of 15.72 Da indicates that tyrosine oxidation with + 14 Da 
occurred besides methionine and/or tyrosine + 16 Da oxidation.  
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Figure 1: mAb stability in glass, COP and Multishell® vials stored at 4 °C for up to 48 weeks was assessed. MFI 
was used to determine the total particle count/mL (particles/mL ≥ 1 µm) (A). The amount of soluble mAb 
monomer was obtained by HP-SEC (B). Chemical modifications were analyzed and quantified by HP-IEX (C), 
whereas Protein A Chromatography (D), ABS assay (E) and LC-MS (F) showed the occurrence of oxidation 
(Native + 16 in LC-MS). 
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5.3.2 Results of the mAb stored at 25 °C 
After 48 weeks at 25 °C the amount of subvisible particles in glass vials was 
915 particles/mL, while increases to 1,425 particles/mL in COP vials and 1,343 particles/mL 
in Multishell® vials were observed (Figure 2A). DLS showed no changes in the hydrodynamic 
radius of the mAb (data not shown). However, a mAb fragmentation of around 1.6 % was 
detected after 48 weeks by HP-SEC (Figure 2B). This fragmentation after 48 weeks was also 
confirmed by SDS-PAGE (data not shown). HP-IEX showed increased chemical changes of 
the mAb in all vial types by a factor of around 4.2 (Figure 2C). After 48 weeks methionine 
oxidation was detected by Protein A Chromatography (Figure 2D). While methionine 
oxidation was the strongest in COP vials with 1.97 %, followed by Multishell® vials with 
1.74 %, the amount of oxidized methionine in glass vials was 0.39 %. With the ABS assay no 
changes were observed in all cases except in the samples stored in Multishell® vials after 
48 weeks (Figure 2E). Here, an increase of 12.2 % of the fluorescence intensity was 
observed. The detected protein modifications were further confirmed by LC-MS (Figure 2F). 
Already after 12 weeks the mAb showed two oxidations in the heavy chain whereas no 
oxidation was seen in the light chain. For the mAb sample stored in glass vials for 24 weeks 
a shoulder for a double oxidation was visible. However, the share of this shoulder could not 
be determined with the software and resulted in slightly too high values for the remaining 
native species, based on the data obtained for the glass vial sample at 4 °C and 40 °C after 
12 weeks. The amount of single and double oxidized protein species increased further during 
storage time. In the end after 48 weeks, more than 84 % of the mAb were oxidized in the 
plastic vials, whereas the share of native mAb remained highest in glass vials with 43 %. The 
mass difference between native and single oxidized mAb after 12 weeks was below 16 Da 
and it was increased in plastic vials to values above 17 Da in the following weeks. This 
change did not occur in glass vials where the mass difference between the native and single 
oxidized protein species remained below 16 Da. The second oxidation (around + 32 Da) 
showed in the beginning a mass difference of 17.6 Da (glass) to 17.96 Da (Multishell®) and 
decreased to 16 Da after 48 weeks for plastic vials, whereas in glass vials the mass 
difference was 17 Da. The results indicate that in the beginning the single oxidation was a 
combination of tyrosine + 14 Da and tyrosine + 16 Da as well as methionine oxidation 
(+ 16 Da) and later a combination of methionine oxidation and tyrosine + 18 Da oxidation. In 
contrast, the second oxidation was mainly of a tyrosine (+ 18 Da) and then shifts towards a 
mixture of tyrosine and methionine oxidation over storage time. The LC-MS results match 
with the Protein A Chromatography results. 
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Figure 2: Data of six methods characterizing the mAb solution which was stored at 25 °C for up to 48 weeks in 
three different vial types is shown. The total particle count/mL (particles/mL ≥ 1 µm) was analyzed by MFI (A), 
whereas the soluble protein content was measured with HP-SEC (B). HP-IEX (C), Protein A Chromatography (D), 
ABS assay (E) and LC-MS (F) were applied to detect chemical protein alterations. Molecular weight was changed 
by one (Native + 16 Da) or two (Native + 32 Da) oxidations as determined by LC-MS. 
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5.3.3 Results of the mAb stored at 40 °C 
At 40 °C the particle count in glass vials was 610 particles/mL after 24 weeks and showed 
values of 1,675 particles/mL in COP vials and 1,207 particles/mL in Multishell® vials 
(Figure 3A). Equally as detected at lower temperatures DLS showed no changes (data not 
shown). Fragmentation was observed from week 12 onwards with a share of 3.07 % in glass 
vials and up to 3.47 % in COP vials as determined by HP-SEC. The amount of fragments 
increased to 4.18 % in glass vials, 5.04 % in COP vials and 4.47 % in Multishell® vials after 
24 weeks (Figure 3B). SDS-PAGE data confirmed the HP-SEC findings (data not shown). 
HP-IEX showed chemical modifications of the mAb after a storage period of 24 weeks. 
64.37 % respectively 64.62 % of the mAb stored in glass and Multishell® vials were altered, 
while the mAb solution stored in COP vials showed values of 69.55 % (Figure 3C). 
Methionine oxidation after 24 weeks was the lowest in glass vials with 1.63 %, followed by 
Multishell® vials with 6.80 % and COP vials with 8.97 % as determined by Protein A 
Chromatography (Figure 3D). In a time dependent manner the ABS assay showed an 
increase of the fluorescence intensity for all vial types indicating an oxidation of tyrosine and 
phenylalanine (Figure 3E). LC-MS confirmed the so far described results (Figure 3F). In 
plastic vials more than 90 % of the mAb were oxidized, whereas 26.7 % remained as native 
species in glass vials after 24 weeks. Double oxidations, detectable as early as 4 weeks after 
the beginning of the study, accounted after 24 weeks for more than 50 % of the oxidation 
modifications in plastic vials, while in glass vials single oxidation with 50.9 % was dominating. 
Over the storage period the mass differences between native and single oxidized mAb rose, 
indicating that tyrosine oxidations were dominating, which correlated with the observed 
increase of the fluorescence intensity of the ABS assay. For the double oxidation values of 
around 17.1 Da were obtained for plastic vials, whereas for glass vials the mass difference 
was reduced from 17.4 Da to 16.7 Da. The molecular changes of the mAb, which was stored 
in COP vials at 40 °C, are displayed in Figure 4 as detected with LC-MS.  
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Figure 3: Physical and chemical stability of the mAb stored at 40 °C for up to 24 weeks in the three vial types was 
monitored by MFI (A), HP-SEC (B). HP-IEX (C), Protein A Chromatography (D), ABS assay (E) and LC-MS (F). A 
mass increase of + 16 Da and + 32 Da was observed by LC-MS. 
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Figure 4: Mass spectrum of the mAb stored in COP vials at 40 °C after 0 weeks is shown in (A). The light chain is 
shown for clarity in a greater magnification (highlighted with the frame) in (A) as well. Magnifications of the heavy 
chain at different points of analysis (0, 4, 12 and 24 weeks) show the oxidation of the native mAb (B to E). The 
peak of the native heavy chain of the mAb and its oxidized versions are labeled. 
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The particle numbers in the three vial materials were overall on a low level and differed only 
by a few hundred particles/mL. Changes to a similar extent were observed for all vial 
materials at the three temperatures regarding the physical protein stability. However, while at 
4 °C chemical alterations detected by HP-IEX, Protein A Chromatography and ABS were low 
and differences between the vial materials were minor, LC-MS showed a higher amount of 
native mAb in glass vials. At 25 °C and 40 °C similar results were obtained for plastic vials, 
whereas glass vials conserved the native mAb best.  
Table 1 provides a summary of the alterations in mAb stability at the different storage 
conditions and vial materials. 
 
Table 1: Overview of the changes regarding the chemical and physical stability of the mAb, which was stored at 
4 °C and 25 °C over the storage period of up to 48 weeks and at 40 °C for up to 24 weeks in different vial types 
 
 Glass Vial COP Vial Multishell® Vial 
 
4 °C 
Visual O O O 
MFI + O/+ O 
DLS O O O 
HP-SEC O O O 
SDS-PAGE O O O 
HP-IEX O/+ O/+ O/+ 
Protein A Chromatography O O O 
ABS O O O 
LC-MS O/+ + + 
 
25 °C 
Visual O O O 
MFI O + + 
DLS O O O 
HP-SEC O/+ O/+ O/+ 
SDS-PAGE O/+ O/+ O/+ 
HP-IEX +/++ +/++ +/++ 
Protein A Chromatography O O/+ O/+ 
ABS O O O/+ 
LC-MS + +/++ +/++ 
 
40 °C 
Visual O O O 
MFI O + + 
DLS O O O 
HP-SEC + + + 
SDS-PAGE + + + 
HP-IEX ++ ++ ++ 
Protein A Chromatography + ++ ++ 
ABS + ++ ++ 
LC-MS +/++ ++ ++ 
 
       O = no or minor changes; + = changes; ++ = major changes. 
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5.3.4 Results of the cytokine stored at 4 °C 
The particle level of the cytokine was very low at the starting point with 50 particles/mL in 
glass vials, 72 particles/mL in COP vials and 124 particles/mL in Multishell® vials. Over 
48 weeks at 4 °C the particle burden increased to 1,316 particles/mL in glass vials, 
395 particles/mL in COP vials and 1,365 particles/mL in Multishell® vials (Figure 5A). The 
hydrodynamic radius of the cytokine remained similar to the start value (data not shown). 
According to HP-SEC (Figure 5B) and SDS-PAGE only the monomer was present (data not 
shown). HP-IEX showed for all vial types a share of 0.54 % chemically modified protein 
(Figure 5C), but no alterations were detected by RP-HPLC after 48 weeks (data not shown). 
Lower fluorescence intensity for cytokine stored in glass vials compared to plastic vials was 
obtained in the ABS assay at week 0 (Figure 5D). Therefore, it is not sure, if the increase of 
the fluorescence intensity was based on tyrosine and phenylalanine oxidation in glass vials. 
The fluorescence intensity was not elevated for plastic vials after 48 weeks. LC-MS with N-
glycan deglycosylated cytokine was carried out to quantify oxidation. After N-glycan 
deglycosylation only O-glycosylated isoforms of the cytokine remained. The major isoform 
had the composition of NeuAc2Hex1HexNAc1, whereas the other isoform was 
NeuAc1Hex1HexNAc1 [37]. NeuAc2Hex1HexNAc1 showed peaks with + 16 Da and 
approximately 26 % of this predominant isoform were already oxidized at the beginning of 
the study. Over the storage period the amount of oxidized protein increased in plastic vials 
and remained stable in glass vials after 48 weeks. Further, around 5.47 % of 
NeuAc2Hex1HexNAc1 were O-acetylated as identified with a mass increase of 42 Da [37]. 
This share was reduced to the lowest value of 4.49 % found for COP vials. Dehydration of 
aspartic acid was detected in 1.2 % of the main isoform (Figure 5E). The 
NeuAc1Hex1HexNAc1 isomer was also altered by oxidation. 
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Figure 5: Cytokine stability in glass, COP and Multishell® vials was determined at 4 °C for up to 48 weeks. The 
total particle count/mL (particles/mL ≥ 1 µm) was determined with MFI (A), the soluble protein species was 
analyzed with HP-SEC (B), the amount of chemically modified protein species was assessed by HP-IEX (C). 
Oxidation processes were observed using the ABS assay (D) and LC-MS (E), which detected acetylation 
(+ 42 Da), oxidation (+ 16 Da) and dehydration (- 18 Da). 
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5.3.5 Results of the cytokine stored at 25 °C 
At 25 °C the particle number of the cytokine solutions increased in all vial types. After 
48 weeks Multishell® vials had the lowest count with 663 particles/mL followed by glass vials 
with 1,299 particles/mL and COP vials with 1,490 particles/mL (Figure 6A). The 
hydrodynamic radius of the cytokine remained similar over time (data not shown). Aggregate 
formation was detected by HP-SEC to a low extent of approximately 0.3 % in all three vial 
types after 48 weeks (Figure 6B), but not by SDS-PAGE (data not shown). HP-IEX revealed 
that around 1.49 % of the protein was chemically altered in all three vial types at the end 
point (Figure 6C). RP-HPLC detected no changes until week 24 (Figure 6D). In week 24 
hydrophilic changes of 0.93 % were noted which increased until week 48 to 2.07 % in glass 
vials, 2.24 % in COP vials and 2.45 % in Multishell® vials. In addition hydrophobic alterations 
in the range of 0.27 % to 0.59 % for glass and COP vials were observed after 48 weeks. The 
ABS assay showed for all vial types an increase of the fluorescence intensity over time 
(Figure 6E). High start values of the plastic vials lead to a smaller increase of fluorescence 
intensity than for glass vials. Based on HP-IEX and RP-HPLC chromatography and LC-MS 
results, however, it could be stated that the fluorescence increase could be attributed to 
oxidation. LC-MS revealed for all vials a higher level of oxidation (Figure 6F). The share of 
oxidized species rose from approximately 26 % to 36.5 % in glass vials, to 42.1 % in COP 
vials and to 41.4 % in Multishell® vials. Further, the share of acetylated cytokine was reduced 
from around 5.5 % to 3.8 % in glass vials and to around 4.1 % in plastic vials. The amount of 
dehydrated cytokine increased from 1.2 % to a range of 1.6 % to 1.8 % in all vial types.  
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Figure 6: Physical and chemical stability of the cytokine was evaluated at 25 °C for up to 48 weeks in glass, COP 
and Multishell® vials. The total particle count/mL (particles/mL ≥ 1 µm) was determined with MFI (A) and the 
amounts of native and aggregated protein species were assessed by HP-SEC (B). Chemical modifications were 
detected with HP-IEX (C), RP-HPLC (D) and ABS (E). LC-MS (F) revealed acetylation (+ 42 Da), oxidation 
(+ 16 Da) and dehydration (- 18 Da) processes. 
Chapter 5 
 
174 
5.3.6 Results of the cytokine stored at 40 °C 
At 40 °C the particle counts of the cytokine solutions were below 1,000 particles/mL for all 
vials after 24 weeks. The lowest particle burden was detected in COP vials with 
599 particles/mL and in Multishell® vials with 815 particles/mL. The highest particle 
concentration was measured in glass vials with 972 particles/mL (Figure 7A). DLS showed a 
similar hydrodynamic radius for the cytokine after 24 weeks (data not shown). HP-SEC 
revealed the formation of soluble aggregates after 12 weeks. At least 10 % of the protein was 
aggregated after 12 weeks in glass and Multishell® vials, whereas in COP vials an amount of 
16.6 % of aggregates was found. Protein loss of more than 45 % was observed after 
24 weeks. Aggregates were still detected and accounted for 3.7 % in glass vials, 7.4 % in 
COP vials and 4.4 % in Multishell® vials of the recovered protein (Figure 7B). SDS-PAGE 
showed in contrast to HP-SEC aggregate formation already after 4 weeks (data not shown). 
Moreover, the aggregate bands intensified over time. These findings were supported by HP-
IEX and RP-HPLC results. HP-IEX showed after 24 weeks that 22.9 % of the cytokine were 
altered in COP vials and 13.7 % in glass vials and 14.8 % in Multishell® vials (Figure 7C). 
The same tendency was obtained by RP-HPLC (Figure 7D). In the first 12 weeks only 
hydrophilic changes and after 24 weeks also hydrophobic alterations were observed. In total 
27.6 % of the cytokine were altered in glass vials, 25.9 % of the cytokine were changed in 
Multishell® vials and 34.4 % of the cytokine were modified in COP vials. The ABS assay 
showed that tyrosine and/or phenylalanine were oxidized over the storage period with the 
strongest increase in the fluorescence intensity in glass vials (Figure 7E). The ABS data 
correlated with LC-MS data (Figure 7F). Glass vials showed the highest amount of oxidized 
cytokine after 24 weeks with 58.6 %, followed by Multishell® vials with 45.8 % and COP vials 
with 44.6 %. Further, COP vials showed the highest amount of dehydrated cytokine with 
18.0 %. A share of 11.42 % dehydrated protein was measured in Multishell® vials and 9.2 % 
of dehydrated cytokine were detected in glass vials. As observed at lower temperatures, the 
amount of acetylated cytokine vanished in glass vials and dropped to 4.6 % in COP vials and 
to 3.4 % in Multishell® vials. In conclusion, around 32 % of native cytokine were found in 
glass and COP vials and 39.4 % of native cytokine were found in Multishell® vials. In Figure 8 
the chemical modifications of the cytokine at molecular level are displayed as determined by 
LC-MS. Figure 8 is representative for the other vial types and storage conditions. The 
intensity of the alterations may vary though. 
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Figure 7: The cytokine was stored at 40 °C for up to 24 weeks in glass, COP and Multishell® vials and the results 
of six methods are displayed. The total particle count/mL (particles/mL ≥ 1 µm) was determined by MFI (A). 
Soluble cytokine species were analyzed with HP-SEC (B) and chemical alterations were quantified with HP-
IEX (C) and RP-HPLC (D). The ABS assay (E) and LC-MS (F) analysis detected oxidative alterations. Along with 
oxidation (+ 16 Da) acetylation (+ 42 Da) and dehydration (- 18 Da) were observed by LC-MS. 
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Figure 8: Mass spectrum of N-deglycosylated cytokine stored in COP vials at 40 °C after 0 weeks is 
displayed (A). The magnification (B) shows the two main peaks from (A) and enlargements of these two peak 
groups (marked with a frame) of the cytokine at week 0. Molecular alterations of the main isoform occurring over 4 
to 24 weeks at a storage temperature of 40 °C are presented in (C) to (E). Peaks of interest are labeled based on 
the mass differences from the native protein.  
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The particle numbers increased from less than 125 particles/mL to a few hundred with the 
maximum at 1,500 particles/mL in all vial materials and storage temperatures. Overall, the 
particle count between the vial materials was comparable. The vial material had only a minor 
impact on the physical stability of the cytokine. The chemical stability, although differences 
exist, was to a similar extent negatively impacted in all three vial types. However, at 4°C and 
25 °C glass vials showed in LC-MS analysis better results.  
Table 2 summarizes the stability changes occurring to the cytokine at all storage conditions. 
 
Table 2: Overview of the quantity of cytokine alterations at 4 °C, 25 °C and 40 °C in three different vial types as 
determined with nine different methods over the storage period of up to 48 weeks  
 
 Glass Vial COP Vial Multishell® Vial 
 
4 °C 
Visual O O O 
MFI +/++ + +/++ 
DLS O O O 
HP-SEC O O O 
SDS-PAGE O O O 
HP-IEX O O O 
RP-HPLC O O O 
ABS O O O 
LC-MS O O/+ O/+ 
 
25 °C 
Visual O O O 
MFI +/++ +/++ + 
DLS O O O 
HP-SEC O O O 
SDS-PAGE O O O 
HP-IEX O/+ O/+ O/+ 
RP-HPLC O/+ O/+ O/+ 
ABS O/+ O O/+ 
LC-MS O/+ + + 
 
40 °C 
Visual O O O 
MFI +/++ + +/++ 
DLS O O O 
HP-SEC ++ ++ ++ 
SDS-PAGE ++ ++ ++ 
HP-IEX +/++ ++ +/++ 
RP-HPLC +/++ ++ +/++ 
ABS ++ +/++ +/++ 
LC-MS ++ ++ ++ 
 
      O = no or minor changes; + = changes; ++ = major changes   
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5.3.7 Oxygen permeation into nitrogen filled vials 
The permeation of oxygen into nitrogen filled glass and plastic vials was monitored for 
24 weeks at 4 °C and 40 °C and is listed in Table 3. The oxygen concentration was at its 
highest in COP vials and at its lowest in glass vials. An elevated temperature led to an 
increased amount of oxygen within the vial during the same incubation time. 
 
Table 3: Overview of the increase of the oxygen concentration [%] in nitrogen filled glass, COP and Multishell® 
vials which were stored in at least 75 % oxygen atmosphere over time 
 
4 °C Glass COP Multishell® 
0 weeks 0.96 ± 0.34   1.21 ± 0.23 1.13 ± 0.59 
1 week 0.80 ± 0.31   9.24 ± 0.23 1.14 ± 0.50 
2 weeks 0.64 ± 0.29 15.87 ± 0.18 1.36 ± 0.38 
4 weeks 0.58 ± 0.11 26.11 ± 0.23 1.68 ± 0.24 
8 weeks 1.39 ± 0.13 41.50 ± 0.34 3.49 ± 0.35 
24 weeks 1.63 ± 0.14 53.62 ± 0.31 7.04 ± 0.49 
 
40 °C Glass COP Multishell® 
0 weeks 0.96 ± 0.34      1.21 ± 0.23   1.13 ± 0.59 
1 week 1.24 ± 0.43   20.38  ± 0.30   2.66 ± 0.60 
2 weeks 1.32 ± 0.19   29.55  ± 0.12   3.70 ± 0.28 
4 weeks 2.20 ± 0.44   40.68  ± 0.17   6.30 ± 0.28 
8 weeks 3.37 ± 0.31   49.93  ± 1.44 10.69 ± 0.54 
24 weeks 8.36 ± 0.95   68.12  ± 0.40 21.13 ± 0.89 
 
 
 
5.4. Discussion 
The study assessed new vial materials for the long-term storage of biopharmaceuticals in 
comparison to the commonly used glass vials. The impact of the packaging material on the 
chemical and physical stability of a mAb and a cytokine was determined.  
First, the particle level of the protein solutions in the three different vial types is discussed. 
Second, the focus is on the chemical alterations, in particular of those detected by LC-MS, 
on the mAb and then on the cytokine. Next, the oxygen barrier properties of plastic vials and 
possible improvements regarding their oxygen permeability are outlined.   
 
Based on the particle counts of the protein solutions, it is not possible to define the most 
promising vial material. The number of particles in mAb solutions remained similarly low to 
the starting point values. In contrast, cytokine solutions had an increase in the particle count 
by factors up to 26. However, less than 150 particles/mL were quantified in the cytokine 
solution directly after vial filling and no more than 1,500 particles/mL were found later. In 
general, the measured particle numbers were low in all three vial materials, also in 
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comparison to other protein formulations [38-40]. Unlike syringes which can differ in their 
particle count due to different siliconization techniques or the absence of silicone oil in some 
polymer syringes [41-43], the vial material apparently had no major impact on the particle 
count of the protein solutions.  
 
Methionine sulfoxide formation in the Fc region of the mAb was observed at 25 °C after 
48 weeks and in particular at 40 °C after 24 weeks as determined by Protein A 
Chromatography. The ABS assay detected tyrosine and phenylalanine oxidation at 40 °C 
from week 12 onwards. It is possible to say that the elevated fluorescence intensity 
measured in the ABS assay is an indicator for an increased amount of oxidized methionine 
and therefore confirmed the results obtained by Protein A Chromatography. It has already 
been shown that a quantitative correlation between the amount of methionine sulfoxide, 
which was quantified by LC-MS, and the concentration of oxidized tyrosine and 
phenylalanine exists [44]. Further, oxidation was only detected by LC-MS in the heavy chain 
of the mAb and not in the light chain independent of the storage condition. The mass 
difference between the native and oxidized species of the mAb, as analyzed by LC-MS, led 
to conclusions which amino acids were affected by oxidation. This is based on the fact that 
tyrosine oxidation products with a molecular weight increase of + 14 Da, + 16 Da and 
+ 18 Da can be formed according to a tyrosine oxidation mechanism proposed by Steinmann 
et al. [36]. LC-MS data matched with the results of the other methods at higher temperatures. 
Only LC-MS showed major differences between the three vial materials at 4 °C. Generally, 
for all temperatures glass vials protected the mAb best, followed by Multishell® and COP 
vials.  
 
All methods beside LC-MS showed a similar chemical stability of the cytokine stored in the 
three different vial types at lower temperatures. However, at 40 °C cytokine solutions stored 
in COP vials showed the highest amount of altered protein species in HP-IEX and RP-HPLC 
analytics. Oxidation of tyrosine and phenylalanine were also indicated by an increase of the 
fluorescence intensity of the ABS assay. LC-MS revealed at all storage temperatures 
molecular changes of the cytokine. Besides oxidation of a methionine or a carbohydrate [45], 
it was in particular at 40 °C noted that deacetylation and dehydration occurred to a high 
extent. Both mechanisms, deacetylation and dehydration, are temperature dependent [46-
48]. Deacetylation of probably an O-acetylated sialic acid took place in the course of longer 
storage periods and higher temperatures [37]. The observed mass loss of - 18 Da was 
attributed to dehydration of aspartate [47]. An aspartate-serine motif, as can be found in the 
amino acid sequence of the cytokine, is known to promote the dehydration of aspartate [47]. 
The obtained LC-MS data for the cytokine correlated well with literature [47, 48]. The highest 
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stability of the cytokine was obtained in glass vials at 4 °C and 25 °C. The performance of 
Multishell® and glass vials at 40 °C was similar to each other and both performed better than 
COP vials. 
 
Oxidation occurring over the storage period can be caused by oxygen that either derives 
from the headspace within the vial or permeates into the vial. The container closure integrity 
of glass vials was excellent as the oxygen permeability study showed. Over 24 weeks at 4 °C 
the oxygen concentration in nitrogen filled glass vials increased only from 0.96 ± 0.34 % to 
1.63 ± 0.14 %, whereas in COP vials the oxygen amount was multiplied by a factor of 44.3. 
For Multishell® vials the amount of oxygen rose from 1.13 ± 0.59 % to 7.04 ± 0.49 % in 
24 weeks. Such a high oxygen permeability of the primary packaging cannot be accepted for 
oxygen sensitive biopharmaceuticals. That was already concluded by Qadry et al., who 
calculated a 15 day half life time of the increase of the oxygen concentration in COP vials 
[23, 29]. Therefore, nitrogen blanketing of the headspace would not work well for COP vials, 
but could be an option for glass vials. However, other possibilities to use plastic vials as 
primary packaging materials for oxygen sensitive biopharmaceuticals exist. First, the gas 
barrier properties can be improved by coating the interior with a silicon dioxide layer [34]. 
Second, multilayer vials with an incorporated oxygen absorbing resin may prevent oxygen 
permeation into the container [49]. Third, oxygen absorbers in the secondary packaging can 
control the amount of oxygen in the container and its packaging [50, 51]. Finally, vials could 
simply be stored in gas tight aluminum pouches, which provide additional protection from 
light and could be filled with nitrogen.  
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5.5. Conclusion 
New vial materials as primary packaging materials were evaluated for the long-term storage 
of biopharmaceuticals and compared to commonly used glass vials. The plastic vials 
consisted either of a COP monolayer or a COP/polyamide/COP multilayer. The chemical 
stability of a mAb and a cytokine was best preserved in glass vials. Even at 4 °C, which is the 
standard storage temperature for biopharmaceuticals, oxidation processes were more 
pronounced in plastic vials than in glass vials as LC-MS measurements revealed. Regarding 
the physical stability the particle level was similar and low in all vial types over the 
investigated period. Plastic vials can provide an alternative for the storage of 
biopharmaceuticals. However, multilayer vials showing higher gas barrier properties or vials 
stored in secondary packaging (e.g. aluminum pouches) with controlled oxygen levels should 
be used. 
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Summary 
 
 
 
Nowadays, a correlation between non-native protein species and immunogenicity is 
commonly accepted. Multiple factors such as transportation, storage, handling, drug 
formulation or primary packaging have been shown to influence the formation of protein 
aggregates and particles. As protein particles can adversely affect the health of patients, it is 
of great importance to prevent the formation or to diminish the existent protein aggregates in 
the final protein drug product. In the present thesis novel concepts were investigated and 
evaluated to improve the quality and safety of biopharmaceuticals further. First, the 
application of bedside filtration should lead to increased safety, because virtually any protein 
particle formed during the shelf life of the drug larger than the pore size of the filter could be 
removed. Second, the primary packaging material has to maintain the product quality and 
should not impact the product. However, currently used container materials are not inert and 
may interact with the drug and its formulation.  
 
In Chapter 1 all approved biopharmaceuticals in Germany have been listed and analyzed for 
the first time regarding their filtration recommendations. The focus is in particular on the 
dosage form, the filter membrane and pore size recommendations, the time of filtration – 
during drug preparation and administration – and the protein concentration, dosing and route 
of administration. This review revealed that about 16 % of approved biopharmaceutical drugs 
are filtered during drug preparation or administration. For the majority of these filtered 
biopharmaceuticals, the manufacturers do not recommend a specific filter membrane. 
However, if specific filtration instructions are suggested, filters with a polyethersulfone 
membrane and a pore size of 0.2 µm are predominantly applied. Two thirds of all filtered 
drugs are lyophilisates with most of them being filtered during drug preparation, whereas 
solutions are primarily filtered during drug administration.  
 
Chapter 2 shows that bedside filtration with different filters could be expanded to a broad 
range of protein drug products including proteins with different molecular weights or 
concentrations. This was substantiated by assessing multiple aspects such as filtration 
efficacy, filter cleanliness or protein loss due to adsorption. All investigated filters effectively 
eliminated protein particles. After filtration with a 0.2 µm filter the particle count was always at 
a low level, independent of thousands of particles in the non-filtered solution. In general, the 
investigated filters did not contribute to the particle burden as tested with placebo buffers. 
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Moreover, the concentration of the detected leachables was on a very low level, yet, some 
filters show higher amounts than others. Protein adsorption did not occur in the majority of all 
cases, but if a loss of protein was observed it was in the low µg/mL range. Hence, adsorption 
needs only to be considered for very low dosed biopharmaceuticals. On the other hand 
rather large hold-up volumes of the filters were found, making most filters used nowadays not 
applicable to filtration of low volume products. Bedside filtration did not alter the protein 
structure. Furthermore, measurements showed that the addition of a filter to a syringe did not 
require substantially more ejection force. Based on these findings an expansion and routine 
application of filtration of biopharmaceuticals can be proposed.  
 
It was reported in the literature that elevated and elongated intraocular pressures have been 
observed in patients after injection of aflibercept, bevacizumab and ranibizumab. A higher 
rise of the intraocular pressure has been detected in particular for ranibizumab in comparison 
to aflibercept. An increased particle burden in the ranibizumab product was assumed to be 
the cause for this. To test, if different particle levels in the three biopharmaceuticals can be 
responsible for the varying levels of the intraocular pressure, a direct comparison of the 
particle burden of these drugs was performed and the results are presented in Chapter 3. 
Comparable particle counts were observed for all three proteins, except for one of the two 
repackaged bevacizumab products.  
 
Silicone oil free cyclic olefin polymer syringes might be beneficial for the storage of 
biopharmaceuticals, when silicone oil which can foster protein aggregation is absent. In 
Chapter 4 such polymer syringe was evaluated for the first time over a longer storage period 
for its application as primary packaging container for biopharmaceuticals. This evaluation 
revealed the following three findings. First, the major benefit of the silicone oil free system 
was a significant lower particle count in comparison to glass syringes. The particle level in 
cyclic olefin polymer systems remained stable over the investigation period, whereas in glass 
syringes the particle number increased over time. Second, at 4 °C the chemical stability of 
the two proteins was comparable in polymer and glass syringes. At higher temperatures in 
particular at 40 °C glass syringes showed the best results regarding the chemical stability of 
the mAb, whereas polymer syringes stored in nitrogen filled aluminum pouches were 
identified to be the best packaging configuration for the cytokine. Third, if silicone oil free 
cyclic olefin polymer syringes were stored in nitrogen filled aluminum pouches, the oxidation 
problem can be resolved and they could be used as primary packaging for oxygen sensitive 
biopharmaceuticals.   
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In Chapter 5 monolayer and multilayer silicone oil free plastic vials were investigated as 
alternatives for glass vials as primary packaging materials for biopharmaceuticals. Chemical 
alterations, in particular oxidations, of the protein of interest are stronger pronounced in 
plastic vials than in glass vials, even at 4 °C. The plastic vials also did not show a benefit 
regarding lower particle counts. If plastic vials are considered as primary packaging container 
for oxygen sensitive drugs, multilayer vials with lower gas permeability or oxygen controlled 
secondary packaging should be used. 
 
The results of this thesis show that bedside filtration and novel primary packaging systems 
have the potential to contribute significantly to an improvement of the product quality and 
safety of biopharmaceuticals. Both concepts minimize effectively the number of protein 
aggregates and therefore protect patients. Hence, they should be considered and 
implemented in future applications. 
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